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ABSTRACT 
 The Stoltz group, and moreover the synthetic community at large, has long been 
interested in the synthesis of enantioenriched compounds with interesting biological 
activities. This thesis presents three projects unified in an attempt to access compounds 
with relevance to the medicinal chemistry and natural products communities, 
encompassing reaction development, synthetic strategy and natural product synthesis. 
 A general method for the enantioselective synthesis of carbo- and heterocyclic 
carbonyl compounds bearing fluorinated α-tetrasubstituted stereocenters using 
palladium-catalyzed allylic alkylation is described. These fluorinated, stereochemically 
rich building blocks hold potential value in medicinal chemistry and are prepared using 
an orthogonal and enantioselective approach into such chiral moieties compared to 
traditional approaches, often without the use of electrophilic fluorinating reagents.  
The synthesis of a variety of enantioenriched 2,2-disubstituted pyrrolidines is 
described. A stereogenic quaternary center is first formed utilizing an asymmetric allylic 
alkylation reaction of a benzyloxy imide, which can then be reduced to a chiral 
hydroxamic acid. This compound can then undergo a thermal “Spino” ring contraction to 
afford a carbamate protected 2,2-disubstituted pyrrolidine stereospecifically, allowing 
access to new molecules that could be useful in the medicinal chemistry community. 
Finally, we have developed a synthesis of an enantioenriched [7,7]paracyclophane 
compound using sequential C-H functionalization reactions, including selective Rh-
catalyzed C-H insertion reactions developed by the Davies group at Emory University. 
Investigations are currently ongoing into potential antimicrobial activity of different 
[7,7]paracyclophanes and the total synthesis of naturally occurring [7,7]paracyclophanes. 
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 Csp3–Csp3 Cross-Coupling for the Synthesis 
 of (Poly)fluorinated Chiral Building Blocks* 
 
1.1   INTRODUCTION: 
Organofluorine compounds often play a critical role in the lead optimization 
phase of drug discovery, due to their impact on various physico-chemical properties such 
as absorption, distribution, metabolitic stability, and excretion.  Consequently, more than 
20% of marketed pharmaceuticals contain C–F motifs, despite the fact that 
organofluorinated compounds are exceedingly rare in nature.1 Recently, molecules with 
tetrasubstituted stereocenters have attracted the interest of medicinal chemists aiming to 
incorporate three-dimensionality and added novelty. 2  Importantly, there are many 
successful marketed pharmaceuticals bearing fluorinated tetrasubstituted stereocenters 
(1–3, Figure 1.1.1). For these reasons, there has been renewed interest in the synthesis of 
fluorinated tetrasubstituted stereocenters for use in drug discovery, and in particular, 
access to new classes of fluorinated analogs. Therefore, we believe that a general method 
                                                
* This research was performed in collaboration with Yanhui Lu, an alumni of the Stoltz group.  
Additionally, this research has been published and adapted with permission Lu, Y.; Goldstein, E. L.; Stoltz, 
B. M. Org. Lett. 2018, 20, 5657–5660. 
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for the construction of fluorine-containing tetrasubstituted stereocenters will be of 
particular interest to chemists in the area of drug discovery and development.   
Figure 1.1.1. Marketed Active Pharmaceutical Ingredients Bearing Fluorinated 
Tetrasubstitued Stereocenters. 
  
Methods to construct fluorine-containing α-tetrasubstituted ketones have been the 
subject of intense investigation over the past decade.  The most prevalent strategy for 
fluorine incorporation is intermolecular catalytic asymmetric electrophilic fluorination (or 
trifluoromethylation) of enolates (Scheme 1.1.1A).3  Despite their potential utility in 
organic synthesis, the relatively low abundance of cheap, commercially available 
electrophilic fluorinating and trifluoromethylating reagents prohibit their widespread 
usage.   As far back as 2005, the Stoltz and Nakamura groups independently reported the 
intramolecular asymmetric allylic alkylation of prochiral enolates derived from the 
decarboxylation of 1,3-dicarbonyl substrates (Scheme 1.1.1B).4,5 Using this strategy, 
several optically active α-fluoro α-tetrasubstitued cyclic carbonyl derivatives have been 
synthesized in high yield and enantioselectivity.  
While stereogenic C–F moieties have been previously investigated, the 
compatibility of fluoroalkyl groups in palladium-catalyzed asymmetric allylic alkylation 
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example of the construction of trifluoromethyl-bearing quaternary centers by 
intramolecular decarboxylative allylic alkylation of α-trifluoromethyl β-ketoesters 
(Scheme 1.1.1C).6  Unfortunately, attempts to render their reaction enantioselective were 
unsuccessful.  Due to our interest in the field of asymmetric allylic alkylation, we 
endeavored to build on these previous reports and investigate a number of fluoroalkyl and 
fluoroallyl derivatives in asymmetric allylic alkylation reactions. Herein, we report the 
first general method for the construction of carbo- and heterocyclic carbonyl derivatives 
bearing α-fluoro-, α-fluoroalkyl-, or α-(2-fluoro)allyl substituents using palladium-
catalyzed enantioselective decarboxylative allylic alkylation (Scheme 1.1.1D).  
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1.2.  SYNTHESIS OF FLUORINATED ALLYLIC ALKYLATION 
SUBSTRATES  
 Importantly, with this strategy, a number of fluorinated alkyl and allyl groups are 
introduced into the substrate via standard 1,3-dicarbonyl chemistry (thermal, acidic or 
basic conditions) to produce racemic mixtures of compounds that serve as substrates for 
the mild and neutral asymmetric allylic alkylation reaction. In some cases, these 
fluorinated substrates are synthesized without the use of electrophilic fluorinating 
reagents. Furthermore, this allows for the non-asymmetric formation of the C–F or C–
CF3 bonds, which are significantly more developed than their asymmetric equivalents. 
For example, 1,1,1,-trifluoropropyl groups can be installed using standard β-keto ester 
alkylation conditions utilizing 1,1,1-trifluoropropyl iodide  and  base in moderate yields 
(Scheme 1.2.1A). The synthesis of 1,1,1-trifluoroethyl substituted β-keto esters 
proceeded smoothly with the use of 2,2,2-Trifluoroethyl (mesityl)iodonium 
trifluoromethanesulfonate 7  (available in 2 steps from commercial materials) in the 
presence of LiHMDS. (Scheme 1.2.1B) During the preparation of this manuscript, a 
report using 2,2,2-Trifluoroethyl(mesityl) iodonium trifluoromethanesulfonate  for the 
alkylation of 1,3-dicarbonyls was disclosed using similar conditions.8 
In addition to α-fluoroalkyl groups, a number of 2-fluoro allyl substrates were 
prepared without the use of electrophilic fluorinating reagents. Starting from 
commercially available Methyl 2-fluoroacrylate, reduction of the ester to the alcohol, 
followed by treatment with 1,1’-carbonyldiimidazole (CDI) resulting in the formation of 
an acylating reagent (Scheme 1.2.1C). This reagent could then be used as previously 
reported9 to form a β-keto ester (Scheme 1.2.1D), which can be subsequently alkylated 
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or fluorinated.4,5  Additionally, using known chemistry, α-fluoro β-keto esters can be 
synthesized using Selectfluor5d and α-trifluoromethyl β-keto esters can be synthesized 
using Umemoto’s Reagent10, both of which are commercially available. 
Scheme 1.2.1. Synthesis of Fluorinated β-Ketoesters 
 
1.3  INITIAL REACTION OPTIMIZATION 
Initial reaction optimization started with trifluoroethyl substituted β-ketoester 4a 
using catalytic Pd2(dba)3 at 23 °C in diethylether in the presence of a chiral PHOX ligand 







































THF, 0 °C → 23 °C, 2 h
up to 54% yield
1. AlCl3, LiAlH4
    Et2O, 0 °C, 1 h
2. 1,1’–carbonyldiimidazole
     THF–CH2Cl2, 0 °C, 3 h

















THF, —78 °C → 23 °C, 2 h







A: Synthesis of α-trifluoropropyl β-ketoester
B: Synthesis of α-trifluoroethyl  β-ketoester
C: Synthesis of 2-fluoroallyl acyl imidazole
D: Synthesis of 2-fluoroallyl β-ketoester
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ligand 6, the desired product was formed in 88% yield and 85% ee (entry 1).  Switching 
to the electron deficient (S)-(CF3)3-t-BuPHOX  ligand 7, the desired product was 
furnished in an improved 99% yield and 90% ee (entry 2).  Solvent effects were not very 
significant (entries 3–5), however THF gave a decreased ee of 86% (entry 3), while the 
less polar TBME and non-polar toluene performed similarly to diethyl ether.  Based on 
these results, we determined that using Pd2(dba)3 (5.0 mol %) with (S)-(CF3)3-t-BuPHOX 
in toluene (0.033 M) at room temperature proved optimal. 12 
Table 1.3.1. Optimization of Conditions for Enantioselective Palladium-Catalyzed 
Allyllic Alkylationa 
 a Conditions: β-ketoester 4a (0.1 mmol), Pd2(dba)3 (5.0 mol %), 
ligand (12.5 mol %), toluene (3 mL). b Determined by analytical 
chiral SFC. 
 
1.4  EXPLORATION OF REACTION SCOPE 
 Subsequently, we explored the substrate scope of the enantioselective allylic 
alkylation of fluorine-containing 1,3-dicarbonyl compounds (Table 1.4.1).  We found that 
our reaction was tolerant of a variety of α-fluoro-, α-fluoroalkyl-, and α-fluoroallyl 
Pd2(dba)3 (5 mol %)
ligand (12.5 mol %)
solvent (0.033 M)









































(S)-t-BuPHOX, 6 (S)-(CF3)3-t-BuPHOX, 7
CF3
CF3
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substituents to deliver five- and six-membered ketone and lactam products bearing 
fluorinated tetrasubstituted stereocenters in high yields and enantioselectivities.  
Trifluoropropyl substituted 4b exhibited similar enantio-induction as 4a to furnish 5b in 
92% ee and an extremely high yield.  α-Fluoro tetrasubstituted compounds, which are 
usually introduced by direct fluorination with fluorine reagents and chiral catalysts,3 were 
prepared in a very efficient manner with high enantioselectivity (5c, 5d), even in the 
presence of a chloroallyl substituent (5d).  Surprisingly, 2-fluoroallyl groups survived the 
palladium-catalyzed allylic alkylation even at elevated temperatures (40 °C),13 albeit in a 
slightly decreased enantioselectivity (5e).  Recently, Shibata and coworkers described 
that enantioenriched indanone α-trifluoromethyl β-ketoesters lost their optical activity 
under the palladium-catalyzed allylic alkylation reaction conditions in the presence of 
achiral ligands to deliver a racemic α-quaternary ketone, and when they tried to render 
the transformation enantioselective, they were unsuccessful.6   However, we were pleased 
to see that α-trifluoromethyl substituted tetralone substrate 4f reacted to furnish 5f with a 
moderate level of enantioselectivity.   Generally, five membered cyclic β-ketoesters have 
performed worse than the corresponding 6-membered ring substrates, often providing the 
α-tetrasubstituted ketone products in comparatively low ee.4k Under these conditions, 
alkylation of the five membered indanone substrates 4g and 4h occurred with levels of 
enantioinduction similar to those observed for the tetralone substrates, with only a 
slightly diminished 87% ee for trifluoropropyl-substituted indanone 5h. Indanone 
substrates bearing a 2-fluoroallyl substituent proceeded in high yield, but only moderate 
enantioselectivity, to form products 5i and 5j, following the trend of the 2-fluoroallyl 
tetralone substrates. Gratifyingly, lactam substrates were also well tolerated in the 
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reaction.  Trifluoropropyl-substituted N-benzoyl δ-valero-lactam (5k) was obtained in 
94% yield, and 89% ee.  Surprisingly, in contrast to the negative influence of the 2-
fluoroallyl substituent on substrates 5e, 5i, and 5j, the fluorine on the allyl group of N-
benzoyl δ-valerolactam 4l enhanced the enantioselectivity, providing 5l in 97% ee.  
Additionally, trifluoropropyl-substituted N-benzyloxy glutarimide was furnished in 89% 
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Table 1.4.1. Substrate Scope of Fluorine-Containing compounds in Enantioselective 
Allylic Alkylation 
 
a Unless otherwise noted, all reported yields are isolated yields. 
Enantiomeric excess (ee) was determined by chiral SFC. Standard 
conditions: β-ketoester 5 (0.1 mmol), Pd2(dba)3 (5 mol %), (S)-
(CF3)3-t-BuPHOX (12.5 mol %), toluene (3 mL), 23 °C, 24 h. 
bReaction performed at 40 °C. cReaction performed in the 
presence of Pd2(pmdba)3 instead of Pd2(dba)3. dReaction 
performed at 60 °C. e Reaction performed at 23 °C for 70 h. 
 
1.5  CONCLUSIONS 
 In conclusion, we have developed a general method to construct fluorine-
containing tetrasubstitued stereocenters by enantioselective palladium-catalyzed 
decarboxylative allylic alkylation.  A strategy was adopted with the pre-introduction of 
fluorine on racemic substrates, which could be used as an orthogonal approach to the 
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demonstrated significant substitution tolerance to furnish a wide range of five- and six-
membered ketone and lactam products bearing fluorinated tetrasubstituted stereocenters 
in high yields and enantioselectivities.  Furthermore, we provide the first examples 
demonstrating that 2-fluoroallyl substituents can survive in the presence of certain 
palladium sources, and deliver related fluoroalkylated products in elevated enantiopurity. 
1.6  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
1.6.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed in flame-dried or oven-dried glassware 
under an argon or nitrogen atmosphere using dry, deoxygenated solvents (distilled or 
passed over a column of activated alumina).14  Commercially obtained reagents were used 
as received with the exception of dipalladium tris(dibenzylideneacetone) (Pd2(dba)3), 
tetrakis(triphenylphosphine)palladium(0), which were stored in a nitrogen-filled 
glovebox. Dipalladium tris(para-methoxydibenzylideneacetone) (Pd2(pmdba)3),15 (S)-t-
BuPHOX,16 (S)-(CF3)3-tBuPHOX,17 were prepared by known methods. Reactions 
requiring external heat were modulated to the specified temperatures using an IKAmag 
temperature controller. Reaction progress was monitored by thin-layer chromatography 
(TLC), which was performed using E. Merck silica gel 60 F254 precoated glass plates 
(0.25 mm) and visualized by UV fluorescence quenching, potassium permanganate, or p-
anisaldehyde staining. Silicycle SiliaFlash® P60 Academic Silica gel (particle size 40-63 
nm) was used for column chromatography. 1H and 13C NMR spectra were recorded on a 
Varian Inova 500 (500 MHz and 126 MHz, respectively), and a Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz 
and 101 MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 
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(δ 7.26 and δ 77.16, respectively). 19F NMR spectra were recorded on a Varian Inova 300 
spectrometer (282 MHz) and are reported in terms of absolute chemical shift according to 
IUPAC standard recommendations from CFCl3. Data for 1H NMR are reported as 
follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). 
Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, m = multiplet, br 
s = broad singlet, app t = apparently triplet. Infrared (IR) spectra were recorded on a 
Perkin Elmer Paragon 1000 spectrometer using thin films deposited on NaCl plates and 
are reported in frequency of absorption (cm–1). Optical rotations were measured with a 
Jasco P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100 mm 
path-length cell and are reported as: [α]DT (concentration in g/100 mL, solvent). 
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing Chiralpak (AD-H, AS-H, IC) or Chiralcel (OD-H, OJ-
H) columns (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. High 
resolution mass spectra were obtained from the Caltech Mass Spectral Facility using a 
JEOL JMS-600H. High Resolution Mass Spectrometer in fast atom bombardment 
(FAB+) ionization mode or a Agilent 6200 Series TOF with an Agilent G1978A 
Multimode source in electrospray ionization (ESI+), atmospheric pressure chemical 
ionization (APCI+), or mixed (ESI/APCI) ionization mode. Julabo Presto LH45 was used 
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1.6.2  EXPERIMENTAL PROCEDURES 
 
Allyl 1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
(4a): To a solution of 818 (780 mg, 3.39 mmol, 1.0 equiv) in THF (10 mL) was added 
LiHMDS (2M solution in THF, 4.0 mmol, 1.2 equiv) at 0 °C, the resulting solution was 
allowed to stir at room temperature for 15 min. Then the mixture was cooled again to 0 
°C, followed an addition of a THF solution (7 mL) of mesityl(2,2,2-trifluoroethyl)-λ3-
iodanyl trifluoromethanesulfonate19 (2.1 g, 4.4 mmol, 1.3 equiv). After 2 hours stirring at 
room temperature, the mixture was quenched with aqueous solution of NH4Cl, extracted 
with Et2O, dried over Na2SO4, filtered, and concentrated in vacuo. The crude oil was 
purified by column chromatography (SiO2, 5% EtOAc in hexane) to afford ketoester 4a 
(570 mg, 54% yield) as a white solid; Rf = 0.43 (10:1 Hexane:EtOAc); 1H NMR (500 
MHz, CDCl3) δ 8.06 (dd, J = 7.9, 1.4 Hz, 1H), 7.50 (app td, J = 7.5, 1.5 Hz, 1H), 7.33  
(app t, J = 7.7 Hz, 1H), 7.24 (d, J = 7.7 Hz, 1H), 5.82 – 5.74 (m, 1H), 5.20 – 5.13 (m, 
2H), 4.66 – 4.54 (m, 2H), 3.26 – 3.16 (m, 1H), 3.10 – 3.00 (m, 1H), 2.98 – 2.91 (m, 2H), 
2.74 (dt, J = 14.0, 4.3 Hz, 1H), 2.35 – 2.30 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
192.29, 169.54, 143.06, 134.14, 131.25, 131.05, 128.94, 128.54, 127.08, 126.02 (q, JC-F = 
278.5 Hz, 1C), 118.94, 66.58, 54.70 (q, JC-F = 1.8 Hz, 1C), 37.35 (q, JC-F = 29.3 Hz, 1C), 
29.74 (q, JC-F = 1.7 Hz, 1C), 25.83. 19F NMR (282 MHz, CDCl3) δ -59.46 (t, J = 11.1 Hz, 
3F).  IR (thin film, NaCl) 1737, 1693, 1601, 1260, 1134 cm -1. HRMS (APCI/ESI) m/z 
















Chapter 1:Palladium-Catalyzed Enantioselective Csp3–Csp3 Cross Coupling for the 




(4b): To a suspension of NaH (60% in oil, 72 mg, 1.8 mmol, 1.2 equiv) in THF (2 mL) 
was added a THF solution of 8 (345 mg, 1.5 mmol, 1.0 equiv), the mixture was allowed 
to stir at room temperature for 15 minutes followed the addition of 1,1,1-trifluoro-3-
iodopropane. The resulting mixture was allowed to heat at 60 °C for 24 hours. After 
cooling to room temperature, quenched with aqueous solution of NH4Cl, extracted with 
Et2O, dried over Na2SO4, filtered, and concentrated in vacuo. The crude oil was purified 
by column chromatography (SiO2, 10% Et2O in hexane) to afford ester 4b (148 mg, 30% 
yield) as a colorless oil; Rf = 0.43 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 
8.05 (dd, J = 7.9, 1.4 Hz, 1H), 7.49 (app td, J = 7.5, 1.5 Hz, 1H), 7.33 (dd, J = 7.9 Hz, 
1H), 7.23 (d, J = 7.6 Hz, 1H), 5.79 (ddt, J = 17.6, 10.1, 5.6 Hz, 1H), 5.26 – 5.09 (m, 2H), 
4.70 – 4.51 (m, 2H), 3.14 – 3.05 (m, 1H), 2.96 (dt, J = 17.4, 5.0 Hz, 1H), 2.59 (dt, J = 
13.6, 4.9 Hz, 1H), 2.47 – 2.30 (m, 1H), 2.28 – 2.06 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 194.82, 171.10, 142.74, 133.93, 131.89, 131.25, 128.89, 128.17, 127.13, 127.09 (q, JC-F 
= 277.4 Hz, 1C), 118.87, 66.08, 56.26, 31.62, 29.80 (q, JC-F = 29.1 Hz, 1C), 26.67 (q, JC-F 
= 3.2 Hz, 1C), 25.90. 19F NMR (282 MHz, CDCl3) δ -66.78 (t, J = 11.1 Hz, 3F).  IR (thin 
film, NaCl) 1735, 1670, 1602, 1258, 1228 cm-1. HRMS (APCI/ESI) m/z calc’d for 










THF (0.5 M), 60 °C, 24 h
CF3
4b8
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Allyl 2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (4c): The title 
compound 4c was synthesized according to the known method as describe. All 
spectroscopic data were in agreement with the literature.20 1H NMR (500 MHz, CDCl3) δ 
8.07 (d, J = 7.9 Hz, 1H), 7.55 (app td, J = 7.5, 1.4 Hz, 1H), 7.36 (m, 1H), 7.28 (d, J = 7.8 
Hz, 1H), 5.91 – 5.82 (m, 1H), 5.30 – 5.22 (m, 2H), 4.76 – 4.68 (m, 2H), 3.19 (dt, J = 
17.2, 5.2 Hz, 1H), 3.08 (ddd, J = 17.1, 7.8, 5.0 Hz, 1H), 2.79 – 2.70 (m, 1H), 2.60 – 2.52 
(m, 1H). 13C NMR (101 MHz, CDCl3) δ 188.51 (d, JC-F = 19.0 Hz, 1C), 167.05 (d, JC-F = 
25.9 Hz, 1C), 143.17, 134.66, 130.81, 130.47, 128.84, 128.37 (d, JC-F = 0.94 Hz, 1C), 
127.29, 119.12, 93.25 (d, JC-F = 194.2 Hz, 1C), 66.56, 31.87 (d, JC-F = 22.6 Hz, 1C), 24.83 




2-chloroallyl 2-fluoro-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (4d): 
To the mixture of 1,1-carbonyldiimidazole (CDI) (4.86 g, 30 mmol) and THF (15 mL) 
was added a solution of 2-chloro allyl alcohol (20 mmol) in 15 mL of CH2Cl2 at 0 °C 
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solvent was removed in vacuo and the crude product was purified by column 
chromatography (SiO2, 35% EtOAc in hexane) to afford 2-chloroallyloxycarbonyl 
imidazole (9) (3.2 g, 86% yield) as a white solid; Rf = 0.15 (3:1 Hexane:EtOAC); 1H 
NMR (500 MHz, CDCl3) δ 8.18 (m, 1H), 7.46 (m, 1H), 7.10 (dd, J = 1.6, 0.8 Hz, 1H), 
5.61 (dt, J = 2.1, 1.0 Hz, 1H), 5.55 (d, J = 2.0 Hz, 1H), 4.97 (dd, J = 1.1, 0.4 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 148.11, 137.27, 134.40, 131.05, 117.35, 117.24, 69.30. IR 
(thin film, NaCl) 3137, 3122, 1755, 1650, 892, 758 cm-1. HRMS (APCI/ESI) m/z calc’d 
for C7H8ClN2O2 [M+H]+: 187.0269, found: 187.0265. 
To a solution of Tetralone (585 mg, 4 mmol, 1.0 equiv) in THF (8 mL) was added 
LiHMDS (2M solution in THF, 4.4 mmol, 1.1 equiv) at -78 °C, the resulting solution was 
allowed to stir at the same temperature for 15 min. Then a THF solution (7 mL) of 2-
chloroallyloxycarbonyl imidazole (9) (896 mg, 4.8 mmol, 1.2 equiv) was added. After 2 
hours stirring at room temperature, the mixture was quenched with aqueous solution of 
NH4Cl, extracted with Et2O, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude oil was purified by column chromatography (SiO2, 5% EtOAc in hexane) to afford 
10 (718 mg, 67% yield) as a light yellow oil; Rf = 0.41 (10:1 Hexane:EtOAc); Mixture of 
enol ketone form (3/2).  1H NMR (500 MHz, CDCl3): for enol form:  δ 12.22 (s, 0.6H), 
7.81 (dd, J = 7.6, 1.4 Hz, 0.6H), 7.36 – 7.25 (m, 1.2H), 7.20 – 7.18 (m, 0.6H), 5.70 – 5.37 
(m, 1.2H), 4.77 – 4.72 (m, 1.2H), 2.85 (dd, J = 8.8, 6.7 Hz, 1.2H), 2.64 (dd, J = 8.8, 6.6 
Hz, 1.2H); for ketone form δ 8.05 (dd, J = 7.9, 1.4 Hz, 0.4H), 7.51 (app td, J = 7.5, 1.5 
Hz, 0.4H), 7.36 – 7.25 (m, 0.4H), 5.67 – 5.37 (m, 0.8H), 4.80 (s, 0.8H), 3.70 (dd, J = 
10.8, 4.7 Hz, 0.4H), 3.29 – 2.93 (m, 0.8H), 2.55 (dddd, J = 13.4, 10.9, 9.6, 5.0 Hz, 0.4H), 
2.48 – 2.36 (m, 0.4H). 13C NMR (101 MHz, CDCl3): for enol form: δ 169.44, 166.16, 
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139.61, 135.95, 130.94, 129.81, 128.95, 127.59, 126.73, 114.82, 96.44, 65.84, 27.78, 
26.47; for ketone form: 13C NMR (101 MHz, CDCl3) δ 192.86, 171.65, 143.67, 135.29, 
134.13, 131.71, 127.84, 127.07, 124.57, 115.07, 66.40, 54.60, 27.75, 20.50. IR (thin film, 
NaCl) 1750, 1686, 1651, 1617, 1597, 1569, 1266, 1212, 1132, 1085 cm-1. HRMS 
(APCI/ESI) m/z calc’d for C14H14ClO2 [M+H]+: 265.0626, found: 265.0627. 
Neat TiCl4 (10 μL, 0.09 mmol, 0.09 equiv) was added to a solution of 10  (265 mg, 1.0 
mmol, 1.0 equiv) in CH3CN (5 mL), resulting in an immediate color change from pale 
yellow to dark orange-brown. After 5 min, Selectfluor (425 mg, 1.2 mmol, 1.2 equiv) was 
added in one portion. The mixture was stirred vigorously at room temperature for 2 h, 
during which time the dark orange-brown color faded to yellow. The reaction was 
quenched by addition of H2O, extracted with Et2O, dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude oil was purified by column chromatography (SiO2, 10% 
EtOAc in hexane) to afford ester 4d (217 mg, 77% yield) as a colorless oil;7 Rf = 0.12 
(10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.08 (dd, J = 7.9, 1.4 Hz, 1H), 7.56 
(app td, J = 7.5, 1.4 Hz, 1H), 7.38 (app t, J = 7.8 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 5.49 – 
5.34 (m, 2H), 4.79 (dd, J = 13.7, 41.56 Hz, 2H), 3.22 (ddd, J = 17.2, 7.7, 5.7 Hz, 1H), 
3.11 (ddd, J = 17.2, 7.4, 5.0 Hz, 1H), 2.86 – 2.69 (m, 1H), 2.67 – 2.53 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 188.16 (d, JC-F = 18.5 Hz), 166.56 (d, JC-F = 26.8 Hz, 1C), 143.18, 
134.78, 134.35, 130.30, 128.88, 128.37 (d, JC-F = 1.2 Hz, 1C), 127.32, 115.82, 93.22 (d, 
JC-F = 194.0 Hz, 1C), 66.96, 31.79 (d, JC-F = 22.2 Hz, 1C), 24.67 (d, JC-F = 7.1 Hz, 1C). 19F 
NMR (282 MHz, CDCl3) δ -164.46 (dd, J = 23.7, 11.3 Hz, 1F). IR (thin film, NaCl) 
1764, 1701, 1600,1272, 1184, 1084 cm-1. HRMS (APCI/ESI) m/z calc’d for C14H13ClFO3 
[M+H]+: 283.0532, found: 283.0530. 
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2-fluoroallyl 2-methyl-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (4e): 
The procedure for preparation of 2-fluoroprop-2-en-1-ol was adapted from the work of 
Herzon and coworkers.21 
Solid aluminum chloride (1.0 g, 8.78 mmol, 1.0 equiv) was added portion-wise over 10 
min to a solution of lithium aluminum hydride (1.17 g, 26.3 mmol, 3.0 equiv) in Et2O (20 
mL) at 0 °C. The resulting mixture was stirred for 30 min at 0 °C. Methyl 2-
fluoroacrylate (820 μL, 8.78 mmol, 1.0 equiv) was then added dropwise via syringe to the 
mixture. The reaction mixture was stirred for 1 h at 0 °C at atmosphere of nitrogen. 
Distilled water (1.0 mL) and 15% aqueous sodium hydroxide solution (1.0 mL) were then 
added in sequence dropwise via syringe over 20 min (10 min addition of each reagent). A 
second portion of distilled water (3.0 mL) was then added dropwise via syringe over 5 
min. The resulting mixture was stirred for 10 min at 0 °C. The heterogeneous mixture 
was filtered through a Buchner funnel, and the filter cake was rinsed with Et2O (100 mL). 
The filtrates were combined and and dried over anhydrous MgSO4. The dried solution 
was filtered and the filtrate was concentrated (150 torr, 0 °C).  The product is very 
volatile; therefore Et2O was not completely removed. The solution of 2- fluoroallyl 
alcohol in Et2O was used directly and immediately in the following step. 
To the mixture of 1,1-carbonyldiimidazole (CDI)(1.3 g, 8 mmol) and CH2Cl2 (5 mL) was 
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resulting mixture was allowed to stir for 3 h at the same temperature. Most solvent was 
removed in vacuo and the crude product was purified by column chromatography (SiO2, 
50% EtOAc in hexane) to afford 2-flouroallyloxycarbonyl imidazole (11) (1.3 g, 86% 
yield over two steps) as a white solid; Rf = 0.43 (1:1 Hexane:EtOAC); 1H NMR (500 
MHz, CDCl3) δ 8.16 (m, 1H), 7.44 (dd, J = 2.8, 1.4 Hz, 1H), 7.09 (m, 1H), 4.96 (ddd, J = 
15.1, 3.5, 1.2 Hz, 1H), 4.92 (d, J = 15.5 Hz, 2H), 4.79 (dd, J = 46.2, 3.5 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 158.55 (d, JC-F = 258.7 Hz, 1C), 148.26, 137.29, 131.05, 
117.26, 96.83 (d, JC-F = 16.9 Hz, 1C), 64.73 (d, JC-F = 32.7 Hz, 1C).  19F NMR (282 MHz, 
CDCl3) δ -105.69 – -106.02 (m, 1F). IR (thin film, NaCl) 1766, 1682, 1408, 1384, 1316, 
1295, 1242, 1168, 997 cm-1. HRMS (APCI/ESI) m/z calc’d for C7H7FN2O2 [M+H]+: 
171.0564, found: 171.0564. 
To a solution of Tetralone (585 mg, 4 mmol, 1.0 equiv) in THF (8 mL) was added 
LiHMDS (2M solution in THF, 4.8 mmol, 1.2 equiv) at -78 °C, the resulting solution was 
allowed to stir at the same temperature for 15 min. Then a THF solution (7 mL) of 2-
fluoroallyloxycarbonyl imidazole (11) (817 mg, 4.8 mmol, 1.2 equiv) was added. After 2 
hours stirring at room temperature, the mixture was quenched with aqueous solution of 
NH4Cl, extracted with Et2O, dried over Na2SO4, filtered, and concentrated in vacuo. The 
crude oil was purified by column chromatography (SiO2, 10% Et2O in hexane) to afford 
12 (417 mg, 42% yield) as a light yellow oil; Rf = 0.43 (10:1 Hexane:EtOAc); Mixture of 
enol ketone form (3/2). 1H NMR (500 MHz, CDCl3): for enol form: δ 12.22 (s, 0.6H), 
7.86 – 7.76 (m, 0.6H), 7.42 – 7.27 (m, 1.2H), 7.22 – 7.15 (m, 0.6H), 4.86 (dd, J = 16.0, 
3.2 Hz, 0.6H), 4.79 – 4.69 (m, 1.8H), 2.90 – 2.78 (m, 1.2H), 2.69 – 2.57 (m, 1.2H); for 
ketone form: δ 8.09 – 8.00 (m, 0.4H), 7.51 (dd, J = 7.5, 1.5 Hz, 0.4H), 7.38 – 7.28 (m, 
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0.8H), 4.83 (dd, J = 16.3, 3.3 Hz, 0.4H), 4.74 – 4.64 (m, 1.2H), 3.69 (dd, J = 11.0, 4.7 
Hz, 0.4H), 3.13 – 2.99 (m, 0.8H), 2.57 – 2.49 (m, 0.4H), 2.44 – 2.36 (m, 0.4H). 13C NMR 
(101 MHz, CDCl3): for enol form δ 169.69, 166.15, 160.39 (d, JC-F = 257.9 Hz, 0.6C), 
139.69, 130.97, 129.87, 128.97, 127.63, 124.62, 96.51, 94.56 (d, JC-F = 17.1 Hz, 0.6C), 
61.31 (d, JC-F = 34.4 Hz, 0.6C), 27.84, 26.48; for ketone form: δ 192.88, 171.88, 159.94 
(d, JC-F = 257.9 Hz, 0.4C), 143.70, 134.17, 131.75, 127.93, 127.13, 126.77, 94.63 (d, JC-F 
= 16.8 Hz, 0.4C), 61.89 (d, J = 34.8 Hz, 0.4C), 54.66, 27.84, 20.55. 19F NMR (282 MHz, 
CDCl3) δ -105.33 – -105.98 (m, 1F).  IR (thin film, NaCl) 1749, 1686, 1651, 1617, 1598, 
1569, 1263, 1210, 1198, 1132, 1085 cm-1. HRMS (APCI/ESI) m/z calc’d for C14H14FO3 
[M+H]+: 249.0921, found: 249.0923. 
The mixture of 12 (451 mg, 1.81 mmol, 1.0 equiv), cesium carbonate (1.29 g, 3.92 mmol, 
2.0 equiv) and MeI (244 mL, 3.92 mmol, 2.0 equiv) in CH3CN was heated at 50 °C for 12 
hours. After cooling, the solution was filtered and concentrated in vacuo. The crude 
product was purified by column chromatography (SiO2, 10% Et2O in hexane) to furnish 
β-ketoester 4e (370 mg, 78% yield) as a colorless oil; Rf = 0.28 (10:1 Hexane:EtOAC); 
1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 7.8, 1.4 Hz, 1H), 7.48 (app td, J = 7.5, 1.5 
Hz, 1H), 7.32 (app t, J = 7.8 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 4.72 (dd, J = 16.1, 3.3 Hz, 
1H), 4.69 – 4.54 (m, 2H), 4.48 (dd, J = 3.3, 47.7 Hz, 1H), 3.06 (ddd, J = 17.4, 9.3, 4.9 
Hz, 1H), 2.97 (dt, J = 17.3, 5.5 Hz, 1H), 2.70 (ddd, J = 13.6, 6.2, 4.8 Hz, 1H), 2.15 (ddd, 
J = 13.9, 9.2, 4.9 Hz, 1H), 1.54 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 195.79, 172.35, 
159.79 (d, JC-F = 258.7 Hz, 1C), 143.16, 133.76, 131.59, 128.90, 128.22, 127.02, 94.15 
(d, JC-F = 16.5 Hz, 1C), 61.72 (d, JC-F = 35.2 Hz, 1C), 54.07, 33.81, 25.95, 20.47. 19F 
NMR (282 MHz, CDCl3) δ -106.01 – -106.32 (m, 1F). IR (thin film, NaCl) 1738, 1682, 
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allyl 1-oxo-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (4f): 
The procedure for preparation of 4f was adapted from the work of Shibata and 
coworkers.22 
To a stirred solution of methyl 1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate23 (224 
mg, 1.1 mmol, 1.0 equiv) in CH3CN (11 mL) was added DBU (328 mL, 2.2 mmol, 2.0 
equiv) at room temperature. After stirring at room temperature for 15 min, the mixture 
was cooled down to 0 °C and a solution of the trifluoromethylating reagent (561 mg, 1.65 
mmol, 1.5 equiv.) in acetonitrile (11 mL) was added dropwise at the same temperature. 
Reaction mixture was stirred 10 min, and then warmed up to room temperature, the 
solvent was evaporated, after which the crude product was purified by column 
chromatography (SiO2, 10% EtOAc in pentane) to furnish α-trifluoromethyl-β-ketoester 
13 (281mg, 94% yield) as a colorless oil; Rf = 0.18 (10:1 Hexane:EtOAc).  
To a stirred solution of 13 (281mg, 1.03 mmol, 1.0 equiv) in allyl alcohol (30.0 equiv.) 
was added Ti(OiPr)4 (2.0 equiv) at 80 °C under nitrogen atmosphere. After reaction 
mixture was stirred at the same temperature for 24 h, it was cooled down to room 
temperature and quenched with aqueous solution of NH4Cl. Aqueous layer was extracted 
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over Na2SO4, filtered, and concentrated in vacuo. The crude oil was purified by column 
chromatography (SiO2, 10% EtOAc in hexane) to afford 4f (242 mg, 74% yield) as a light 
yellow oil; Rf = 0.50 (5:1 Hexane:EtOAc); All spectroscopic data were in agreement with 
the literature.9 1H NMR (500 MHz, CDCl3) δ 8.12 (dd, J = 7.8, 1.4 Hz, 1H), 7.53 (app td, 
J = 7.5, 1.4 Hz, 1H), 7.38 –7.32 (m, 1H), 7.24 (d, J = 7.8 Hz, 1H), 5.92 – 5.67 (m, 1H), 
5.32 – 5.07 (m, 2H), 4.84 – 4.56 (m, 2H), 3.22 – 2.97 (m, 2H), 2.85 (dt, J = 13.6, 4.2 Hz, 
1H), 2.50 (ddd, J = 13.6, 10.3, 6.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 187.09, 
165.11 (q, JC-F = 1.9 Hz, 1C), 142.14, 134.44, 131.62 (q, JC-F = 1.5 Hz, 1C), 130.53, 
128.82, 128.54, 127.44, 123.95 (q, JC-F = 284.0 Hz, 1C), 119.28, 67.09, 62.15 (q, JC-F = 




Allyl 1-oxo-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-indene-2-carboxylate (4g): was 
synthesized using the same method with 4a from allyl 1-oxo-2,3-dihydro-1H-indene-2-
carboxylate (14).24 The crude oil was purified by column chromatography (SiO2, 50% 
CH2Cl2 in hexane) to afford 4g (110 mg, 37% yield) as a light yellow oil; Rf = 0.38 (1:1 
Hexane:CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.78 (dd, J = 7.7, 0.9 Hz, 1H), 7.66 (app 
td, J = 7.5, 1.2 Hz, 1H), 7.53 (app dt, J = 7.7, 1.0 Hz, 1H), 7.42 (app td, J = 7.9, 0.9 Hz, 
1H), 5.81 (ddt, J = 17.2, 10.5, 5.6 Hz, 1H), 5.39 – 5.15 (m, 2H), 4.64 – 4.53 (m, 2H), 3.88 
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(101 MHz, CDCl3) δ 199.24, 168.43, 153.15, 136.10, 133.83, 131.18, 128.20, 126.50, 
126.10 (q, JC-F = 277.7 Hz, 1C), 125.32, 118.86, 66.91, 57.37 (q, JC-F = 1.9 Hz, 1C), 37.62 
(q, JC-F = 29.1 Hz, 1C), 35.34 (q, JC-F = 1.7 Hz 1C). 19F NMR (282 MHz, CDCl3) -60.61 
(t, J = 10.5 Hz, 3F).  IR (thin film, NaCl) 1745, 1719, 1608, 1257, 1169 cm-1. HRMS 
(APCI/ESI) m/z calc’d for C15H14F3O3 [M+H]+: 299.0890, found: 299.0898. 
 
 
Allyl 1-oxo-2-(3,3,3-trifluoropropyl)-2,3-dihydro-1H-indene-2-carboxylate (4h): The 
mixture of allyl 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (14) (216 mg, 1.0 mmol, 1.0 
equiv), Cesium carbonate (652 mg, 2.0 mmol, 2.0 equiv) and 1,1,1-trifluoro-3-
iodopropane (447 mL, 2.0 mmol, 2.0 equiv) in CH3CN (5 mL) was heated at 50 °C for 48 
hours. After cooling, the solution was filtered and concentrated in vacuo. The crude 
product was purified by column chromatography (SiO2, 50% CH2Cl2 in hexane) to furnish 
β-ketoester 4h (98 mg, 31% yield) as a colorless oil; Rf = 0.37 (1:1 Hexane:CH2Cl2); 1H 
NMR (500 MHz, CDCl3) δ 7.80 (ddd, J = 7.7, 1.3, 0.8 Hz, 1H), 7.66 (app td, J = 7.5, 1.2 
Hz, 1H), 7.50 (app dt, J = 7.7, 0.9 Hz, 1H), 7.44 (ddd, J = 7.9, 7.2, 0.9 Hz, 1H), 5.83 (ddt, 
J = 17.1, 10.4, 5.6 Hz, 1H), 5.34 – 5.14 (m, 2H), 4.69 – 4.54 (m, 2H), 3.73 (d, J = 17.2 
Hz, 1H), 3.06 (d, J = 17.2 Hz, 1H), 2.39 – 2.24 (m, 2H), 2.22 – 2.06 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 201.52, 170.28, 152.45, 135.93, 134.96, 131.37, 128.34, 126.89 (q, 
JC-F = 275.9 Hz, 1C), 126.58, 125.20, 118.83, 66.36, 58.81, 37.62, 29.70 (q, JC-F = 29.2 
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Hz, 3F).  IR (thin film, NaCl) 1741, 1711, 1255, 1141 cm-1. HRMS (APCI/ESI) m/z 
calc’d for C16H16F3O3 [M+H]+: 313.1046, found: 313.1040. 
 
 
2-Fluoroallyl 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (15): was synthesized using 
the same method with 11 from 1-Indanone and 14. The crude oil was purified by column 
chromatography (SiO2, 20% Et2O in hexane) to afford 15 (515 mg, 73% yield) as a 
colorless oil; Rf = 0.28 (10:1 Hexane: EtOAc); Mixture of enol ketone form (1/4). 1H 
NMR (300 MHz, CDCl3): ketone form δ 7.82 – 7.74 (m, 0.8H), 7.69 – 7.59 (m, 0.8H), 
7.56 – 7.47 (m, 0.8H), 7.47 – 7.36 (m, 0.8H), 4.95 – 4.57 (m, 3.2H), 3.79 (dd, J = 8.3, 4.2 
Hz, 0.8H), 3.70 – 3.51 (m, 0.8H), 3.49 – 3.30 (m, 0.8H). 13C NMR (101 MHz, CDCl3): 
ketone form δ 199.00, 168.60, 159.81 (d, JC-F = 257.5 Hz, 0.8C), 153.54, 135.70, 135.23, 
128.06, 126.70, 124.92, 94.69 (d, JC-F = 16.6 Hz, 0.8C), 62.20 (d, JC-F = 35.1 Hz, 0.8C), 
53.16, 30.38. 19F NMR (282 MHz, CDCl3) δ -105.40 – -105.71 (m, 0.2F), -105.72 – -
106.08 (m, 0.8F).  IR (thin film, NaCl) 1745, 1713, 1685, 1204, 1150, 761 cm-1; HRMS 
(APCI/ESI) m/z calc’d for C13H10FO3 [M-H]–: 233.0619, found: 233.0618. 
2-Fluoroallyl 2-fluoro-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4i): was 
synthesized using the same method with 4d from 15. The crude oil was purified by 
column chromatography (SiO2, 10% EtOAc in hexane) to afford 4i (176 mg, 70% yield) 
as a pale solid; Rf  = 0.28 (10:1 Hexane:EtOAc);  1H NMR (500 MHz, CDCl3) δ 7.85 (dd, 
J = 7.7, 0.7 Hz, 1H), 7.72 (app td, J = 7.5, 1.2 Hz, 1H), 7.55 – 7.43 (m, 2H), 4.85 – 4.64 
(m, 3H), 4.60 (dd, J = 47.0, 3.5 Hz, 1H), 3.82 (dd, J = 17.7, 11.7 Hz, 1H), 3.48 (dd, J = 
TiCl4 (0.09 eq.)
select-fluor (1.2 eq.)
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23.3, 17.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 194.81 (d, J C-F = 18.2 Hz, 1C), 166.79 
(d, J C-F = 28.5 Hz, 1C), 158.91 (d, JC-F = 257.6 Hz, 1C), 150.85 (d, J C-F = 3.4 Hz, 1C), 
137.02, 133.20, 128.88, 126.76 (d, JC-F = 1.3 Hz, 1C), 125.87 (d, JC-F = 1.1 Hz, 1C), 95.41 
(d, J = 16.6 Hz, 1C), 94.57 (d, JC-F = 202.0 Hz, 1C), 62.67 (d, JC-F = 34.7 Hz, 1C), 38.33 
(d, JC-F = 23.8 Hz, 1C). 19F NMR (282 MHz, CDCl3) δ -106.19 – -106.51 (m, 1F), -
164.54 (dd, J = 23.3, 11.9 H, 1F).  IR (thin film, NaCl) 1771, 1724, 1600, 1282, 1184, 




2-Fluoroallyl 2-methyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4j): was 
synthesized using the same method with 4e from 15. The crude oil was purified by 
column chromatography (SiO2, 100% CH2Cl2) to afford 4j (170 mg, 69% yield) as a 
colorless oil; Rf = 0.34 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.80 (dd, J 
= 7.7, 0.5 Hz, 1H), 7.64 (app td, J = 7.5, 1.2 Hz, 1H), 7.49 (app dt, J = 7.7, 1.0 Hz, 1H), 
7.45 – 7.40 (m, 1H), 4.75 (dd, J = 16.1, 3.3 Hz, 1H), 4.70 – 4.47 (m, 3H), 3.74 (dd, J = 
17.1, 0.9 Hz, 1H), 3.04 (dq, J = 17.0, 0.7 Hz, 1H), 1.55 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 203.01, 171.38, 159.77 (d, JC-F = 257.4 Hz, 1C), 152.58, 135.62, 134.61, 
128.07, 126.63, 125.18, 94.21 (d, JC-F = 16.6 Hz, 1C), 61.90 (d, JC-F = 35.4 Hz, 1C), 
56.08, 40.04, 21.13.  19F NMR (282 MHz, CDCl3) δ -106.09 – -106.41 (m, 1F). IR (thin 
film, NaCl) 1748, 1712, 1606, 1280, 1156, 1091 cm-1; HRMS (APCI/ESI) m/z calc’d for 
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Allyl 1-benzoyl-2-oxo-3-(3,3,3-trifluoropropyl)piperidine-3-carboxylate (4k): was 
synthesized using the same method as 4b from allyl 1-benzoyl-2-oxopiperidine-3-
carboxylate (16) 12. The crude oil was purified by column chromatography (SiO2, 100% 
CH2Cl2) to afford 4k (142 mg, 37% yield) as a colorless oil; Rf = 0.54 (3:1 
Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.70 (m, 2H), 7.52 – 7.48 (m, 
1H), 7.41 – 7.38 (m, 2H), 5.99 (ddt, J = 17.2, 10.4, 6.1 Hz, 1H), 5.43 (dq, J = 17.1, 1.4 
Hz, 1H), 5.37 (dq, J = 10.4, 1.1 Hz, 1H), 4.76 (dq, J = 6.1, 1.1 Hz, 2H), 3.87 – 3.25 (m, 
2H), 2.52 – 2.40 (m, 1H), 2.42 – 2.28 (m, 1H), 2.18 – 1.99 (m, 5H), 1.87 (ddd, J = 13.7, 
9.6, 5.9 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 174.99, 171.51, 171.21, 135.65, 132.12, 
131.09, 128.31 (2C), 128.22 (2C), 126.89 (q, JC-F = 276.4 Hz, 1C), 120.47, 67.02, 55.42, 
46.71, 31.71, 29.97 (q, JC-F = 29.0 Hz), 28.41 (q, JC-F = 3.3 Hz, 1C), 20.24. 19F NMR (282 
MHz, CDCl3) δ -66.79 (t, J = 10.1 Hz, 3F). IR (thin film, NaCl) 1735, 1685, 1451, 1393, 
1276, 1256, 1147 cm-1. HRMS (APCI/ESI) m/z calc’d for C19H21F3NO4 [M+H]+: 
384.1417, found: 384.1414. 
 
 
2-Fluoroallyl 1-benzoyl-2-oxopiperidine-3-carboxylate (17): was synthesized using the 
same method as 10 from 1-benzoylpiperidin-2-one and 9. The crude oil was purified by 
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colorless oil; Rf = 0.37 (3:1 Hexane: EtOAc); 93% purity, ketone form. 1H NMR (500 
MHz, CDCl3) δ 7.73 – 7.64 (m, 2H), 7.52 – 7.46 (m, 1H), 7.42 – 7.36 (m, 2H), 4.87 (ddd, 
J = 15.6, 3.4, 0.6 Hz, 1H), 4.78 – 4.64 (m, 3H), 3.95 – 3.78 (m, 2H), 3.64 (t, J = 6.6 Hz, 
1H), 2.39 – 2.32 (m, 1H), 2.26 – 2.18 (m, 1H), 2.14 – 2.06 (m, 1H), 2.03 – 1.93 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 174.60, 169.34, 169.05, 159.56 (d, JC-F = 258.1 Hz, 1C), 
135.46, 132.06, 128.33 (2C), 128.29 (2C), 95.53 (d, JC-F = 16.9 Hz, 1C), 62.51 (d, JC-F = 
33.1 Hz, 1C), 51.03, 46.40, 25.59, 20.75.  19F NMR (282 MHz, CDCl3) δ -105.57 (dq, J = 
46.2, 15.1 Hz, 1F). IR (thin film, NaCl) 1744, 1682, 1449, 1394, 1283, 1257, 1151, 1114 
cm-1. HRMS (APCI/ESI) m/z calc’d for C16H17FNO4 [M+H]+: 306.1136, found: 
306.1131. 
2-Fluoroallyl 1-benzoyl-3-methyl-2-oxopiperidine-3-carboxylate (4l): was synthesized 
using the same method as 4e from 17. The crude oil was purified by column 
chromatography (SiO2, 100% CH2Cl2) to afford 4l (186 mg, 56% yield) as light yellow 
oil; Rf = 0.30 (3:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.66 (m, 2H), 
7.52 – 7.45 (m, 1H), 7.41 – 7.35 (m, 2H), 4.90 (dd, J = 15.5, 3.4 Hz, 1H), 4.82 – 4.63 (m, 
3H), 3.89 (dt, J = 12.8, 7.1 Hz, 1H), 3.83 – 3.76 (m, 1H), 2.68 – 2.43 (m, 1H), 2.12 – 1.96 
(m, 2H), 1.91 – 1.80 (m, 1H), 1.52 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 175.06, 
172.57, 172.32, 159.58 (d, JC-F = 258.4 Hz, 1C), 135.91, 131.84, 128.22 (2C), 128.06 
(2C), 95.76 (d, JC-F = 17.0 Hz, 1C), 62.63 (d, JC-F = 32.5 Hz, 1C), 52.99, 46.91, 33.87, 
22.58, 20.25. 19F NMR (282 MHz, CDCl3) δ-105.20 – -105.53 (m, 1F). IR (thin film, 
NaCl) 1718, 1684, 1458, 1390, 1276, 1189, 1127 cm-1; HRMS (APCI/ESI) m/z calc’d for 
C17H19FNO4 [M+H]+: 320.1293, found: 320.1298. 
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(4m): was synthesized using the same method with 4h from allyl 1-(benzyloxy)-2,6-
dioxopiperidine-3-carboxylate (18)25 except that the temperature was 70 °C and reaction 
time was 24 hours. The crude oil was purified by column chromatography (SiO2, 50% 
EtOAc in hexane) to afford 4m (120 mg, 30% yield) as a colorless oil; Rf = 0.28 (3:1 
Hexane: EtOAc); (99.7% purity determined by 19F NMR). 1H NMR (500 MHz, CDCl3) δ 
7.53 – 7.49 (m, 2H), 7.40 – 7.34 (m, 3H), 5.87 (ddt, J = 16.5, 10.3, 6.0 Hz, 1H), 5.36 (dq, 
J = 17.2, 1.4 Hz, 1H), 5.32 (dq, J = 10.4, 1.1 Hz, 1H), 5.02 (s, 2H), 4.69 (d, J = 6.1 Hz, 
2H), 2.81 (ddd, J = 18.1, 5.0, 3.3 Hz, 1H), 2.69 (ddd, J = 18.0, 12.6, 5.3 Hz, 1H), 2.49 – 
2.30 (m, 1H), 2.29 – 1.98 (m, 4H), 1.90 (td, J = 13.2, 5.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 169.37, 166.85, 166.65, 133.69, 130.52, 130.24 (2C), 129.44, 128.60 (2C), 
126.64 (q, JC-F = 276.4 Hz, 1C), 120.74, 77.98, 67.29, 54.56, 30.21, 29.58 (q, JC-F = 29.5 
Hz, 1C), 27.82 (q, J C-F = 3.3 Hz, 1C), 26.30. 19F NMR (282 MHz, CDCl3) δ -66.78 (t, J = 
10.1 Hz, 3F). IR (thin film, NaCl) 1738, 1710, 1454, 1258, 1189, 1160, 1000, 977 cm-1. 
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Allyl 1-benzoyl-2-oxo-3-(3,3,3-trifluoropropyl)pyrrolidine-3-carboxylate (4n): was 
synthesized using the same method with 4h from allyl 1-benzoyl-2-oxopyrrolidine-3-
carboxylate (19).26 The crude oil was purified by column chromatography (SiO2, 25% 
EtOAc in hexane) to afford 4n (170 mg, 46% yield) as a colorless oil; Rf = 0.50 (3:1 
Hexane: EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.62 – 7.59 (m, 2H), 7.57 – 7.52 (m, 
1H), 7.44 – 7.39 (m, 2H), 5.92 (ddt, J = 17.1, 10.3, 5.8 Hz, 1H), 5.37 (dq, J = 17.1, 1.4 
Hz, 1H), 5.32 (dq, J = 10.4, 1.2 Hz, 1H), 4.71 (dt, J = 5.8, 1.3 Hz, 2H), 4.08 (ddd, J = 
11.4, 8.7, 3.6 Hz, 1H), 3.96 (ddd, J = 11.4, 8.2, 7.7 Hz, 1H), 2.63 (ddd, J = 13.3, 7.7, 3.7 
Hz, 1H), 2.54 – 2.36 (m, 1H), 2.28 – 1.97 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 
171.49, 170.34, 169.63, 133.73, 132.44, 130.95, 128.94 (2C), 128.05 (2C), 126.74 (q, JC-F 
= 276.0 Hz, 1C), 119.86, 66.89, 56.37, 43.49, 29.41 (q, JC-F = 29.4 Hz, 1C), 28.62, 26.64 
(q, JC-F = 3.4 Hz, 1C).  19F NMR (282 MHz, CDCl3) δ -66.79 (t, J = 9.9 Hz, 3F). IR (thin 
film, NaCl) 1748, 1731, 1682, 1449, 1293, 1253, 1218, 1131 cm-1. HRMS (APCI/ESI) 
m/z calc’d for C18H19F3NO4 [M+H]+: 370.1261, found: 370.1254. 
 
Representative Procedure 1: Enantioselective Allylic Alkylation. 
Oven-dried half-dram vials were charged with the palladium source (Pd2dba3 or 
Pd2pmdba3, 0.005 mmol, 0.05 equiv) and  (S)-(CF3)3-tBu-PHOX (7.4 mg, 0.0125 mmol, 
0.125 equiv) and toluene (2 mL) in a nitrogen-filled glovebox. After stirring at ambient 
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equiv) in 1 mL of toluene were added. The reaction vials were tightly capped and 
removed from the glovebox. After 24 hours at ambient temperature or heating at the 
desired temperatures, the solvent was removed by vacuo. The crude mixture were 
separated on the preparative thin layer plate, filtered, washed with Et2O, removed solvent 
and analyzed for enantiomeric excess and optical rotations (see Methods for the 
Determination of Enantiomeric Excess).  
Representative Procedure 2: Racemic Allylic Alkylation. 
Oven-dried half-dram vials were charged with the Pd(PPh3)4 (0.1 equiv) and substrate 
(1.0 equiv) and toluene (0.1 M) in a nitrogen-filled glovebox. The reaction vials were 
tightly capped and removed from the glovebox. After 24 hours at ambient temperature or 
heating at the desired temperatures, the solvent was removed by vacuo. The crude 
mixture were separated on the preparative thin layer plate, filtered, washed with Et2O, 
removed solvent to give the desired racemic products. 
Representative Procedure 3: Racemic Allylic Alkylation. 
Oven-dried half-dram vials were charged with the palladium source (Pd2dba3 or 
Pd2pmdba3, 0.05 equiv) and Gly-PHOX (0.125 equiv) and toluene (0.1 M) in nitrogen-
filled glovebox. After stirring at ambient glovebox temperature (~28 °C) for 30 min, 
solutions of the substrates (1.0 equiv) in toluene were added. The reaction vials were 
tightly capped and removed from the glovebox. After 24 hours at ambient temperature or 
heating at the desired temperatures, the solvent was removed by vacuo. The crude 
mixture was separated on the preparative thin layer plate, filtered, and washed with Et2O, 
and the solvent removed to give desired racemic products. 
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Representative Procedure 4: Preparatory Scale Reaction. 
An oven-dried 250 mL Schlenck flask was charged with Pd2dba3 (94 mg, 0.103 mmol, 
0.05 equiv) and  (S)-(CF3)3-t-Bu-PHOX (152 mg, 0.26 mmol, 0.125 equiv) and toluene 
(12 mL) in a nitrogen-filled glovebox. After stirring at ambient glovebox temperature 
(~28 °C) for 30 min, a solution of 4c (512 mg, 2.06 mmol, 1.0 equiv) in 50 mL of toluene 
was added. The reaction vessel was sealed and removed from the glovebox. After 24 
hours at ambient temperature the solvent was removed in vacuo. The product was 
purified by column chromatography (SiO2,  5% EtOAc in hexanes) to afford 5c (419 mg, 
99% yield, 92% ee). 
 
 
(S)-2-allyl-2-(2,2,2-trifluoroethyl)-3,4-dihydronaphthalen-1(2H)-one (5a): 26.5 mg, 
99% yield; colorless oil; Rf = 0.47 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 
8.07 (dd, J = 7.9, 1.4 Hz, 1H), 7.50 (app td, J = 7.5, 1.5 Hz, 1H), 7.33 (app t, J = 7.6 Hz, 
1H), 7.24 (d, J = 7.8 Hz, 1H), 5.72 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.19 (d, J = 10.1 Hz, 
1H), 5.12 (dd, J = 16.9, 1.6 Hz, 1H), 3.14 (ddd, J = 16.9, 11.6, 4.9 Hz, 1H), 3.00 – 2.82 
(m, 2H), 2.49 (dd, J = 14.3, 7.4 Hz, 1H), 2.41 – 2.24 (m, 3H), 2.17 (dt, J = 14.0, 4.4 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 198.27, 142.73, 133.72, 132.15, 130.92, 128.88, 
128.58, 127.08, 126.79 (q, JC-F = 277.8 Hz, 1C), 120.17, 45.95, 38.58, 37.54 (d, JC-F = 
28.8 Hz, 1C), 29.60 (q, JC-F = 1.7 Hz, 1C), 24.88. 19F NMR (282 MHz, CDCl3) δ -58.69 
(t, J = 11.7 Hz, 3F). IR (thin film, NaCl) 1683, 1600, 1256, 1130, 740 cm-1. HRMS 
(FAB) m/z calc’d for C15H16F3O [M+H]+: 269.1148, found: 269.1159. 
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(R)-2-allyl-2-(3,3,3-trifluoropropyl)-3,4-dihydronaphthalen-1(2H)-one (5b): 27.4 mg, 
97% yield; colorless oil; Rf = 0.50 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 
8.04 (ddd, J = 7.9, 1.4, 0.5 Hz, 1H), 7.49 (app td, J = 7.5, 1.5 Hz, 1H), 7.32 (app t, J = 7.6 
Hz, 1H), 7.24 (d, J = 7.5 Hz, 1H), 5.75 (ddt, J = 16.8, 10.2, 7.4 Hz, 1H), 5.23 – 5.04 (m, 
2H), 3.07 (ddd, J = 17.5, 7.9, 5.6 Hz, 1H), 2.99 (dt, J = 17.5, 6.0 Hz, 1H), 2.45 (ddt, J = 
14.2, 7.3, 1.2 Hz, 1H), 2.33 (ddt, J = 14.1, 7.4, 1.2 Hz, 1H), 2.24 – 2.01 (m, 4H), 1.97 (td, 
J = 13.7, 4.4 Hz, 1H), 1.79 (td, J = 13.5, 4.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
200.39, 142.94, 133.64, 132.82, 131.53, 128.91, 128.23, 127.42 (q, JC-F = 276.9 Hz, 1C), 
127.02, 119.27, 46.63, 38.72, 31.04, 28.93 (q, JC-F = 28.8 Hz, 1C), 26.54 (q, JC-F = 3.3 Hz, 
1C), 24.99. 19F NMR (282 MHz, CDCl3) δ -66.62 (t, J = 10.4 Hz, 3F). IR (thin film, 
NaCl) 1682, 1601, 1259, 1136, 743 cm-1. HRMS (APCI/ESI) m/z calc’d for C16H18F3O 
[M+H]+: 283.1304, found: 283.1305.  
 
(R)-2-allyl-2-fluoro-3,4-dihydronaphthalen-1(2H)-one (5c)27, 28: 20.3 mg, 99% yield; 
colorless oil; Rf = 0.28 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J 
= 7.8, 1.4 Hz, 1H), 7.52 (app td, J = 7.5, 1.5 Hz, 1H), 7.35 (app td, J = 7.5, 1.1 Hz, 1H), 
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(ddd, J = 17.3, 9.6, 5.3 Hz, 1H), 2.77 – 2.66 (m, 1H), 2.64 – 2.49 (m, 1H), 2.48 – 2.26 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 194.12 (d, JC-F = 17.6 Hz, 1C), 142.82, 134.20, 
130.97 (d, JC-F = 4.1 Hz, 1C), 128.87, 128.40, 128.39, 127.23, 120.01, 95.11 (d, JC-F = 
185.0 Hz, 1C), 38.09 (d, JC-F = 23.5 Hz, 1C), 32.01 (d, JC-F = 22.6 Hz, 1C), 26.01 (d, JC-F 
= 10.1 Hz, 1C). 19F NMR (282 MHz, CDCl3) δ -159.85 – -160.09 (m, 1F). IR (thin film, 
NaCl) 1678, 1602, 1221, 930, 741 cm-1. HRMS (APCI/ESI) m/z calc’d for C13H14FO 
[M+H]+: 205.1023, found: 205.1023.  
 
 
(R)-2-(2-chloroallyl)-2-fluoro-3,4-dihydronaphthalen-1(2H)-one (5d): 22.9 mg, 96% 
yield; colorless oil; Rf = 0.43 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.06 
(dd, J = 7.8, 1.3 Hz, 1H), 7.54 (app td, J = 7.5, 1.5 Hz, 1H), 7.36  (app t, J = 7.8 Hz, 1H), 
7.28 (d, J = 7.8 Hz, 1H), 5.45 (d, J = 1.2 Hz, 1H), 5.39 (d, J = 0.7 Hz, 1H), 3.24 – 3.01 
(m, 3H), 2.90 (dd, J = 27.4, 15.3 Hz, 1H), 2.60 – 2.42 (m, 2H).  13C NMR (101 MHz, 
CDCl3) δ 192.92 (d, JC-F = 18.5 Hz, 1C), 142.94, 134.78 (d, JC-F = 2.6 Hz, 1C), 134.41, 
130.74, 128.88, 128.60 (d, JC-F = 1.2 Hz, 1C), 127.31, 118.62 (d, JC-F = 1.1 Hz, 1C), 94.03 
(d, JC-F = 185.8 Hz, 1C), 42.67 (d, JC-F = 24.4 Hz, 1C), 31.69 (d, JC-F = 22.3 Hz, 1C), 
26.00 (d, JC-F = 9.9 Hz, 1C). 19F NMR (282 MHz, CDCl3) δ -158.17 – -158.43 (m, 1F).  
IR (thin film, NaCl) 1680, 1631, 1602, 1223, 743 cm-1. HRMS (APCI/ESI) m/z calc’d for 
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(S)-2-(2-fluoroallyl)-2-methyl-3,4-dihydronaphthalen-1(2H)-one (5e): 20.0 mg, 92% 
yield; colorless oil; Rf = 0.53 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.04 
(dd, J = 7.9, 1.4 Hz, 1H), 7.47 (app td, J = 7.4, 1.5 Hz, 1H), 7.31 (app t, J = 7.5 Hz, 1H), 
7.23 (d, J = 7.7 Hz, 1H), 4.64 (dd, J = 17.2, 2.6 Hz, 1H), 4.32 (dd, J = 49.5, 2.6 Hz, 1H), 
3.09 – 2.94 (m, 2H), 2.66 (dd, J = 20.5, 14.6 Hz, 1H), 2.50 (dd, J = 25.1, 14.6 Hz, 1H), 
2.17 (dddd, J = 14.4, 9.1, 5.2, 1.3 Hz, 1H), 2.04 (dddd, J = 13.8, 6.0, 5.0, 1.1 Hz, 1H), 
1.26 (d, J = 0.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 201.14, 164.07 (d, JC-F = 157.8 
Hz, 1C), 143.28, 133.41, 131.34, 128.81, 128.28, 126.86, 93.85 (d, JC-F = 20.2 Hz, 1C), 
44.26 (d, JC-F = 3.3 Hz, 1C), 39.39 (d, JC-F = 25.7 Hz, 1C), 33.30 (d, JC-F = 1.8 Hz, 1C), 
25.48, 21.94 (d, JC-F = 1.5 Hz, 1C).  19F NMR (282 MHz, CDCl3) δ -88.59 – -88.99 (m, 
1F). IR (thin film, NaCl) 1680, 1601, 1222, 741 cm-1. HRMS (APCI/ESI) m/z calc’d for 
C14H16FO [M+H]+: 219.1180, found: 219.1185. 
 
(R)-2-allyl-2-(trifluoromethyl)-3,4-dihydronaphthalen-1(2H)-one (5f)29: 22.8 mg, 90% 
yield; colorless oil; Rf = 0.36 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 8.07 
(dd, J = 7.9, 1.4 Hz, 1H), 7.51 (app td, J = 7.5, 1.5 Hz, 1H), 7.34 (app t, J = 7.6 Hz, 1H), 
7.25 (d, J = 7.9 Hz, 1H), 5.87 – 5.65 (m, 1H), 5.21 – 5.11 (m, 2H), 3.10 (dt, J = 17.5, 6.7 
Hz, 1H), 3.02 (dt, J = 17.3, 6.1 Hz, 1H), 2.76 (dd, J = 14.3, 7.3 Hz, 1H), 2.59 (dd, J = 
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134.20, 131.84, 131.57 (d, J = 1.5 Hz), 128.88, 128.50, 127.18, 126.57 (q, JC-F = 285.3 
Hz, 1C), 120.08, 53.58 (q, JC-F = 22.3 Hz, 1C), 35.56 (q, JC-F = 2.2 Hz, 1C), 26.47 (q, JC-F 
= 2.0 Hz, 1C), 24.71. 19F NMR (282 MHz, CDCl3) δ -69.26 (s, 3F). IR (thin film, NaCl) 
1688, 1601, 1161, 741cm-1. 
 
 
(R)-2-allyl-2-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-inden-1-one (5g): 21.8 mg, 86% 
yield; colorless oil; Rf = 0.40 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.77 
(d, J = 7.7 Hz, 1H), 7.62 (app td, J = 7.5, 1.2 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.40 (app 
t, J = 7.4 Hz, 1H), 5.58 – 5.47 (m, 1H), 5.19 – 4.96 (m, 2H), 3.36 (d, J = 17.6 Hz, 1H), 
3.14 (d, J = 17.6 Hz, 1H), 2.64 – 2.48 (m, 2H), 2.45 (dd, J = 13.7, 6.7 Hz, 1H), 2.34 (dd, 
J = 13.7, 8.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 207.28, 152.43, 135.55, 135.38, 
131.99, 127.87, 126.60 (q, JC-F = 278.7 Hz, 1C), 126.59, 124.51, 119.93, 49.03 (d, JC-F = 
1.7 Hz, 1C), 42.44, 39.20 (q, JC-F = 27.7 Hz, 1C), 36.24 (q, JC-F = 1.9 Hz, 1C). 19F NMR 
(282 MHz, CDCl3) δ -59.71 (t, J = 11.3 Hz, 3F). IR (thin film, NaCl) 1715, 1608, 1258, 
1122 cm-1. HRMS (FAB+) m/z calc’d for C14H14F3O [M+H]+: 255.0991, found: 255.0995. 
 
 
(R)-2-allyl-2-(3,3,3-trifluoropropyl)-2,3-dihydro-1H-inden-1-one (5h): 24.8 mg, 92% 
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(app dt, J = 7.6, 0.9 Hz, 1H), 7.62 (app td, J = 7.5, 1.2 Hz, 1H), 7.45 (app dt, J = 7.7, 0.9 
Hz, 1H), 7.39 (app t, J = 7.6 Hz, 1H), 5.53 (dddd, J = 16.8, 10.1, 8.0, 6.7 Hz, 1H), 5.12 
(dq, J = 16.9, 1.5 Hz, 1H), 5.03 (dd, J = 10.1, 1.0 Hz, 1H), 3.17 (dd, J = 17.4, 0.9 Hz, 
1H), 2.91 (d, J = 17.4 Hz, 1H), 2.42 (ddt, J = 13.7, 6.6, 1.3 Hz, 1H), 2.34 (ddt, J = 13.7, 
8.1, 1.0 Hz, 1H), 2.16 – 1.90 (m, 3H), 1.86 – 1.74 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 209.23, 152.52, 136.37, 135.51, 132.76, 127.92, 127.09 (q, JC-F = 276.0 Hz, 1C), 
126.67, 124.31, 119.33, 50.95, 41.37, 37.27, 31.54 – 27.19 (m, 2C). 19F NMR (282 MHz, 
CDCl3) δ -66.65 (t, J = 10.3 Hz, 3F). IR (thin film, NaCl) 1709, 1608, 1256, 1150 cm-1. 
HRMS (APCI/ESI) m/z calc’d for C15H16F3O [M+H]+: 269.1148, found: 269.1158. 
 
 
(R)-2-fluoro-2-(2-fluoroallyl)-2,3-dihydro-1H-inden-1-one (5i): 20.0 mg, 96% yield; 
colorless oil; Rf = 0.30 (5:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.82 (ddd, J 
= 7.7, 1.3, 0.7 Hz, 1H), 7.67 (App td, J = 7.5, 1.3 Hz, 1H), 7.50 – 7.40 (m, 2H), 4.71 (dd, 
J = 17.0, 3.0 Hz, 1H), 4.48 (dd, J = 49.1, 3.0 Hz, 1H), 3.61 (ddt, J = 17.8, 13.7, 0.7 Hz, 
1H), 3.40 (dd, J = 23.7, 17.8 Hz, 1H), 3.00 (ddd, J = 22.5, 15.1, 10.7 Hz, 1H), 2.77 – 2.63 
(m, 1H). 13C NMR (101 MHz, CDCl3) δ 199.64 (d, JC-F = 17.6 Hz, 1C), 160.59 (dd, JC-F = 
257.4, 7.6 Hz, 1C), 150.61 (d, JC-F = 3.4 Hz, 1C), 136.67, 133.63 (d, JC-F = 1.2 Hz, 1C), 
128.49, 126.85 (d, JC-F = 1.2 Hz, 1C), 125.33, 95.17 (dd, JC-F = 18.7, 1.3 Hz, 1C), 94.75 
(dd, JC-F = 188.4, 2.4 Hz, 1C), 37.73 (dd, JC-F = 24.6, 2.3 Hz, 1C), 37.28 (t, JC-F = 27.1 Hz, 
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IR (thin film, NaCl) 1732, 1608, 1227, 730 cm-1. HRMS (APCI/ESI) m/z calc’d for 
C12H11F2O [M+H]+: 209.0772, found: 209.0770. 
 
 
(S)-2-(2-fluoroallyl)-2-methyl-2,3-dihydro-1H-inden-1-one (5j): 21.8 mg, 97% yield; 
colorless oil; Rf = 0.33 (10:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.76 (dt, J = 
7.6, 1.0 Hz, 1H), 7.60 (app td, J = 7.4, 1.2 Hz, 1H), 7.44 (dt, J = 7.7, 1.0 Hz, 1H), 7.38 
(app td, J = 7.4, 0.9 Hz, 1H), 4.58 (ddd, J = 17.3, 2.8, 0.7 Hz, 1H), 4.30 (ddd, J = 49.6, 
2.8, 0.7 Hz, 1H), 3.36 (d, J = 17.3 Hz, 1H), 2.93 (d, J = 17.3 Hz, 1H), 2.58 – 2.45 (m, 
2H), 1.25 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 209.74, 164.02 (d, JC-F = 258.2 Hz, 1C), 
152.63, 135.20, 127.66, 126.76, 124.62, 93.46 (d, JC-F = 19.9 Hz, 1C), 47.85 (d, JC-F = 2.8 
Hz, 1C), 43.62 – 34.74 (m, 2C), 24.19. 19F NMR (282 MHz, CDCl3) δ -91.35 – -91.74 
(m, 1F).  IR (thin film, NaCl) 1732, 1608, 1227, 730 cm-1. HRMS (APCI/ESI) m/z calc’d 
for C13H14FO [M+H]+: 205.1023, found: 205.1022.  
 
 
(R)-3-allyl-1-benzoyl-3-(3,3,3-trifluoropropyl)piperidin-2-one (5k): 27.4 mg, 94% 
yield; colorless oil; Rf = 0.37 (3:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.55 – 
7.47 (m, 3H), 7.40 – 7.38 (m, 2H), 5.72 (ddt, J = 17.4, 10.2, 7.3 Hz, 1H), 5.22 – 5.15 (m, 
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1.2 Hz, 1H), 2.21 – 1.93 (m, 5H), 1.93 – 1.86 (m, 2H), 1.84 – 1.77 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 177.21, 175.61, 136.46, 132.11, 131.79, 128.44 (2C), 127.47 (2C), 
127.23 (q, JC-F = 276.9 Hz, 1C), 120.09, 47.20, 46.09, 41.13, 31.62, 29.32, 29.13 (q, JC-F = 
28.8 Hz, 1C), 19.41. 19F NMR (282 MHz, CDCl3) δ -66.53 (t, J = 10.5 Hz, 3F). IR (thin 
film, NaCl) 2950, 1682, 1258, 1149 cm-1; HRMS (APCI/ESI) m/z calc’d for C18H21F3NO2 
[M+H]+: 340.1519, found: 340.1519. 
 
(S)-1-benzoyl-3-(2-fluoroallyl)-3-methylpiperidin-2-one (5l): 23.5 mg, 85% yield; 
colorless oil; Rf = 0.52 (3:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.55 – 7.50 
(m, 2H), 7.49 – 7.44 (m, 1H), 7.41 – 7.35 (m, 2H), 4.67 (ddd, J = 17.3, 2.7, 0.7 Hz, 1H), 
4.32 (ddd, J = 49.7, 2.7, 0.5 Hz, 1H), 4.00 – 3.84 (m, 1H), 3.79 – 3.62 (m, 1H), 2.76 (dd, 
J = 19.4, 14.6 Hz, 1H), 2.41 (ddd, J = 24.8, 14.6, 0.8 Hz, 1H), 2.19 – 1.95 (m, 3H), 1.93 – 
1.75 (m, 1H), 1.42 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 176.80 (d, JC-F = 289.8 Hz, 
1C), 163.47 (d, JC-F = 258.1 Hz, 1C), 136.47, 131.55, 128.28 (2C), 127.52 (2C), 94.42 (d, 
JC-F = 20.0 Hz, 1C), 47.16, 43.60 (d, JC-F = 3.1 Hz, 1C), 41.10 (d, JC-F = 25.5 Hz, 1C), 
33.28 (d, JC-F = 1.9 Hz, 1C), 25.83 (d, JC-F = 1.5 Hz, 1C), 19.72. 19F NMR (282 MHz, 
CDCl3) δ -89.31 – 89.70 (m, 1F).  IR (thin film, NaCl) 2942, 1697, 1672, 1277, 1144 cm-
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(R)-3-allyl-1-(benzyloxy)-3-(3,3,3-trifluoropropyl)piperidine-2,6-dione (5m): 33.0 mg, 
93% yield; colorless oil; Rf = 0.24 (3:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 
7.51 – 7.46 (m, 2H), 7.40 – 7.34 (m, 3H), 5.61 (ddt, J = 17.4, 10.1, 7.4 Hz, 1H), 5.25 – 
5.06 (m, 2H), 5.02 (s, 2H), 2.83 – 2.70 (m, 2H), 2.39 (ddt, J = 14.2, 7.3, 1.2 Hz, 1H), 2.30 
(ddt, J = 14.2, 7.4, 1.1 Hz, 1H), 2.09 – 1.94 (m, 2H), 1.90 – 1.80 (m, 2H), 1.78 – 1.66 (m, 
2H).  13C NMR (101 MHz, CDCl3) δ 171.63, 167.45, 133.67, 131.03, 130.38 (2C), 
129.45, 128.54 (2C), 126.88 (q, JC-F = 275.9 Hz, 1C), 120.75, 78.04, 45.18, 39.76, 29.22, 
28.75 (q, JC-F = 29.2Hz, 1C), 27.76 (q, J = 3.0 Hz, 1C), 25.35. 19F NMR (282 MHz, 
CDCl3) δ -66.56 (t, J = 10.1 Hz, 3F).  IR (thin film, NaCl) 1741, 1702, 1258, 1184 cm-1. 
HRMS (APCI/ESI) m/z calc’d for C18H21F3NO3 [M+H]+: 356.1468, found: 356.1470. 
 
 
(R)-3-allyl-1-benzoyl-3-(3,3,3-trifluoropropyl)pyrrolidin-2-one (5n): 26.7 mg, 82% 
yield; colorless oil; Rf = 0.35 (5:1 Hexane:EtOAc); 1H NMR (500 MHz, CDCl3) δ 7.58 – 
7.51 (m, 3H), 7.45 – 7.39 (m, 2H), 5.76 (dddd, J = 17.1, 10.2, 7.8, 7.0 Hz, 1H), 5.29 – 
5.16 (m, 2H), 3.96 – 3.85 (m, 2H), 2.38 (ddt, J = 13.8, 7.0, 1.3 Hz, 1H), 2.34 – 2.28 (m, 
1H), 2.28 – 2.06 (m, 3H), 1.95 (ddd, J = 13.3, 8.3, 6.4 Hz, 1H), 1.86 – 1.81 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 176.93, 170.74, 134.18, 132.23, 131.91, 128.90 (2C), 128.00 
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1C), 28.02 (q, JC-F = 3.0 Hz, 1C), 27.60.  19F NMR (282 MHz, CDCl3) δ -66.60 (t, J = 
10.4 Hz, 3F). IR (thin film, NaCl) 1738, 1678, 1305, 1258, 1138 cm-1. HRMS 


















1.6.3  METHODS FOR THE DETERMINATION OF ENANTIOMERIC 
EXCESS 
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0% IPA isocratic, 2.5 mL/min
t (major) = 9.21
t (minor) = 8.65
SFC, Chiralcel OD-H
1% IPA isocratic, 2.5 mL/min
t (major) = 5.71
t (minor) = 8.86
SFC, Chiralcel OJ-H
0% IPA isocratic, 2.5 mL/min
t (major) = 6.38
t (minor) = 5.98
SFC, Chiralpak AD-H
3% IPA isocratic, 2.5 mL/min
t (major) = 9.73
t (minor) = 11.11
SFC, Chiralpak IC
5% IPA isocratic, 2.5 mL/min
t (major) = 4.78
t (minor) = 4.21
SFC, Chiralpak AS-H
0% IPA isocratic, 2.5 mL/min
t (major) = 2.81
t (minor) = 2.55
SFC, Chiralpak AD-H
5% IPA isocratic, 2.5 mL/min
t (major) = 2.72
t (minor) = 3.04
SFC, Chiralpak AD-H
3% IPA isocratic, 2.5 mL/min
t (major) = 3.85
















5% IPA isocratic, 2.5 mL/min
t (major) = 2.98




3% IPA isocratic, 2.5 mL/min
t (major) = 8.09






5% IPA isocratic, 2.5 mL/min
t (major) = 6.15






5% IPA isocratic, 2.5 mL/min
t (major) = 9.04
t (minor) = 11.38
SFC, Chiralcel OJ-H
3% IPA isocratic, 2.5 mL/min
t (major) = 10.67
t (minor) = 9.86
SFC, Chiralpak AD-H
10% IPA isocratic, 2.5 mL/min
t (major) = 2.28
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 Figure A1.2. Infrared spectrum (Thin Film, NaCl) of compound 4a. 
 
	Figure A1.3. 13C NMR (101 MHz, CDCl3) of compound 4a. 
	

















































Figure A1.4. 19F NMR (282 MHz, CDCl3) of compound 4a.	





































































































































 Figure A1.6. Infrared spectrum (Thin Film, NaCl) of compound 4b. 
 
	Figure A1.7. 13C NMR (101 MHz, CDCl3) of compound 4b. 
	

















































Figure A1.8. 19F NMR (282 MHz, CDCl3) of compound 4b.	




































































































































 Figure A1.10. Infrared spectrum (Thin Film, NaCl) of compound 4c. 
 
	Figure A1.11. 13C NMR (101 MHz, CDCl3) of compound 4c. 
	

















































Figure A1.12. 19F NMR (282 MHz, CDCl3) of compound 4c.	














































































































 Figure A1.14. Infrared spectrum (Thin Film, NaCl) of compound 9. 
 
	Figure A1.14. 13C NMR (101 MHz, CDCl3) of compound 9. 
	




































































































































 Figure A1.17. Infrared spectrum (Thin Film, NaCl) of compound 10. 
 
	Figure A1.18. 13C NMR (101 MHz, CDCl3) of compound 10. 
	





































































































































 Figure A1.20. Infrared spectrum (Thin Film, NaCl) of compound 4d. 
 
	Figure A1.21. 13C NMR (101 MHz, CDCl3) of compound 4d. 
	


























Figure A1.22. 19F NMR (282 MHz, CDCl3) of compound 4d.	





































































































































 Figure A1.24. Infrared spectrum (Thin Film, NaCl) of compound 11. 
 
	Figure A1.25. 13C NMR (101 MHz, CDCl3) of compound 11. 
	

















































Figure A1.26. 19F NMR (282 MHz, CDCl3) of compound 11.	




































































































































 Figure A1.28. Infrared spectrum (Thin Film, NaCl) of compound 12. 
 
	Figure A1.29. 13C NMR (101 MHz, CDCl3) of compound 12. 
	

















































Figure A1.30. 19F NMR (282 MHz, CDCl3) of compound 12.	





































































































































 Figure A1.32. Infrared spectrum (Thin Film, NaCl) of compound 4e. 
 
	Figure A1.33. 13C NMR (101 MHz, CDCl3) of compound 4e. 
	

















































Figure A1.34. 19F NMR (282 MHz, CDCl3) of compound 4e.	




































































































































 Figure A1.35. Infrared spectrum (Thin Film, NaCl) of compound 4g. 
 
	Figure A1.36. 13C NMR (101 MHz, CDCl3) of compound 4g. 
	

















































Figure A1.36. 19F NMR (282 MHz, CDCl3) of compound 4g.	




































































































































 Figure A1.40. Infrared spectrum (Thin Film, NaCl) of compound 4h. 
 
	Figure A1.41. 13C NMR (101 MHz, CDCl3) of compound 4h. 
	

















































Figure A1.42. 19F NMR (282 MHz, CDCl3) of compound 4h.	



































































































































 Figure A1.44. Infrared spectrum (Thin Film, NaCl) of compound 15. 
 
	Figure A1.45. 13C NMR (101 MHz, CDCl3) of compound 15. 
	

















































Figure A1.46. 19F NMR (282 MHz, CDCl3) of compound 15.	












































































































 Figure A1.48. Infrared spectrum (Thin Film, NaCl) of compound 4i. 
 
	Figure A1.49. 13C NMR (101 MHz, CDCl3) of compound 4i. 
	


























Figure A1.50. 19F NMR (282 MHz, CDCl3) of compound 4i.	





































































































































 Figure A1.52. Infrared spectrum (Thin Film, NaCl) of compound 4j. 
 
	Figure A1.53. 13C NMR (101 MHz, CDCl3) of compound 4j. 
	


























Figure A1.54. 19F NMR (282 MHz, CDCl3) of compound 4j.	







































































































































 Figure A1.56. Infrared spectrum (Thin Film, NaCl) of compound 4k. 
 
	Figure A1.57. 13C NMR (101 MHz, CDCl3) of compound 4k. 
	


























Figure A1.58. 19F NMR (282 MHz, CDCl3) of compound 4k.	






































































































































 Figure A1.60. Infrared spectrum (Thin Film, NaCl) of compound 17. 
 
	Figure A1.61. 13C NMR (101 MHz, CDCl3) of compound 17. 
	


























Figure A1.62. 19F NMR (282 MHz, CDCl3) of compound 17.	







































































































































 Figure A1.64. Infrared spectrum (Thin Film, NaCl) of compound 4l. 
 
	Figure A1.65. 13C NMR (101 MHz, CDCl3) of compound 4l. 
	

















































Figure A1.66. 19F NMR (282 MHz, CDCl3) of compound 4l.	









































































































































 Figure A1.68. Infrared spectrum (Thin Film, NaCl) of compound 4m. 
 
	Figure A1.69. 13C NMR (101 MHz, CDCl3) of compound 4m. 
	

















































Figure A1.70. 19F NMR (282 MHz, CDCl3) of compound 4m.	






































































































































 Figure A1.72. Infrared spectrum (Thin Film, NaCl) of compound 4n. 
 
	Figure A1.73. 13C NMR (101 MHz, CDCl3) of compound 4n. 
	















































Figure A1.74. 19F NMR (282 MHz, CDCl3) of compound 4n.	































































































































 Figure A1.76. Infrared spectrum (Thin Film, NaCl) of compound 5a. 
 
	Figure A1.77. 13C NMR (101 MHz, CDCl3) of compound 5a. 
	















































Figure A1.78. 19F NMR (282 MHz, CDCl3) of compound 5a.	































































































































 Figure A1.80. Infrared spectrum (Thin Film, NaCl) of compound 5b. 
 
	Figure A1.81. 13C NMR (101 MHz, CDCl3) of compound 5b. 
	















































Figure A1.82. 19F NMR (282 MHz, CDCl3) of compound 5b.	






























































































































 Figure A1.84. Infrared spectrum (Thin Film, NaCl) of compound 5c. 
 
	Figure A1.85. 13C NMR (101 MHz, CDCl3) of compound 5c. 
	















































Figure A1.86. 19F NMR (282 MHz, CDCl3) of compound 5c.	































































































































 Figure A1.88. Infrared spectrum (Thin Film, NaCl) of compound 5d. 
 
	Figure A1.89. 13C NMR (101 MHz, CDCl3) of compound 5d. 
	















































Figure A1.90. 19F NMR (282 MHz, CDCl3) of compound 5d.	






























































































































 Figure A1.92. Infrared spectrum (Thin Film, NaCl) of compound 5e. 
 
	Figure A1.93. 13C NMR (101 MHz, CDCl3) of compound 5e. 
	















































Figure A1.94. 19F NMR (282 MHz, CDCl3) of compound 5e.	































































































































 Figure A1.96. Infrared spectrum (Thin Film, NaCl) of compound 5f. 
 
	Figure A1.97. 13C NMR (101 MHz, CDCl3) of compound 5f. 
	















































Figure A1.98. 19F NMR (282 MHz, CDCl3) of compound 5f.	































































































































 Figure A1.100. Infrared spectrum (Thin Film, NaCl) of compound 5g. 
 
	Figure A1.101. 13C NMR (101 MHz, CDCl3) of compound 5g. 
	















































Figure A1.102. 19F NMR (282 MHz, CDCl3) of compound 5g.	
































































































































 Figure A1.104. Infrared spectrum (Thin Film, NaCl) of compound 5h. 
 
	Figure A1.105. 13C NMR (101 MHz, CDCl3) of compound 5h. 
	















































Figure A1.106. 19F NMR (282 MHz, CDCl3) of compound 5h.	
































































































































 Figure A1.108. Infrared spectrum (Thin Film, NaCl) of compound 5i. 
 
	Figure A1.109. 13C NMR (101 MHz, CDCl3) of compound 5i. 
	















































Figure A1.110. 19F NMR (282 MHz, CDCl3) of compound 5i.	































































































































 Figure A1.112. Infrared spectrum (Thin Film, NaCl) of compound 5j. 
 
	Figure A1.113. 13C NMR (101 MHz, CDCl3) of compound 5j. 
	















































Figure A1.114. 19F NMR (282 MHz, CDCl3) of compound 5j.	


































































































































 Figure A1.116. Infrared spectrum (Thin Film, NaCl) of compound 5k. 
 
	Figure A1.117. 13C NMR (101 MHz, CDCl3) of compound 5k. 
	















































Figure A1.118. 19F NMR (282 MHz, CDCl3) of compound 5k.	

































































































































 Figure A1.120. Infrared spectrum (Thin Film, NaCl) of compound 5l. 
 
	Figure A1.121. 13C NMR (101 MHz, CDCl3) of compound 5l. 
	















































Figure A1.122. 19F NMR (282 MHz, CDCl3) of compound 5l.	



































































































































 Figure A1.124. Infrared spectrum (Thin Film, NaCl) of compound 5m. 
 
	Figure A1.125. 13C NMR (101 MHz, CDCl3) of compound 5m. 
	















































Figure A1.126. 19F NMR (282 MHz, CDCl3) of compound 5m.	


































































































































 Figure A1.128. Infrared spectrum (Thin Film, NaCl) of compound 5n. 
 
	Figure A1.129. 13C NMR (101 MHz, CDCl3) of compound 5n. 
	

























	 Figure A1.130. 
19F NMR (282 MHz, CDCl3) of compound 5n.	
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Synthesis of enantioenriched 2,2-disubstituted 
 pyrrolidines via sequential asymmetric allylic  
alkylation and ring contraction* 
 
2.1   INTRODUCTION 
More than half of current FDA approved drug molecules contain at least one 
nitrogen containing heterocycle, with the most common motifs (in order) being 
piperidine, pyridine, piperazine, cephem and pyrrolidine.1  Additionally, it has been 
demonstrated that three-dimensionality, particularly in the form of stereogenic centers, is 
of great interest to the medicinal chemistry community.2 For these reasons, unsaturated 
nitrogen heterocycles containing tetrasubstituted chiral centers have proven desirable. 
Looking more closely at the pyrrolidine containing drug molecules, it is quickly apparent 
that none contain tetrasubstituted centers (e.g. Figure 2.1.1, 20–24), and many are derived 
from the amino acid proline 20, such as 21, 22, and 23.1 We envisioned an opportunity to 
                                                
* This research was performed in collaboration with Hirokazu Takada, Yuji Sumii and Katsuaki Baba, all 
alumni of the Stoltz group.  
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bring novelty to this motif in pharmaceutical compounds by developing a divergent 
approach to related molecules containing tetrasubstituted stereocenters. 
Figure 2.1.1 Pharmaceutical compounds containing chiral pyrrolidines 
 
Much progress has been made in the synthesis of proline derivatives as 
demonstrated by the prevalence of that motif in pharmaceutical compounds. In fact, the 
synthesis of chiral proline derivatives was described in a review by Cativiela,3 of which 
an example is highlighted in Scheme 2.1.1 from the pioneering work of Seebach et al.4 
Starting from proline 20, condensation affords oxazolidinone 25, which can undergo 
enolate formation followed by alkylation resulting in 26. Hydrolysis of the resulting 
oxazolidinone then affords the proline derivative 27 in good yield and high ee. While this 
method is successful for the synthesis of a number of interesting molecules, it is limited 
to the synthesis of proline derivatives. Additionally, deprotection of the oxazolidinone 
can require harsh conditions, which may not be amenable to all substrates. We believed 
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pyrrolidines would allow for the synthesis of previously unknown compounds that would 
be of interest to the medicinal chemistry and natural products communities. 
Scheme 2.1.1 Synthesis of tetrasubstituted proline derivatives by Seebach et al.4 
 
Our overall strategy toward the synthesis of chiral 2,2-disubstituted pyrrolidines is 
summarized in Scheme 2.1.2.  The imides 28 can be synthesized in a known procedure 
from glutaric anhydride, followed by a decarboxylative asymmetric allylic alkylation as 
described previously to afford 29. These imides can then undergo a series of functional 
group manipulations to afford hydroxamic acids 30, which we propose would undergo a 
stereospecifc ring contraction to afford chiral 2,2-disubstituted pyrrolidines 31. The final 
ring contraction, pioneered by Spino,5 has previously not been investigated with respect 
to stereochemical fidelity, although we hypothesized that it would be stereospecific. 
Scheme 2.1.2 Proposed synthesis of chiral 2,2-disubstituted pyrrolidines 
 
2.2  SYNTHESIS OF CHIRAL BENZYLOXYIMIDES 
Our lab has a long-standing interest in allylic alkylation reactions for the synthesis 
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reaction in 2004 using cyclic enol carbonates or enol silanes to afford α-quaternary 
ketone products under palladium catalysis utilizing chiral phosphinooxazaline (PHOX) 
ligand 6 (Scheme 2.2.1A–B) 6. A year later, we demonstrated the decarboxylative 
asymmetric allylic alkylation reaction of cyclic β-keto esters, affording the same α-
quaternary ketone products (Scheme 2.2.1C).7  Since those initial reports, we have 
significantly expanded the scope of this reaction to include various ring sizes and 
heterocycles, particularly following our development of an electron deficient PHOX 
ligand (7).8 Of particular note is the advancement in the realm of nitrogen heterocyles, 
including both lactams and imides, in the decarboxylative allylic alkylation reaction.9 We 
were pleased to note that a variety of β-amidoesters were tolerated in this reaction with 
only small changes to the reaction conditions (Scheme 2.2.1D). We believed that we 
could use some of these products as intermediates for the synthesis of chiral 2,2-
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Scheme 2.2.1 Progression of the asymmetric allylic alkylation reaction in the Stoltz 
laboratory 
 
The substrates for this reaction, as mentioned above, can be synthesized from 
glutaric anhydride 32 in a previously reported four-step procedure, involving 
condensation of O-benzylhydroxylamine with glutaric anhydride followed by enolate α–
acylation and alkylation events (Scheme 2.2.2A). 10  During the course of our 
investigations, we discovered a number of small changes to this procedure that improved 
material throughput (Scheme 2.2.2B). First, we determined that O-benzyloxyimide 33 
could be isolated by recrystallization, affording the product in an improved yield over 
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reaction instead of allylcyanoformate afforded a better yield of the desired α–carboxy 
lactams 28. In addition to the higher material throughput, use of commercially available 
allylchloroformate is preferable to the use of allylcyanoformate. The latter must be 
prepared from allylchloroformate and involves the use of cyanide, which necessitates 
more complicated workup and waste disposal procedures.  We were able to use 
conditions optimized for the synthesis of 28a to access a number of β-amidoesters for the 
asymmetric allylic alkylation reaction, as shown in Scheme 2.2.2C. 
Scheme 2.2.2 Synthesis of β-amidoesters 
 
With a reliable synthesis of substrates in hand, we turned our attention to the 
asymmetric allylic alkylation reaction. While we had previously reported similar 
chemistry on this class of substrates,9 we aimed to improve a couple of aspects, 
particularly with regard to larger scale reactions. Specifically, we pursued a lower 
catalyst loading and an increased concentration of the reaction. We first started by 




1. BnONH2, K2CO3, 
    CH2Cl2











1. LiHMDS, THF‚ –78 °C;
    allyl cyanoformate
2. Cs2CO3, MeI
    MeCN, 50 °C














1. LiHMDS, THF‚ –78 °C;
    allyl chloroformate
2. Cs2CO3, MeI
    MeCN, 50 °C
80% yield over 2 stepsRecrystallization
99% yield
1. BnONH2, K2CO3, 
    CH2Cl2











1. LiHMDS, THF‚ –78 °C;
    allyl chloroformate
2. Cs2CO3, RX
    MeCN, 50 °C R
RX= EtI, BnBr,








Chapter 2: Synthesis of enantioenriched 2,2-disubstitutedpyrrolidines via sequential 
asymmetric allylic alkylation and ring contraction 
150	
very pleased to note that reducing the catalyst loading in half did not adversely effect the 
enantioselectivity of the reaction (Entry 2). We previously reported conditions with low 
catalyst loadings that utilize Pd(OAc)2, instead of Pd2(dba)3 or Pd2(pmdba)3, and TBME 
(tert-butyl methyl ether) instead of toluene. So, we continued our investigations with 
these two changes (Entry 3),11 and were pleased to note that the yield and selectivity 
remained the same. Increasing the concentration to 0.1 M resulted in a slightly 
accelerated reaction with similar selectivity and yield (Entry 4), but increasing the 
concentration further resulted in lower yields and selectivities (Entry 5–6). Lowering the 
catalyst loading even further (Entry 7-9) resulted in similar selectivity and reactivity, 
although extended reaction times and elevated temperatures were required. Thus, we 
decided that the best overall combination of reactivity and catalyst loading is achieved in 
Entry 7.  
Table 2.2.1 Asymmetric allylic alkylation optimization 
 
(a) Pd2(pmdba)3, toluene, 50 °C, (b) Pd2(pmdba)3 (c) 60 °C, 51 hr 
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With these optimized conditions in hand, we turned our attention to investigating 
the reactivity of the other substrates, one of which had never been investigated in an 
asymmetric allylic alkylation reaction. We were pleased again to observe good reactivity 
and selectivity for the parent substrate 29a on a larger scale, up to 11 g of substrate 
(Table 2.2.2). Additionally, compound 29b also performed well under these conditions. 
Unfortunately, the enantioselectivity was diminished when slightly more complex 
substrates (29c, 5m) were investigated, though the reactivity remained good. While this 
was somewhat disappointing, we were able to demonstrate that both of those substrates 
could be synthesized in good enantiomeric excess when the previously reported 
conditions for 5m were applied to both substrates (Entry B).12 With all four of our desired 
compounds in hand, we turned our attention to advancing the compounds toward chiral 
pyrrolidines.  
Table 2.2.2 Scope of the asymmetric allylic alkylation reaction 
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2.3   REDUCTION OF BENZYLOXY IMIDE TO HYDROXAMIC ACID 
In order to test the ring contraction reaction, a number of functional group 
manipulations were required. We were pleased to discover that a three-step sequence of 
reactions afforded the desired hydroxamic acids 30a–d (Scheme 2.3.1). First, a selective 
carbonyl reduction proceeded with good yield in the presence of DIBAL-H to afford 
alcohols 34a–d as a mixture of diastereomers. A subsequent dehydroxylation afforded 
lactams 35a–d in nearly quantitative yield upon treatment with a mixture of triethylsilane 
and trifluoroacetic acid (TFA). Finally, the protected hydroxamic acids underwent 
debenzylation with boron trichloride to afford the free hydroxamic acids 30a–d. This 
sequence of reactions was highly scalable and has been performed on up to 6 g scale on 
substrate 29a (R=Me). 
Scheme 2.3.1 Synthesis of chiral hydroxamic acids 
 
2.4   THERMAL RING CONTRACTION OF HYDROXAMIC ACID 
Spino and coworkers have previously reported the ring contraction of lactams to 
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mesyloxy5b (Scheme 2.4.1b) lactams, or a thermal process from hydroxamic acids 
through a N–trifloxy lactam5c (Figure 2.4.1c). These reactions are proposed to occur via 
an isocyanate-like intermediate in a manner similar to that proposed for the Hofmann 
rearrangement (Scheme 2.4.1d).5  As the Hofmann rearrangement is known to proceed in 
a stereospecific fashion, we envisioned that the Spino reaction would also display the 
same specificity, and we were poised to address this fundamental question. With our 
enatioenriched lactams 30a–d in hand and Spino’s effort on the ring contraction of 
lactams in mind, we proceeded to investigate the stereospecificity of that ring contraction 
for the synthesis of asymmetric 2,2-disubstituted pyrrolidines. 
Scheme 2.4.1 Ring contraction reactions as reported by Spino et al.5 
 
With a number of substrates in hand, we first began investigating the thermal ring 
contraction of parent substrate 30a (Scheme 2.4.2). We were very pleased to discover that 
using the conditions developed by Spino and coworkers, we observed an 83% yield of the 
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chromatography of the N-trifloxylactam 36a was unnecessary to obtain good yields, 
allowing for a more streamlined synthesis.  
Scheme 2.4.2 Thermal ring contraction of chiral hydroxamic acid 
 
At this stage, owing to our interest in further functionalizing these pyrrolidines, 
we investigated the removal of the methyl carbamate group to afford free pyrrolidine 37. 
In our hands, this proved to be a challenge, as described in Table 2.4.1. A variety of basic 
conditions (Entries 1-3), acidic conditions (Entries 5-6), and other previously reported 
conditions (Entries 7-9) mostly displayed low conversion to product, and when 
significant reactivity was detected, decomposition or undesired byproduct 38 were 
observed. In fact, only when subjecting the substrate to concentrated KOH in a mixture of 
water and 1,2-propanediol under microwave irradiation at 200 °C for an hour were we 
able to finally detect our desired product, which upon exposure to anhydrous HCl could 















MeO2C83% yield (over 2 steps)
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Table 2.4.1 Removal of methyl carbamate group 
 
*Desired compound 37 was isolated as an HCl salt. 
While we were in fact able to isolate the pyrrolidine 37 as an HCl salt, we 
believed the harsh conditions required were not ideal for more functionalized substrates, 
and the necessity of microwave irradiation proved to be a bottleneck when applied to 
larger scales. With these thoughts in mind, we wondered whether it would be possible to 
synthesize other carbamates through a similar procedure, such as benzyl or tert-butyl 
(Cbz and Boc, respectively), which have more well known reactivity and are often used 
as protecting groups. Returning our attention to the proposed mechanism for the reaction, 
we were reminded that the methyl carbamate arose due to the methanol solvent, and 
decided to investigate the use of benzyl or tert-butyl alcohol as a solvent. We were 
pleased to discover that using a 3:1 mixture of toluene and the desired alcohol, we could 
synthesize both the Cbz and Boc protected pyrrolidines (Table 2.4.2, 31b and 31c, 
respectively) in good yield when slightly longer reactions times were applied. 
Additionally, we were able to use these conditions to access Cbz protected pyrrolidines 






































200 °C (µ wave)
reflux
reflux














Chapter 2: Synthesis of enantioenriched 2,2-disubstitutedpyrrolidines via sequential 
asymmetric allylic alkylation and ring contraction 
156	
Table 2.4.2 Synthesis of chiral 2,2-disubstituted pyrrolidines 
 
With the synthesis of these compounds completed, we proceeded to investigate 
our hypothesis that this reaction proceeds with stereoretention. Our development of the 
synthesis of Cbz protected pyrrolidines proved to expedite this process significantly, as 
we could use super-critical fluid chromatography (SFC) to determine the enantiomeric 
excess of pyrrolidine 31b. We began by synthesizing racemic allylic alkylation product 
29a and advancing it toward pyrrolidine 31b via the synthetic sequence described in this 
paper (Scheme 2.4.3A). Upon SFC analysis, we were able to determine that both 
compounds had 0% ee. We then proceeded to follow the same sequence again, except 
utilizing enantioenriched allylic alkylation product 29a (92% ee, Scheme 2.4.3B). We 
were pleased to observe that pyrrolidine product 31b derived from enantioenriched 29a 
also retained the same enantiomeric excess (92% ee). Therefore, we could conclude that 
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Scheme 2.4.3 Investigation of stereochemistry 
 
2.5   REACTIONS OF HYDROXAMIC ACID PRODUCTS 
With this new method for synthesizing chiral pyrrolidines in hand, we sought to 
apply our new strategy toward the synthesis of a natural product. We believed that 
tylohirsuticine 39, a seco-phenanthroindolizidine alkaloid, would serve as a good target 
for synthesis (Scheme 2.5.1).14 Retrosynthetically, we believed that a cross-coupling 
reaction of indolizidine 40 with an arene would result in the natural product. That mono-
arylated indolizidine 40 could arise from a ring closing metathesis (RCM) of 41, which 
could itself arise from an N-alkylation of 37 (which we have previously demonstrated the 
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Scheme 2.5.1 Retrosynthetic analysis of tylohirsuticine 
  
In the forward sense, starting from the HCl salt of pyrrolidine 37 and allyl 
bromide 42, N-alkylation proceeded smoothly to afford 41 in good yield in the presence 
of potassium carbonate in refluxing acetonitrile (Scheme 2.5.2).  With diallyl 41 in hand, 
we were pleased to observe promising reactivity under standard RCM conditions using 
Grubbs II catalyst 44 to afford desired product 40 (Table 5), though incomplete 
conversion and the presence of undesired isomerization byproduct 43 resulted in the need 
for some optimization (Entry 1). Switching to the Hoveyda-Grubbs II catalyst 45 
provided higher reactivity, but the undesired isomerization product was still observed 
(Entry 2), and the addition of 1,4-benzoquinone proved only to favor isomerization 
(Entry 3). However, when we applied conditions disclosed by Lindsley and coworkers 
(Entry 4) we were delighted to observe an 85% yield of our desired product 40, and no 
observed isomerization product.16 As they believed that this difference in reactivity was 
due to the formation of a TFA salt, we also performed the reaction using the same 
conditions with the exception of TFA (Entry 5). In this case, we again saw significant 
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selectivity in this reaction. With this indolizidine compound 40 in hand, we began our 
investigation into the total synthesis of tylohirsuticine, which is currently ongoing. 
Scheme 2.5.2 N–alkylation of chiral pyrrolidine 
 
Table 2.5.1 Optimization of ring-closing metathesis 
 
2.6   CONCLUSIONS 
The first catalytic enantioselective method for the synthesis of chiral 2,2-
disubstituted pyrrolidines is reported, consisting of an asymmetric allylic alkylation 
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to afford the desired products. A number of compounds were synthesized using this 
method to afford products with three different carbamate protecting groups on 
pyrrolidine, which could prove useful for further derivitization of these compounds. 
Furthermore, we demonstrated that one of these substrates can be further elaborated to 
form a new indolizidine compound, which we hope to further advance to the natural 
product tylohirsuticine in the future. 
2.7  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
2.7.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed in flame-dried or oven-dried 
glassware under an argon or nitrogen atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).17  Commercially obtained 
reagents were used as received with the exception of dipalladium 
tris(dibenzylideneacetone) (Pd2(dba)3), tetrakis(triphenylphosphine)palladium(0), which 
were stored in a nitrogen-filled glovebox. Dipalladium tris(para-
methoxydibenzylideneacetone) (Pd2(pmdba)3),18 (S)-t-BuPHOX,19 (S)-(CF3)3-tBuPHOX,20 
were prepared by known methods. Reactions requiring external heat were modulated to 
the specified temperatures using an IKAmag temperature controller. Reaction progress 
was monitored by thin-layer chromatography (TLC), which was performed using E. 
Merck silica gel 60 F254 precoated glass plates (0.25 mm) and visualized by UV 
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining. Silicycle 
SiliaFlash® P60 Academic Silica gel (particle size 40-63 nm) was used for column 
chromatography. 1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 
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MHz and 126 MHz, respectively), and a Bruker AV III HD spectrometer equipped with a 
Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 101 MHz, respectively) 
and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and δ 77.16, 
respectively). 19F NMR spectra were recorded on a Varian Inova 300 spectrometer (282 
MHz) and are reported in terms of absolute chemical shift according to IUPAC standard 
recommendations from CFCl3. Data for 1H NMR are reported as follows: chemical shift 
(δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as 
follows: s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet, app t = 
apparently triplet. Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 
spectrometer using thin films deposited on NaCl plates and are reported in frequency of 
absorption (cm–1). Optical rotations were measured with a Jasco P-2000 polarimeter 
operating on the sodium D-line (589 nm), using a 100 mm path-length cell and are 
reported as: [α]DT (concentration in g/100 mL, solvent). Analytical SFC was performed 
with a Mettler SFC supercritical CO2 analytical chromatography system utilizing 
Chiralpak (AD-H, AS-H, IC) or Chiralcel (OD-H, OJ-H) columns (4.6 mm x 25 cm) 
obtained from Daicel Chemical Industries, Ltd. High resolution mass spectra were 
obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H. High 
Resolution Mass Spectrometer in fast atom bombardment (FAB+) ionization mode or a 
Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray 
ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or mixed 
(ESI/APCI) ionization mode. Julabo Presto LH45 was used to control reaction 
temperatures inside the nitrogen-filled glovebox. 
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2.7.2  EXPERIMENTAL PROCEDURES 
1-(benzyloxy)piperidine-2,6-dione (33)  
 
O-Benzyloxyamine hydrochloride (10.30 g, 64.57 mmol, 1.1 equiv) in a 500 mL round-
bottom flask was taken up in CH2Cl2 (117 mL) and saturated aqueous K2CO3 (117 mL) 
and stirred for 1 hour. The mixture was transferred to a separatory funnel and the phases 
were separated. The aqueous phase was extracted twice with dichloromethane (120 mL), 
the combined organic phases were washed with brine (120 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting crude colorless oil was 
diluted with dichloromethane (58.7 mL, 1.0 M) in a 250 mL round-bottom flask and 
glutaric anhydride 32 (6.70 g, 58.7 mmol, 1.00 equiv) was added. An exotherm was 
observed, and the mixture was immediately concentrated under reduced pressure. The 
resulting residue was taken up in EtOAc (78.3 mL, 0.75 M) and acetyl chloride (11.6 mL, 
164.36 mmol, 2.81 equiv) was added. A water condenser was affixed and the reaction 
was heated to a gentle reflux (oil bath, 85 °C) for 12 h. The reaction was diluted with 
EtOAc (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
The residue was purified by recrystallization in a 1:1 mixture of CH2Cl2/hexanes to afford 
N-benzyloxyimide 33 (12.77 g, 99% yield) as a white solid. Spectral data were in 
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allyl 1-(benzyloxy)-3-methyl-2,6-dioxopiperidine-3-carboxylate (28a) 
 
A flame-dried flask charged with a magnetic stir-bar, imide 33 (12.5 g, 57.0 mmol, 1.0 
equiv), and THF (570 mL) was lowered into a –78 °C bath. A flame-dried 250 mL round-
bottom flask was cycled into a glove box and loaded with LiHMDS (16.21 g, 96.9 mmol, 
1.7 equiv). The flask was removed from the glove box, reconnected to a manifold, and 
charged with THF (96.9 mL, 1 M). This 1 M solution of LiHMDS was added to the flask 
containing imide 17 dropwise. After 1 h at –78 °C, allylchloroformate (6.08 mL, 57.0 
mmol, 1 equiv) was added dropwise and the reaction was stirred for 5 min before being 
quenched with saturated aqueous ammonium chloride and transferred to a separatory 
funnel, where the aqueous layer was extracted with ether (500 mL). The combined 
organics were washed with brine, dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The resulting crude oil was purified by flash column chromatography 
(SiO2, CH2Cl2 to 10% Et2O in CH2Cl2) to afford 18 as a yellow oil (14.26 g, 83% yield). 
Spectral data were in agreement with the literature.10 
The resulting yellow oil was taken up in acetonitrile (156 mL, 0.3 M) in a flame-dried 
250 mL Schlenck flask equipped with a magnetic stir bar. Cs2CO3 (19.8 g, 60.84 mmol, 
1.30 equiv) and methyl iodide (8.74 mL, 140.4 mmol, 3.00 equiv) were added and the 
reaction was heated to 50 °C and stirred for 10 h. The reaction was diluted with 50 mL 
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oil was purified by flash column chromatography (SiO2, 20% to 33% EtOAc in hexanes) 
to afford imide 28a (14.25 g, 96% yield) as a pale yellow oil. Spectral data were in 
agreement with the literature.10 
allyl 1-(benzyloxy)-3-ethyl-2,6-dioxopiperidine-3-carboxylate (28b) 
  
Compound 28b was prepared according to the procedure for 28a using Ethyl iodide. The 
crude product was purified by column chromatography (SiO2, 20% EtOAc in hexanes) to 
furnish 28b (888 mg, 81% yield). Spectral data were in agreement with the literature.10 
allyl 3-benzyl-1-(benzyloxy)-2,6-dioxopiperidine-3-carboxylate (28c) 
  
Compound 28c was prepared according to the procedure for 28a using benzyl bromide. 
The crude product was purified by column chromatography (SiO2, 15% EtOAc in 
hexanes) to furnish 28c (367 mg, 81% yield) as a white solid. Rf = 0.67 (hexanes/EtOAc 
= 2:1); IR (neat film, NaCl) 3528, 3031, 2945, 1734, 1707, 1496, 1454, 1232, 1175, 993, 
972, 941, 749, 700; 1H NMR (500 MHz, CDCl3) δ 7.53 (dq, J = 8.1, 4.5, 4.0 Hz, 2H), 
7.41 (ddd, J = 6.3, 4.7, 2.5 Hz, 4H), 7.38 – 7.31 (m, 4H), 7.29 – 7.25 (m, 2H), 5.95 (ddt, J 
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J = 13.7 Hz, 1H), 3.28 (d, J = 13.7 Hz, 1H), 2.75 – 2.68 (m, 2H), 2.25 – 2.18 (m, 1H), 
1.89 (ddd, J = 13.9, 11.2, 7.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 169.90, 167.12, 
166.56, 140.91, 134.72, 133.75, 130.85, 130.70, 129.98, 129.09, 128.55, 128.39, 127.61, 
127.48, 126.96, 120.08, 77.84, 66.99, 65.34, 56.93, 40.22, 30.13, 24.78.; HRMS (m/z): 
[M+H]+ calcd for C23H24NO5, 394.1649; found, 394.1662. 
allyl 1-(benzyloxy)-2,6-dioxo-3-(3,3,3-trifluoropropyl)piperidine-3-carboxylate (4m) 
 
Compound 4m was prepared according to the procedure for 10a using trifluoropropyl 
iodide. The crude product was purified by column chromatography (SiO2, 33% EtOAc in 
hexanes) to furnish 4m (723 mg, 30% yield). Spectral data were in agreement with the 
literature.12 
 (S)-3-allyl-1-(benzyloxy)-3-methylpiperidine-2,6-dione (29a)  
 
An oven-dried scintillation vial was cycled into a glove box and loaded with Pd(OAc)2 (2 
mg, 0.008 mmol, 0.01 equiv), (S)-(CF3)3-t-BuPHOX (14 mg, 0.023 mmol, 0.03 equiv), 
and TBME (1.6 mL). The flask was stirred for 30 min. Imide 28a (242 mg, 0.76 mmol, 1 
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was stirred at 65 °C for 66 hours. The reaction mixture was then cooled, concentrated, 
and purified by flash column chromatography (SiO2, 20% EtOAc in hexanes) to afford 
imide 29a as a pale yellow oil (182 mg, 88% yield, 92% ee). Spectral data were in 
agreement with the literature.10 
Gram Scale Reaction: 
A flame-dried 500 mL Schlenck tube was cycled into a glove box and loaded with 
Pd(OAc)2 (79 mg, 0.35 mmol, 0.01 equiv), (S)-(CF3)3-t-BuPHOX (621 mg, 1.05  mmol, 
0.03 equiv), and TBME (50 mL). The flask was stirred for 30 min. Imide 28a (11.1 g, 35 
mmol, 1 equiv) was taken up in TBME (200 mL), and added to the reaction mixture. The 
reaction was stirred at 65 °C for 66 hours. The reaction mixture was then cooled, 
concentrated, and purified by flash column chromatography (SiO2, 20% EtOAc in 
hexanes) to afford imide 29a as a pale yellow oil (7.71 g, 81% yield, 92% ee). Spectral 
data were in agreement with the literature. 
(S)-3-allyl-1-(benzyloxy)-3-ethylpiperidine-2,6-dione (29b) 
 
Compound 29b was prepared from 28b according to the procedure for 29a. The crude 
product was purified by column chromatography (SiO2, 20% EtOAc in hexanes) to 
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An oven-dried 100 mL Schlenck flask was cycled into a glove box and loaded with 
Pd2(dba)3 (46 mg, 0.051 mmol, 0.05 equiv), (S)-(CF3)3-t-BuPHOX (75 mg, 0.126 mmol, 
0.015 equiv), and toluene (11 mL). The reaction mixture was stirred 30 min. Imide 28c 
(398 mg, 1.01 mmol, 1 equiv) was taken up in 20 mL toluene, and added to the reaction 
mixture. The reaction was stirred at 40 °C for 66 hours. The reaction mixture was then 
cooled, concentrated, and purified by flash column chromatography (SiO2, 20% EtOAc in 
hexanes) to afford imide 29c as a white solid (311 mg, 89% yield, 86% ee). Rf = 0.44 
(hexanes/EtOAc = 4:1); [α]25D +25.3˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3063, 3031, 
2941, 1739, 1698, 1454, 1173, 991, 742, 701; 1H NMR (500 MHz, CDCl3) δ 7.52 – 7.45 
(m, 2H), 7.36 (dp, J = 4.8, 1.9 Hz, 3H), 7.33 – 7.26 (m, 3H), 7.19 – 7.13 (m, 2H), 5.69 
(ddt, J = 17.2, 10.0, 7.3 Hz, 1H), 5.21 – 5.10 (m, 2H), 4.99 – 4.91 (m, 2H), 3.29 (d, J = 
13.6 Hz, 1H), 2.74 (d, J = 13.6 Hz, 1H), 2.68 (ddd, J = 17.8, 8.5, 5.6 Hz, 1H), 2.59 – 2.48 
(m, 2H), 2.27 (dd, J = 13.9, 7.9 Hz, 1H), 1.83 – 1.69 (m, 2H).; 13C NMR (126 MHz, 
CDCl3) δ 172.37, 167.75, 136.05, 133.85, 132.08, 130.52 (2C), 130.14 (2C), 129.14, 
128.55 (2C), 128.42 (2C), 127.22, 120.22, 78.05, 47.81, 42.42, 41.68, 29.49, 24.00.; 
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 (R)-3-allyl-1-(benzyloxy)-3-(3,3,3-trifluoropropyl)piperidine-2,6-dione (5m) 
 
Compound 5m was prepared from 4m according to the procedure for 29c. The reaction 
mixture was then cooled, concentrated, and purified by flash column chromatography 
(SiO2, 20% EtOAc in hexanes) to afford imide 5m (307 mg, 80% yield, 84% ee). Spectral 
data were in agreement with the literature.12 
(3S)-3-Allyl-1-(benzyloxy)-6-hydroxy-3-methylpiperidin-2-one (34a) 
 
To a 10 mL round bottom flask charged with a magnetic stirring bar and a solution of 29a 
(50.4 mg, 184 µmol) in CH2Cl2 (1.84 mL) was slowly added DIBAL-H in CH2Cl2 (1.0 M, 
239 µL, 239 µmol) at –78 ˚C under N2 atmosphere. After being stirred at –78 ˚C for 15 
min, the reaction mixture was quenched with saturated aq. Rochelle salt (2.0 mL) and 
vigorously stirred at room temperature. Resultant two layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3.0 mL × 1). The combined organic layers 
were washed with brine (5.0 mL × 1), dried over sodium sulfate, filtered, and 
concentrated under reduced pressure to afford the crude product. The residue was 
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afford inseparable mixture 34a (d.r. = 1:1, 37.8 mg, 75%) as a colorless oil; Rf = 0.42 
(hexanes/EtOAc = 1:1); [α]25D –174.2 (c 1.00, CHCl3); IR (neat film, NaCl) 3367, 3069, 
2942, 1638, 1455, 1286, 1081, 1006, 920, 748, 699; 1H NMR (500 MHz, CDCl3) δ 7.45-
7.42 (complex m, 2H), 7.40-7,34 (complex m, 3H), 5.77 (m, 1H), 5.13-5.06 (complex m, 
2H), 4.98-4.88 (complex m, 3H), 3.19 (br s, 1/2H), 3.03 (br s, 1/2H), 2.57 (app ddd, J = 
13.7, 6.5, 1.4 Hz, 1/2H), 2.33 (app dd, J = 7.5, 1.2 Hz, 1/2H), 2.22 (app dd, J = 13.7, 8.3 
Hz, 1/2H), 2.13 (app dt, J = 13.4, 3.9 Hz, 1/2H), 2.05-1.91 (complex m, 1H), 1.88-1.78 
(complex m, 2H), 1.60 (m, 1/2H), 1.31 (app ddd, J = 13.9, 4.2, 4.2 Hz, 1/2H); 1.22 (s, 
1.5H), 1.21 (s, 1.5H); 13C NMR (126 MHz, CDCl3) δ 174.9 (1/2C), 174.3 (1/2C), 135.5 
(1/2C), 135.4 (1/2C), 133.9 (1/2C), 133.4 (1/2C), 129.8, 129.7 (1/2C), 129.7 (1/2C), 
128.9 (1/2C), 128.9 (1/2C), 128.6, 128.6, 118.6 (1/2C), 118.6 (1/2C), 82.8 (1/2C), 82.5 
(1/2C), 76.9, 43.6 (1/2C), 43.2 (1/2C), 43.2 (1/2C), 43.0 (1/2C), 27.6 (1/2C), 27.0 (1/2C), 
26.4 (1/2C), 26.4 (1/2C), 24.9 (1/2C), 23.9 (1/2C); HRMS (m/z): [M–H2O] calcd for 
C16H19NO2, 258.1489; found, 258.1477. 
(3S)-3-allyl-1-(benzyloxy)-6-hydroxy-3-ethylpiperidin-2-one (34b) 
 
Compound 34b was prepared from 29b according to the procedure for 34a. The residue 
was purified by silica gel flash column chromatography (SiO2, 15% EtOAc in hexanes) to 
afford inseparable mixture 34b (d.r. = 1:1, 49 mg, 60% yield) as a colorless oil; Rf =  0.42 














Chapter 2: Synthesis of enantioenriched 2,2-disubstitutedpyrrolidines via sequential 
asymmetric allylic alkylation and ring contraction 
170	
2963, 2938, 1650, 1643, 1455, 1284, 1080, 979, 916, 751, 698; 1H NMR (500 MHz, 
CDCl3) δ 7.43 (ddt, J = 8.0, 6.3, 1.9 Hz, 2H), 7.40 – 7.32 (m, 3H), 5.83 – 5.72 (m, 1H), 
5.12 – 5.05 (m, 2H), 4.99 – 4.87 (m, 3H), 3.17 (br s, 1H), 2.55 (ddt, J = 13.8, 6.2, 1.4 Hz, 
1/2H), 2.35 (ddt, J = 7.7, 6.5, 1.2 Hz, 1H), 2.24 – 2.16 (m, 1/2H), 2.12 – 1.93 (m, 1 
1/2H), 1.89 – 1.79 (m, 2H), 1.74 – 1.56 (m, 1H), 1.53 – 1.41 (m, 1 1/2H) 0.91 (td, J = 7.5, 
1.6 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ 174.23 (1/2C), 173.78 (1/2C), 135.44, 
134.19, 133.80, 129.71, 128.93, 128.88, 128.62 (1/2C), 128.58 (1/2C), 118.40 (1/2C), 
118.26 (1/2C), 82.74 (1/2C), 82.62 (1/2C), 47.00 (1/2C), 46.60 (1/2C), 42.26, 40.45, 
30.24 (1/2C), 29.60 (1/2C), 26.17 (1/2C), 26.07 (1/2C), 24.45 (1/2C), 23.73 (1/2C), 8.51 




Compound 34c was prepared from 29c according to the procedure for 34a. The residue 
was purified by silica gel flash column chromatography (SiO2, 15% EtOAc in hexanes) to 
afford inseparable mixture 34c (d.r. = 1:1, 111 mg, 37% yield) as a white solid; Rf = 0.44 
(hexanes/EtOAc = 2:1); [α]25D +29.1˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3390, 3063, 
3028, 2939, 1671, 1495, 1453, 1299, 1071, 997, 919, 750, 700; 1H NMR (400 MHz, 
CDCl3) δ 7.44 – 7.32 (m, 5H), 7.33 – 7.25 (m, 3H), 7.23 – 7.14 (m, 2H), 5.90 – 5.74 (m, 
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(dd, J = 3.3, 1.2 Hz, 1/2H), 2.77 – 2.66 (m, 1 1/2H), 2.61 (d, J = 3.8 Hz, 1/2H), 2.49 (ddt, 
J = 13.8, 7.1, 1.3 Hz, 1/2H), 2.35 (dd, J = 13.9, 7.6 Hz, 1/2H), 2.13 – 1.94 (m, 2H), 1.75 
– 1.63 (m, 1 1/2H), 1.53 – 1.41 (m, 1H).; 13C NMR (126 MHz, CDCl3) δ 172.87 (1/2 C), 
172.86 (1/2 C), 137.43 (1/2 C), 137.30 (1/2 C), 135.54 (1/2 C), 135.50 (1/2 C), 133.84 
(1/2 C), 133.68 (1/2 C), 130.98, 130.69, 129.81, 129.79, 129.07 (1/2 C), 129.05 (1/2 C), 
128.76, 128.73, 128.36, 128.26, 126.93 (1/2 C), 126.69 (1/2 C), 119.12 (1/2 C), 118.94 
(1/2), 82.68 (1/2 C), 82.46 (1/2 C), 48.01 (1/2 C), 47.99 (1/2 C), 44.24, 42.90, 42.72 (1/2 
C), 42.61 (1/2 C), 26.53 (1/2 C), 26.45 (1/2 C), 23.70 (1/2 C), 23.18 (1/2 C). HRMS 
(m/z): [M+H]+ calcd for C22H26NO3, 351.1907; found, 351.1915. 
 (3R)-3-allyl-1-(benzyloxy)-6-hydroxy-3-(3,3,3-trifluoropropyl)piperidin-2-one (34d)  
 
Compound 34d was prepared from 5m according to the procedure for 34a. The residue 
was purified by silica gel flash column chromatography (SiO2, 15% EtOAc in hexanes) to 
afford inseparable mixture 34d (d.r. = 1:1, 125 mg, 41% yield) as a colorless oil;. Rf = 
0.27 (hexanes/EtOAc = 3:1); [α]25D +15.0˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3390, 
3063, 3028, 2939, 1671, 1495, 1453, 1299, 1071, 997, 919, 750, 700; 1H NMR (500 
MHz, CDCl3) δ 7.47 – 7.29 (m, 5H), 5.72 (dddd, J = 16.7, 15.0, 10.2, 7.8 Hz, 1H), 5.21 – 
5.08 (m, 2H), 4.98 – 4.84 (m, 3H), 3.21 (br s, 1H), 2.51 (ddt, J = 13.9, 6.3, 1.5 Hz, 1/2H), 
2.44 – 2.32 (m, 1H), 2.26 (dd, J = 14.0, 8.4 Hz, 1/2H), 2.23 – 2.12 (m, 2H), 2.12 – 1.93 
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1H), 1.42 (dt, J = 14.1, 4.2 Hz, 1/2H).; 13C NMR (126 MHz, CDCl3) δ 173.49, 135.24, 
132.84, 132.51, 129.84 (2C), 129.18, 128.77 (1/2C), 128.75 (1/2C), 127.29 (q, J = 276.5 
Hz), 119.55 (1/2C), 119.52 (1/2C), 82.68, 45.95 (1/2C), 45.23 (1/2C), 42.46 (1/2C), 
40.20 (1/2C), 29.24 (q, J = 29.1 Hz), 29.12 (q, J = 3.0 Hz), 26.15, 25.96 (1/2C), 25.84 
(1/2C), 24.24.; 19F NMR (282 MHz, CDCl3) δ -66.48 – -66.68 (m, 3F); HRMS (m/z): 
[M+H]+ calcd for C18H23F3NO3, 358.1625; found, 358.1641. 
 (S)-3-Allyl-1-(benzyloxy)-3-methylpiperidin-2-one (35a) 
  
To a 250 mL round bottom flask charged with a magnetic stirring bar and a solution of 
34a (1.53 g, 5.56 mmol) in CH2Cl2 (55.6 mL) was added Et3SiH (1.77 mL, 11.1 mmol) 
and TFA (8.51 mL, 111 mmol) at room temperature under N2 atmosphere. After being 
stirred at ambient temperature for 5 min, the reaction mixture was evaporated in vacuo. 
The residue was purified by flash column chromatography (SiO2, 20% EtOAc in 
hexanes) to afford 35a (1.45 g, quant.) as a colorless oil; Rf = 0.38 (hexanes/EtOAc = 
2:1); [α]25D –36.3˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3069, 2944, 2873, 1774, 1654, 
1456, 1324, 1207, 1171, 998, 918, 750, 700; 1H NMR (500 MHz, CDCl3) δ 7.46-7.41 
(complex m, 2H), 7.39-7.32 (complex m, 3H), 5.74 (m, 1H), 5.12-5.05 (complex m, 2H), 
4.95 (d, J = 10.6 Hz, 1H), 4.91 (d, J = 10.5 Hz, 1H), 3.41-3.30 (complex m, 2H), 2.49 
(dd, J = 13.7, 6.8 Hz, 1H), 2.24 (dd, J = 13.7, 8.0 Hz, 1H), 1.82-1.69 (complex m, 3H), 
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(2C), 128.8, 128.5 (2C), 118.6, 75.6, 51.1, 43.7, 43.0, 31.9, 25.1, 19.6; HRMS (m/z): 
[M+H]+ calcd for C16H22NO2, 260.1645; found, 260.1630. 
(S)-3-allyl-1-(benzyloxy)-3-ethylpiperidin-2-one (35b) 
 
Compound 35b was prepared from 34b according to the procedure for 35a. The residue 
was purified by silica gel flash column chromatography (SiO2, 20% EtOAc in hexanes) to 
afford inseparable mixture 35b (60 mg, 94% yield) as a colorless oil; Rf = 0.42 
(hexanes/EtOAc = 4:1); [α]25D –30.5˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3069, 3032, 
2941, 2879, 1777, 1659, 1454, 1308, 1207, 1169, 998, 975, 918, 749, 699; 1H NMR (500 
MHz, CDCl3) δ 7.46 – 7.39 (m, 2H), 7.39 – 7.32 (m, 3H), 5.75 (dddd, J = 16.9, 10.4, 8.0, 
6.8 Hz, 1H), 5.10 (q, J = 1.4 Hz, 1H), 5.07 (dq, J = 10.7, 1.5 Hz, 1H), 4.92 (s, 2H), 3.42 – 
3.34 (m, 2H), 2.49 (ddt, J = 13.7, 6.8, 1.4 Hz, 1H), 2.27 – 2.20 (m, 1H), 1.80 (dddd, J = 
8.8, 7.4, 6.1, 4.9 Hz, 2H), 1.77 – 1.71 (m, 1H), 1.68 – 1.60 (m, 2H), 1.60 – 1.54 (m, 1H), 
0.90 (t, J = 7.5 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ 172.71, 135.14, 133.99, 129.69 
(2C), 128.84, 128.50 (2C), 118.50, 75.83, 51.01, 46.45, 42.02, 30.57, 28.19, 19.59, 8.53.; 
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Compound 35c was prepared from 34c according to the procedure for 35a. The residue 
was purified by silica gel flash column chromatography (SiO2, 20% EtOAc in hexanes) to 
afford inseparable mixture 35c (75 mg, 79% yield) as a colorless oil; Rf = 0.36 
(hexanes/EtOAc = 4:1); [α]25D +15.4˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3065, 3029, 
2943, 2875, 1777, 1651, 1603, 1454, 1209, 1166, 994, 919, 751, 702; 1H NMR (500 
MHz, CDCl3) δ  7.42 – 7.25 (m, 10H), 5.84 (dddd, J = 16.8, 10.1, 8.1, 6.6 Hz, 1H), 5.23 
– 5.12 (m, 2H), 5.01 – 4.85 (m, 2H), 3.39 – 3.31 (m, 2H), 3.19 (ddd, J = 11.6, 6.7, 5.2 
Hz, 1H), 2.75 – 2.66 (m, 2H), 2.27 (dd, J = 13.6, 8.1 Hz, 1H), 1.81 – 1.72 (m, 1H), 1.72 – 
1.66 (m, 2H), 1.61 – 1.53 (m, 1H).; 13C NMR (126 MHz, CDCl3) δ 171.73, 137.35, 
135.10, 133.48, 130.79 (2C), 129.69 (2C), 128.85, 128.51 (2C), 128.26 (2C), 126.71, 
119.20, 76.01, 50.95, 47.61, 43.68, 43.30, 27.60, 19.53.; HRMS (m/z): [M+H]+ calcd for 
C22H26NO2, 336.1958; found, 336.1973. 
(R)-3-allyl-1-(benzyloxy)-3-(3,3,3-trifluoropropyl)piperidin-2-one (35d) 
 
Compound 35d was prepared from 34d according to the procedure for 35a. The residue 
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afford inseparable mixture 35d (45 mg, 54% yield) as a colorless oil; Rf = 0.34 
(hexanes/EtOAc =4:1); [α]25D –4.0˚ (c 0.50, CHCl3); IR (neat film, NaCl) 3068, 3033, 
2952, 2875, 1658, 1454, 1324, 1259, 1149, 983, 919, 750, 699; 1H NMR (500 MHz, 
CDCl3) δ 7.41 (dq, J = 5.4, 3.3, 2.6 Hz, 2H), 7.37 (dt, J = 4.4, 2.9 Hz, 3H), 5.70 (dddd, J 
= 16.9, 10.1, 7.8, 6.9 Hz, 1H), 5.18 – 5.09 (m, 2H), 4.96 – 4.88 (m, 2H), 3.40 (t, J = 6.1 
Hz, 2H), 2.46 (ddt, J = 13.8, 6.8, 1.3 Hz, 1H), 2.30 (dd, J = 13.8, 7.8 Hz, 1H), 2.20 – 2.05 
(m, 2H), 1.90 – 1.78 (m, 3H), 1.74 (ddt, J = 13.6, 11.1, 4.7 Hz, 2H), 1.54 (ddd, J = 13.8, 
8.3, 3.6 Hz, 1H).; 13C NMR (126 MHz, CDCl3) δ 171.52, 134.79, 132.59, 129.73 (2C), 
129.34 (q, JC-F = 276.3 Hz), 129.02, 128.54 (2C), 119.55, 75.77, 50.86, 44.92, 41.44, 
29.53, 29.52 (q, JC-F = 3.4 Hz), 29.15 (q, JC-F = 28.8 Hz), 19.23.; 19F NMR (282 MHz, 
CDCl3) δ -66.54 (t, J=10.7 Hz, 3F);  HRMS (m/z): [M+H]+ calcd for C18H23F3NO2, 
342.1675; found, 342.1692. 
(S)-3-Allyl-1-hydroxy-3-methylpiperidin-2-one (30a) 
 
To a 250 mL round bottom flask charged with a magnetic stirring bar and a solution of 
35a (1.39 g, 5.01 mmol) in CH2Cl2 (50.1 mL) was added BCl3 in CH2Cl2 (1.0 M, 6.01 
mL, 6.01 mmol) dropwise over 10 min at –78 ˚C under N2 atmosphere. After being 
stirred at 0 ˚C for 10 min, the solvent was removed in vacuo. The residue was diluted 
with hexanes/Et2O (v/v = 10/1, 30 mL) and 1N NaOH (30 mL) was carefully added to 
adjust the pH to >14. Resultant two layers were separated and the organic phase was 
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pH to <1, followed by addition of CH2Cl2 (60 mL). The two layers were separated and 
the aqueous phase was extracted with CH2Cl2 (50 mL × 1). The combined organic layers 
were washed with brine (120 mL × 1), dried over sodium sulfate, filtered, and 
concentrated under reduced pressure to afford pure hydroxamic acid 30a (773 mg, 91%) 
as a pale orange crystal, which was used in the next reaction without further purification; 
Rf = 0.38 (CH2Cl2/MeOH = 8:1); mp = 41-42 ˚C; [α]25D –68.0˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3073, 2938, 2869, 1628, 1456, 1329, 1021, 999, 919; 1H NMR (500 MHz, 
CDCl3) δ 5.72 (m, 1H), 5.13-5.05 (complex m, 2H), 3.62 (app t, J = 6.2 Hz, 2H), 2.47 
(app dd, J = 13.7, 6.8 Hz, 1H), 2.27 (dd, J = 13.7, 8.0 Hz, 1H), 1.99-1.92 (complex m, 
2H), 1.83 (m, 1H), 1.53 (m, 1H), 1.23 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 170.0, 
133.9, 118.6, 49.6, 43.6, 41.4, 31.9, 24.7, 19.0; HRMS (m/z): [M+H]+ calcd for 
C9H16NO2, 170.1176; found, 170.1167. 
(S)-3-allyl-3-ethyl-1-hydroxypiperidin-2-one (30b) 
 
Compound 30b was prepared from 35b according to the procedure for 30a. The residue 
was concentrated under reduced pressure to afford pure hydroxamic acid 30b (13 mg, 
62%) as a pale orange solid, which was used in the next reaction without further 
purification; Rf = 0.45 (hexanes/EtOAc = 1:1); [α]25D –40.7˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3076, 2941, 2879, 1626, 1455, 919; 1H NMR (500 MHz, CDCl3) δ 7.26 (br s, 
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1.8 Hz, 2H), 2.46 (ddt, J = 13.8, 6.7, 1.4 Hz, 1H), 2.25 (dd, J = 13.8, 7.9 Hz, 1H), 2.04 – 
1.87 (m, 2H), 1.71 (ddd, J = 12.1, 9.6, 6.4 Hz, 3H), 1.58 (dq, J = 14.6, 7.4 Hz, 1H), 0.88 
(t, J = 7.4 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ 168.86, 134.07, 118.33, 48.75, 44.67, 




Compound 30c was prepared from 35c according to the procedure for 30a. The residue 
was concentrated under reduced pressure to afford pure hydroxamic acid 30c (33 mg, 
80%) as a pale orange solid, which was used in the next reaction without further 
purification; Rf = 0.55 (hexanes/EtOAc = 1:1); [α]25D +18.0˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3076, 3029, 2926, 2869, 1624, 1453, 917, 703; 1H NMR (500 MHz, CDCl3) 
δ 7.37 – 7.25 (m, 3H), 7.24 – 7.17 (m, 2H), 5.81 (dddd, J = 16.6, 10.1, 8.3, 6.3 Hz, 1H), 
5.21 – 5.11 (m, 2H), 3.60 (ddd, J = 12.2, 7.3, 5.3 Hz, 1H), 3.48 (dt, J = 11.0, 5.4 Hz, 1H), 
3.31 (d, J = 13.3 Hz, 1H), 2.74 (d, J = 13.4 Hz, 1H), 2.69 (ddt, J = 13.7, 6.3, 1.4 Hz, 1H), 
2.24 (dd, J = 13.6, 8.3 Hz, 1H), 1.88 (ddtd, J = 13.3, 8.4, 5.5, 2.1 Hz, 1H), 1.81 – 1.63 
(m, 3H).; 13C NMR (126 MHz, CDCl3) δ 167.69, 137.37, 133.74, 130.47 (2C), 128.24 
(2C), 126.65, 118.97, 48.32, 45.78, 43.49, 43.06, 27.96, 18.82.; HRMS (m/z): [M+H]+ 
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Compound 30d was prepared from 35d according to the procedure for 30a. The residue 
was concentrated under reduced pressure to afford pure hydroxamic acid 30d (30 mg, 
81%) as a pale yellow solid, which was used in the next reaction without further 
purification; Rf = 0.60 (hexanes/EtOAc = 1:1); [α]25D –16.9˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3080, 2926, 2855, 1633, 1454, 1324, 1260, 1118, 981, 916; 1H NMR (500 
MHz, CDCl3) δ 9.08 (br s, 1H), 5.70 (dddd, J = 16.9, 10.1, 7.8, 6.9 Hz, 1H), 5.22 – 5.00 
(m, 2H), 3.64 (t, J = 6.2 Hz, 2H), 2.46 (ddt, J = 13.9, 6.8, 1.4 Hz, 1H), 2.33 (dd, J = 13.9, 
7.8 Hz, 1H), 2.26 – 2.09 (m, 2H), 2.07 – 1.92 (m, 2H), 1.90 – 1.73 (m, 3H), 1.63 (ddd, J 
= 13.9, 8.4, 3.8 Hz, 1H).; 13C NMR (126 MHz, CDCl3) δ 167.54, 132.62, 127.15 (q, J = 
276.2 Hz), 119.51, 48.69, 43.14, 41.19, 29.72, 29.29 (q, J = 3.0 Hz), 29.27 (q, J = 28.8 
Hz), 18.55. ; 19F NMR (282 MHz, CDCl3) δ -66.56 (t, J=10.6 Hz, 3F); HRMS (m/z): 
[M+H]+ calcd for C11H17F3NO2, 252.1206; found, 252.1203. 
 (S)-3-Allyl-3-methyl-2-oxopiperidin-1-yl trifluoromethanesulfonate (36a) 
 
To a 100 mL round bottom flask charged with a magnetic stirring bar and a solution of 
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Tf2O (898 µL, 5.47 mmol) at 0 ˚C under N2 atmosphere. After being stirred at 0 ˚C for 5 
min, the reaction mixture was quenched with saturated aq. NH4Cl (50 mL). Resultant two 
layers were separated and the aqueous phase was extracted with CH2Cl2 (50 mL × 1). The 
combined organic layers were washed with brine (100 mL × 1), dried over sodium 
sulfate, filtered, and concentrated under reduced pressure to afford the crude product. 
This resulting triflate 36a was used in the next reaction without further purification due to 
it’s instability; Rf = 0.48 (hexanes/EtOAc = 2:1). 
Methyl (S)-2-allyl-2-methylpyrrolidine-1-carboxylate (31a) 
 
To a 100 mL round bottom flask charged with a magnetic stirring bar and a solution of 
fleshly prepared 36a in freshly distilled MeOH (30.4 mL) was added Et3N (1.26 mL, 9.12 
mmol) at room temperature under N2 atmosphere and the stirred mixture was heated to 
reflux and stirred for 50 min. The reaction mixture was cooled to room temperature 
before the solvent was removed under reduced pressure. The residue was purified by 
flash column chromatography (SiO2, 5% EtOAc in hexanes) to afford 31a (695 mg, 83%) 
as a yellow oil; Rf = 0.48 (hexanes/EtOAc = 2:1); [α]25D –70.3˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 2961, 2927, 2871, 1700, 1444, 1375, 1212, 1189, 1082, 912, 772, 694; 1H 
NMR (500 MHz, CDCl3) δ Rotamer A: 5.70 (m, 1H), 5.11-5.01 (m, 2H), 3.70 (s, 3H), 
3.58 (m, 1H), 3.37 (m, 1H), 2.56 (dd, J = 13.7, 6.9 Hz, 1H), 2.37 (dd, J = 13.7, 7.8 Hz, 
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5.70 (m, 1H), 5.11-5.01 (m, 2H), 3.64 (s, 3H), 3.47 (m, 1H), 3.31 (m, 1H), 2.68 (dd, J = 
13.6, 6.8 Hz, 1H), 2.51 (dd, J = 13.6, 8.0 Hz, 1H), 1.95 (m, 1H), 1.80-1.71 (complex m, 
2H), 1.60 (m, 1H), 1.37 (s, 3H); 13C NMR (126 MHz, CDCl3) δ Rotamer A: 155.7, 134.5, 
118.0, 62.3, 51.9, 49.1, 43.6, 38.9, 25.9, 21.7; Rotamer B: 154.4, 134.8, 117.9, 63.0, 51.7, 
48.1, 42.5, 37.8, 24.7, 22.2; HRMS (m/z): [M+H]+ calcd for C10H18NO2, 183.1259; found, 
183.12. 
benzyl (S)-2-allyl-2-methylpyrrolidine-1-carboxylate (31b) 
 
To a 5 mL round bottom flask charged with a magnetic stirring bar and a solution of 
fleshly prepared 36a (0.21 mmol, 1 equiv) in a 3:1 mixture of toluene and benzyl alcohol 
(1.42 mL, 0.15 M) was added Et3N (0.059 mL, 0.18 mmol, 2 equiv) at room temperature 
under N2 atmosphere and the stirred mixture was heated to reflux and stirred for 3 hours. 
The reaction mixture was cooled to room temperature before the solvent was removed 
under reduced pressure. The residue was purified by flash column chromatography (SiO2, 
5% EtOAc in hexanes) to afford 31b (31 mg, 56% yield, 92% ee) as a orange oil; Rf = 
0.75 (hexanes/EtOAc = 2:1); [α]25D –90.9˚ (c 1.00, CHCl3); IR (neat film, NaCl) 3068, 
3032, 2966, 2875, 1698, 1453, 1403, 1353, 1213, 1128, 1068, 914, 769, 697; 1H NMR 
(500 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H), 5.76 – 5.61 (m, 1H), 5.20 – 4.96 (m, 4H), 3.65 
– 3.52 (m, 1H), 3.39 (tt, J = 10.8, 7.4 Hz, 1H), 2.66 (dddt, J = 63.2, 13.7, 6.8, 1.4 Hz, 
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= 12.5, 6.2 Hz, 1H), 1.36 (d, J = 40.5 Hz, 3H).; 13C NMR (126 MHz, CDCl3) δ Rotamer 
A: 153.77, 137.45, 134.79, 128.51 (2C), 128.20, 127.74 (2C), 118.06, 66.08, 63.24, 
48.30, 42.51, 37.85, 24.83, 22.25. Rotamer B: 155.05, 136.93, 134.47, 128.58 (2C), 
128.01, 127.83 (2C), 118.18, 66.98, 62.58, 49.32, 43.69, 39.03, 26.15, 21.83. HRMS 
(m/z): [M+H]+ calcd for C16H22NO2, 260.1645; found, 260.1656. 
tert-butyl (S)-2-allyl-2-methylpyrrolidine-1-carboxylate (31c) 
 
To a 50 mL round bottom flask charged with a magnetic stirring bar and a solution of 
fleshly prepared 36a (1.93 mmol, 1 equiv) in a 3:1 mixture of toluene and tert-butyl 
alcohol (13 mL, 0.15 M) was added Et3N (0.53 mL, 3.85 mmol, 2 equiv) at room 
temperature under N2 atmosphere and the stirred mixture was heated to reflux and stirred 
for 3 hours. The reaction mixture was cooled to room temperature before the solvent was 
removed under reduced pressure. The residue was purified by flash column 
chromatography (SiO2, 5% EtOAc in hexanes) to afford 31c (280 mg, 65% yield) as a 
yellow oil;. Rf = 0.32 (hexanes/EtOAc = 19:1); [α]25D –55.4˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3078, 2970, 2928, 2870, 1697, 1457, 1387, 1170, 1066, 912, 771; 1H NMR 
(400 MHz, CDCl3) δ  5.70 (dddd, J = 17.6, 9.8, 8.0, 6.7 Hz, 1H), 5.06 (dt, J = 15.6, 3.7 
Hz, 2H), 3.48 (ddt, J = 39.8, 12.0, 6.1 Hz, 1H), 3.28 (ddt, J = 25.5, 10.7, 7.4 Hz, 1H), 
2.61 (dd, J = 13.7, 6.5 Hz, 1H), 2.33 (dd, J = 13.7, 8.0 Hz, 1H), 2.08 – 1.84 (m, 1H), 1.77 
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Hz, 3H).; 13C NMR (101 MHz, CDCl3) δ Rotamer A: 154.49, 134.90, 117.91, 79.41, 
61.98, 48.73, 43.81, 39.12, 28.76 (3C), 26.11, 21.67. Rotamer B: 13C NMR (101 MHz, 




Compound 36b was prepared from compound 30b according to the procedure for 36a, 
and was used without further purification. Compound 31d was prepared from 36b 
according to the procedure for 31b. The residue was purified by flash column 
chromatography (SiO2, 5% EtOAc in hexanes) to afford 31d (90 mg, 66% yield) as a 
colorless oil;. Rf = 0.65 (hexanes/EtOAc = 4:1); [α]25D –69.5˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3069, 3032, 2968, 2877, 1702, 1455, 1403, 1356, 1338, 1214, 1123, 1071, 
914, 768, 697; 1H NMR (500 MHz, CDCl3) δ Rotamer A: 7.39 – 7.33 (m, 4H), 7.33 – 
7.27 (m, 1H), 5.77 – 5.62 (m, 1H), 5.20 – 5.12 (m, 1H), 5.11 (d, J = 2.5 Hz, 1H), 5.09 – 
4.94 (m, 2H), 3.55 – 3.41 (m, 2H), 2.79 (ddt, J = 13.4, 6.8, 1.4 Hz, 1H), 2.36 (dd, J = 
13.5, 7.9 Hz, 1H), 2.07 (dq, J = 13.5, 7.4 Hz, 1H), 1.94 – 1.78 (m, 2H), 1.74 (tdd, J = 
12.4, 8.8, 5.5 Hz, 2H), 1.66 (dt, J = 14.7, 7.4 Hz, 1H), 0.82 (t, J = 7.4 Hz, 3H),; Rotamer 
B: 7.39 – 7.33 (m, 4H), 7.33 – 7.27 (m, 1H), 5.77 – 5.62 (m, 1H), 5.20 – 5.12 (m, 1H), 
5.11 (d, J = 2.5 Hz, 1H), 5.09 – 4.94 (m, 2H), 3.55 – 3.41 (m, 2H), 2.61 (ddt, J = 13.5, 
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8.8, 5.5 Hz, 2H), 1.56 (dq, J = 14.6, 7.4 Hz, 1H), 0.78 (t, J = 7.4 Hz, 3H).; 13C NMR (126 
MHz, CDCl3) δ Rotamer A: 153.63, 137.44, 134.73, 128.42 (2C), 128.15, 127.56 (2C), 
117.89, 66.45, 65.97, 48.84, 41.69, 33.66, 29.98, 22.45, 8.60. Rotamer B: 154.99, 136.84, 
134.45, 128.48 (2C), 127.93, 127.71 (2C), 117.99, 66.90, 65.77, 49.82, 43.13, 35.02, 




Compound 36c was prepared from compound 30c according to the procedure for 36a, 
and was used without further purification. Compound 31e was prepared from 36c 
according to the procedure for 31b. The residue was purified by flash column 
chromatography (SiO2, 5% EtOAc in hexanes) to afford 31e (14 mg, 54% yield) as a 
yellow solid;. Rf = 0.78 (hexanes/EtOAc = 2:1); [α]25D +88.6˚ (c 1.00, CHCl3); IR (neat 
film, NaCl) 3063, 3029, 2954, 2927, 2876, 1697, 1454, 1402, 1357, 1336, 1210, 1103, 
917, 748, 700; 1H NMR (500 MHz, CDCl3) δ 7.49 – 7.30 (m, 5H), 7.25 – 7.14 (m, 3H), 
7.09 – 7.00 (m, 2H), 5.80 – 5.62 (m, 1H), 5.34 – 5.19 (m, 1H), 5.15 – 5.10 (m, 1H), 5.08 
(tdd, J = 6.1, 3.9, 2.3 Hz, 1H), 3.53 (d, J = 13.2 Hz, 1H), 3.34 – 3.21 (m, 2H), 3.15 (ddd, 
J = 10.5, 8.0, 4.4 Hz, 1H), 3.01 (ddt, J = 13.5, 6.5, 1.4 Hz, 1H), 2.67 (t, J = 13.8 Hz, 1H), 
2.44 (dd, J = 13.6, 8.2 Hz, 1H), 1.95 – 1.85 (m, 2H), 1.46 (dddd, J = 14.2, 12.1, 5.8, 4.3 
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138.33, 137.49, 134.20, 130.45 (2C), 128.45 (2C), 128.02 (2C), 127.83, 127.80 (2C), 
126.16, 118.46, 66.64, 66.09, 48.69, 42.42, 42.27, 33.82, 21.82. Rotamer B: 154.81, 
138.00, 136.60, 133.78, 130.29 (2C), 128.60 (2C), 128.52 (2C), 128.20 (2C), 128.16, 
126.40, 118.61, 67.24, 65.91, 49.72, 43.92, 43.57, 35.25, 21.34.; HRMS (m/z): [M+H]+ 
calcd for C22H26NO2, 336.1958; found, 336.1966. 
(R)-3-allyl-1-hydroxy-3-(3,3,3-trifluoropropyl)piperidin-2-one (31f) 
 
Compound 36d was prepared from compound 30d according to the procedure for 36a, 
and was used without further purification. Compound 13f was prepared from 36d 
according to the procedure for 31b. The residue was purified by flash column 
chromatography (SiO2, 5% EtOAc in hexanes) to afford 31f (21 mg, 44% yield) as a 
colorless oil;. Rf = 0.73 (hexanes/EtOAc = 2:1); [α]25D –21.1˚ (c 0.33, CHCl3); IR (neat 
film, NaCl) 3074, 2925, 2852, 1698, 1455, 1403. 1341, 1261, 1142, 1019, 919, 771, 696; 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.27 (m, 5H), 5.77 – 5.59 (m, 1H), 5.20 – 4.95 (m, 
4H), 3.60 – 3.38 (m, 2H), 2.76 (ddt, J = 13.6, 7.0, 1.3 Hz, 1H), 2.47 – 2.24 (m, 2H), 2.10 
– 1.90 (m, 3H), 1.90 – 1.66 (m, 4H).; 13C NMR (101 MHz, CDCl3) δ Rotamer A: 153.82, 
137.19, 133.75, 128.59 (2C), 128.37, 127.84 (2C), 127.46 (q, J = 276.0 Hz), 118.96, 
66.48, 64.99, 48.75, 41.64, 34.51, 29.76 (q, J = 2.7 Hz), 29.48 (q, J = 28.6 Hz), 22.28. 
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276.0 Hz), 119.08, 67.47, 64.22, 49.76, 43.39, 35.75, 29.76 (d, J = 2.7 Hz), 29.48 (d, J = 
28.6 Hz), 21.91.; 19F NMR (282 MHz, CDCl3) δ -66.24 (dt, J = 17.7, 10.5 Hz).;  
(2S)-2-methyl-2-(2-propene-1-yl)-pyrrolidine hydrochloride (37) 
 
To a 10-20 mL microwave vial charged with a magnetic stirring bar and a solution of 31a 
(299 mg, 1.63 mmol) in 1,2-propanediol (12.5 mL) was added KOH (4.12 g, 73.4 mmol) 
and H2O (1.63 mL) at room temperature, after which an exotherm was observed. The 
reaction mixture was submitted to microwave irradiation for 1 h at 200 ˚C. The reaction 
mixture was diluted with H2O (15 mL) and extracted with CH2Cl2 (30 mL × 2). The 
combined organic layers were washed with brine (100 mL × 1), dried over sodium 
sulfate, and filtered, followed by the addition of a solution of HCl in Et2O (2.0 M, 2.45 
mL, 4.89 mmol) to form the HCl salt. This resulting mixture was concentrated under 
reduced pressure to afford 37 (257 mg, 98%) as a hygroscopic pale brown solid which 
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(S)-2-Allyl-1-{2-(3,4-dimethoxyphenyl)allyl}-2-methylpyrrolidine (41)  
 
To a 100 mL round bottom flask charged with a magnetic stirring bar and a solution of 37 
(606 mg, 3.75 mmol) in CH3CN (27.5 mL) was added K2CO3 (2.07 g, 15.0 mmol) and a 
solution of freshly prepared allyl bromide 4215 (1.93 g, 7.50 mmol) in CH3CN (10.0 mL) 
at room temperature under N2 atmosphere. The mixture was heated to reflux and stirred 
for 10 hours, and then the reaction mixture was cooled to room temperature before the 
solvent was removed under reduced pressure. The residue was diluted with Et2O (40 mL), 
washed with H2O (40 mL × 1) and brine (40 mL × 1), dried over sodium sulfate, filtered, 
and concentrated under reduced pressure to afford the crude product. The residue was 
purified by flash column chromatography (SiO2, CH2Cl2 to 10% EtOAc in CH2Cl2) to 
afford 41 (939 mg, 83%) as an orange oil; Rf = 0.50 (hexanes/EtOAc = 2:1); [α]25D –17.8˚ 
(c 1.00, CHCl3); IR (neat film, NaCl) 3074, 2959, 2833, 1579, 1516, 1463, 1257, 1222, 
1144, 1028, 904, 809, 766; 1H NMR (500 MHz, CDCl3) δ 7.12 (d, J = 2.1 Hz, 1H), 7.07 
(dd, J = 8.3, 2.1 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 5.83 (m, 1H), 5.30 (app s, 1H), 5.20 
(app s, 1H), 5.07-4.97 (complex m, 2H), 3.89 (s, 3H), 3.88 (s, 3H), 3.56 (d, J = 13.2 Hz, 
1H), 3.26 (d, J = 13.3, 1H), 2.82 (m, 1H), 2.54 (m, 1H), 2.20 (d, J = 7.3 Hz, 2H), 1.79 (m, 
1H), 1.65 (complex m, 2H), 1.46 (m, 1H), 1.00 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
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To two 10-20 mL microwave vial charged with a magnetic stirring bar and a solution of 
41 (445 mg, 1.48 mmol) in toluene (29.5 mL) were added TFA (126 mL, 1.63 mmol) at 
room temperature followed by addition of Grubbs 2nd generation catalyst (126 mg, 148 
µmol). The reaction mixture was submitted to microwave irradiation for 1 h at 100 ˚C. 
Aqueous 1N HCl (30 mL) was added to the reaction mixture to adjust the pH to <1. 
Resultant two layers were separated and the organic phase was washed with 1N HCl (30 
mL × 1). Aqueous 6N NaOH was added to the combined aqueous layers to adjust the pH 
to >14, and the mixture was extracted with CH2Cl2 (60 mL × 1). The combined organic 
layers were washed with brine (150 mL × 1), dried over sodium sulfate, filtered, and 
concentrated under reduced pressure to afford the crude product. The residue was 
purified by flash column chromatography (SiO2, 2% to 5% to 10% MeOH in CH2Cl2, 
0.3% Et3N) to afford 40 (411 mg, 92%) as a pale brown solid; Rf = 0.50 (hexanes/EtOAc 
= 2:1); mp = 51-53 ˚C; [α]25D +51.8˚ (c 1.00, CHCl3); IR (neat film, NaCl) 2923, 2853, 
1602, 1518, 1456, 1251, 1213, 1168, 1146, 1024, 794, 732; 1H NMR (500 MHz, CDCl3) 
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(s, 3H), 3.66 (d, J = 16.8 Hz, 1H), 3.47 (d, J = 16.9, 1H), 3.04 (m, 1H), 2.77 (m, 1H), 
2.32 (d, J = 17.8 Hz, 1H), 2.13 (ddd, J = 17.5, 5.9, 2.7 Hz, 1H), 1.93-1.83 (complex m, 
2H), 1.79 (m, 1H), 1.69 (m, 1H), 1.02 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 148.8, 
148.3, 133.2, 133.1, 120.7, 117.2, 111.0, 108.5, 57.0, 55.9, 55.9, 50.4, 47.9, 38.5, 35.8, 
20.0, 17.2; HRMS (m/z): [M+H]+ calcd for C17H24NO2, 274.1802; found, 274.1817. 
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Spectra Relevant to Chapter 2: 
Synthesis of enantioenriched 2,2-disubstituted 
 pyrrolidines via sequential asymmetric allylic  









































































































































































 Figure A2-1.2. Infrared spectrum (Thin Film, NaCl) of compound 28c. 
 
	Figure A2-1.3. 13C NMR (126 MHz, CDCl3) of compound 28c. 
	









































































































































 Figure A2-1.5. Infrared spectrum (Thin Film, NaCl) of compound 29c. 
 
	Figure A2-1.6. 13C NMR (126 MHz, CDCl3) of compound 29c. 
	






































































































































 Figure A2-1.8. Infrared spectrum (Thin Film, NaCl) of compound 34a. 
 
	Figure A2-1.9. 13C NMR (126 MHz, CDCl3) of compound 34a. 
	








































































































































 Figure A2-1.11. Infrared spectrum (Thin Film, NaCl) of compound 34b. 
 
	Figure A2-1.12. 13C NMR (126 MHz, CDCl3) of compound 34b. 
	








































































































































 Figure A2-1.14. Infrared spectrum (Thin Film, NaCl) of compound 34c. 
 
	Figure A2-1.15. 13C NMR (126 MHz, CDCl3) of compound 34c. 
	








































































































































 Figure A2-1.17. Infrared spectrum (Thin Film, NaCl) of compound 34d. 
 
	Figure A2-1.18. 13C NMR (126 MHz, CDCl3) of compound 34d. 
	

















































Figure A2-1.19. 19F NMR (282 MHz, CDCl3) of compound 34d.	






































































































































 Figure A2-1.21. Infrared spectrum (Thin Film, NaCl) of compound 35a. 
 
	Figure A2-1.22. 13C NMR (126 MHz, CDCl3) of compound 35a. 
	








































































































































 Figure A2-1.24. Infrared spectrum (Thin Film, NaCl) of compound 35b. 
 
	Figure A2-1.25. 13C NMR (126 MHz, CDCl3) of compound 35b. 
	








































































































































 Figure A2-1.27. Infrared spectrum (Thin Film, NaCl) of compound 35c. 
 
	Figure A2-1.28. 13C NMR (126 MHz, CDCl3) of compound 35c. 
	








































































































































 Figure A2-1.30. Infrared spectrum (Thin Film, NaCl) of compound 35d. 
 
	Figure A2-1.31. 13C NMR (126 MHz, CDCl3) of compound 35d. 
	

















































Figure A2-1.32. 19F NMR (282 MHz, CDCl3) of compound 35d.	






































































































































 Figure A2-1.34. Infrared spectrum (Thin Film, NaCl) of compound 30a. 
 
	Figure A2-1.35. 13C NMR (126 MHz, CDCl3) of compound 30a. 
	






































































































































 Figure A2-1.37. Infrared spectrum (Thin Film, NaCl) of compound 30b. 
 
	Figure A2-1.38. 13C NMR (126 MHz, CDCl3) of compound 30b. 
	






































































































































 Figure A2-1.40. Infrared spectrum (Thin Film, NaCl) of compound 30c. 
 
	Figure A2-1.41. 13C NMR (126 MHz, CDCl3) of compound 30c. 
	








































































































































 Figure A2-1.43. Infrared spectrum (Thin Film, NaCl) of compound 30d. 
 
	Figure A2-1.44. 13C NMR (126 MHz, CDCl3) of compound 30d. 
	

















































Figure A2-1.45. 19F NMR (282 MHz, CDCl3) of compound 30d.	






































































































































 Figure A2-1.47. Infrared spectrum (Thin Film, NaCl) of compound 31a. 
 
	Figure A2-1.48. 13C NMR (126 MHz, CDCl3) of compound 31a. 
	






































































































































 Figure A2-1.50. Infrared spectrum (Thin Film, NaCl) of compound 31b. 
 
	Figure A2-1.51. 13C NMR (126 MHz, CDCl3) of compound 31b. 
	






































































































































 Figure A2-1.53. Infrared spectrum (Thin Film, NaCl) of compound 31c. 
 
	Figure A2-1.54. 13C NMR (101 MHz, CDCl3) of compound 31c. 
	








































































































































 Figure A2-1.56. Infrared spectrum (Thin Film, NaCl) of compound 31d. 
 
	Figure A2-1.57. 13C NMR (126 MHz, CDCl3) of compound 31d. 
	








































































































































 Figure A2-1.59. Infrared spectrum (Thin Film, NaCl) of compound 31e. 
 
	Figure A2-1.60. 13C NMR (126 MHz, CDCl3) of compound 31e. 
	








































































































































 Figure A2-1.62. Infrared spectrum (Thin Film, NaCl) of compound 31f. 
 
	Figure A2-1.63. 13C NMR (101 MHz, CDCl3) of compound 31f. 
	

















































Figure A2-1.64. 19F NMR (282 MHz, CDCl3) of compound 31f.	







































































































































 Figure A2-1.66. Infrared spectrum (Thin Film, NaCl) of compound 41. 
 
	Figure A2-1.67. 13C NMR (126 MHz, CDCl3) of compound 41. 
	


















































































































 Figure A2-1.69. Infrared spectrum (Thin Film, NaCl) of compound 40. 
 
	Figure A2-1.70. 13C NMR (126 MHz, CDCl3) of compound 40. 
	






Progress Toward the Total  
Synthesis of Tylohirsuticine† 
 
A2-2.1  INTRODUCTION: 
As described in Chapter 2, we proposed utilizing our method for the synthesis of 
stereogenic 2,2-disubstituted pyrrolidines to access the natural product tylohirsuticine 
(39). Tylohirsuticine (39) was originally isolated from the aerial parts of Tylophora 
hirsuta and characterized in 1987 by Bhutani and coworkers.1 Tylophora hirsuta has 
been utilized in Indian traditional medicine for treating asthma, high blood pressure, 
diarrhea, rheumatism, and other allergic conditions.2 The Tylophora genus of plants has 
been found in previous studies to have laxative, expectorant, diaphoretic, and purgative 
properties, as well as antiasthmatic, anti-arthritic, and anti-cancer properties.3 Further 
studies by Bashir and coworkers have shown that extracts from Tylophora hirsuta show 
significant antileishmanial (antiplasmodial) activity and moderate antifungal and 
insecticidal activity.1  
 Tylohirsuticine (39) is a member of the phenanthroindolizidine family of natural 
products, which consist of a phenanthrene core fused to an indolizidine bicycle (Figure 
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ways. First, tylohirsuticine (39) is a seco-derivative of the class of natural products, 
meaning it does not have a fully fused phenanthrene core. Second, while most of these 
natural products have an α-secondary amine stereocenter, tylohirsuticine (39) contains a 
tetrasubstituted α-tertiary amine stereocenter. 
Septicine (46) is another example of a seco-phenanthroindolizidine natural 
product, 4  which has been synthesized twice previously by Comins and Reddy. 5 
Hypoestatin 1 (47),6 which includes another example of this α-tertiary amine motif can 
be seen in which has been synthesized once in racemic form in 2007 by Ishibashi,7 and 
then again in an enantioselective sense in 2012 by Wang.8  
Figure A2-2.1.1 Phenanthroindolizidine alkaloids  
 
Septicine (46), was synthesized by Reddy and coworkers from the chiral 
pyroglutamic acid 48 via a known derivative (49, Scheme A2-2.1.1).5b The formation of 
the tetrasubstituted olefin proceeds via a McMurry coupling reaction of dione 50.  This 
dione was synthesized via N–alkylation of pyroglutamic acid derivative 49 to form 1,3-
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Scheme A2-2.1.1 Synthesis of septicine by Reddy et al.5b 
 
Hypoestatin 1 (47) is the only phenanthroindolizidine natural product containing 
an α-tertiary amine that has been synthesized previously. The first reported synthesis 
formed the α-tertiary amine via a radical cyclization reaction of bromide 52.7 (Scheme 
A2-2.1.2A) Five years later, the first asymmetric synthesis of hypoestatin 1 was   
reported.8 (Scheme A2-2.1.2B) The synthesis of this natural product proceeded from 
amino acid 53, which was elaborated to Seebach alkylation substrate 54. This Seebach 
alkylation substrate could be coupled to a functionalized phenanthrene core (55) to form 
the α-tertiary amine stereocenter in 56. Hydrolysis of the product results in the formation 









































3 steps 3 steps
(+)-Septicine, 46 50
51 49 48
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Scheme A2-2.1.2 Synthesis of hypoestatin 1 by Ishibashi7 and Wang8 
 
A2-2.2 ORIGINAL RETROSYNTHETIC ANALYSIS 
 Our discussion will encompass our efforts toward the synthesis of tylohirsuticine 
(39) from indolizidine 40. Our early investigations into the synthesis of 40 are described 
in Chapter 2.5 and will not be discussed further. For purposes of review, our original 
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Scheme A2-2.2.1 Retrosynthetic analysis of tylohirsuticine 
 
With olefin 40 in hand, we began to investigate the installation of the final ring. 
In the interest of efficiency, we first tried coupling the final aryl group directly to 
compound 40 through a Heck-type reaction (Table A2-2.2.1). Unfortunately, the use of 
canonical Heck conditions (Entry 1) and oxidative Heck conditions (Entry 2),9 showed 
no reaction. 
Table A2-2.2.1: Investigation of Heck conditions 
 
 
Therefore, we turned to the next most efficient route, direct bromination of the 
olefin 40 to form alkenyl bromide 58 followed by a subsequent coupling reaction (Table 
A2-2.2.2).  The use of N-bromosuccinimide under multiple reaction conditions resulted 






































1 Pd(OAc)2 (10 mol %), P(o–tol)3 (30 mol %), Et3N (2 equiv), CH3CN, reflux No reaction
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Py•HBr3 resulted in no desired product, though a small amount of a dibrominated 
product was observed by LCMS (Entry 3). 
Table A2-2.2.2: Bromination of the olefin 
 
 
As our most efficient routes had been unsuccessful, we turned to more indirect 
methods of installing the aryl group. Epoxidation of olefin 40 to afford epoxide 59 
(Scheme A2-2.2.2), followed by epoxide opening with a nucleophile and dehydration 
could afford our desired product 39. Unfortunately, the use of m-CPBA as oxidant, 
either alone (Table A2-2.2.3, Entry 1) or in the presence of Na2CO3 (Entry 2) or TFA 
(Entry 3) as additives yielded no desired product. Furthermore, use of urea hydrogen 
peroxide (UHP) as an oxidant, along with TFAA (trifluoroacetic anhydride) and TFA as 
additives, also formed none of the desired product (Entry 4). Attempts to dihydroxylate 
the olefin using OsO4 with NMO as the stoichiometric oxidant to afford 60 also resulted 
in no reaction (Scheme A2-2.2.3). 


























1 N-bromosuccinimide (1.1 equiv), MeOH, 23 °C decomposition
N-bromosuccinimide (1.1 equiv), NaHCO3 (2.2 equiv), CH2Cl2, 23 °C decomposition
3 Py•HBr3 (1.1 equiv), CH2Cl2, 23 °C no desired product
N-bromosuccinimide (1.1 equiv), CH3CN, 0 °C4 no desired product
40 58
2
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Table A2-2.2.3 Epoxidation of the olefin 
 
Scheme A2-2.2.3 Dihydroxylation of the olefin 
 
 Following our lack of success in forming the desired intermediates, we 
investigated the oxidation of olefin 40 to form ketone 61 with the goal of producing enol 
triflate 62. This compound could then be screened with a variety of cross-coupling 
conditions (Scheme A2-2.2.4). 
Scheme A2-2.2.4 Plan for the installation of the final ring 
 
We proposed the oxidation of the olefin via a hydroboration/oxidation sequence, 
first affording alcohol 63 which could subsequently be oxidized to ketone 61. Initial 
attempts to hydroborate the olefin using 9-Borabicyclo[3.3.1]nonane (9-BBN) resulted 









1 m–CPBA (1.2 equiv), CH2Cl2, 23 °C No desired product
m–CPBA (1.2 equiv), Na2CO3, CH2Cl2/H2O (5:1), 23 °C No desired product2
m–CPBA (2.4 equiv), TFA (1.1 equiv) CH2Cl2, 23 °C3 No desired product
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(or BH3•DMS) resulted in no product formation, which we hypothesized was due to the 
complexation of BH3 with the tertiary amine (Entry 2). Gratifyingly, increasing the 
loading of BH3•THF to 15 equiv resulted in the formation of the desired product 63, 
though it was difficult to purify via chromatography or other methods (Entry 3). 
Table A2-2.2.4 Hydroxylation of the olefin 
 
Nevertheless, we decided to continue investigating this route further through 
oxidation of crude alcohol 63 to ketone 61 (Table A2-2.2.5). The use of Swern 
conditions resulted in detection of the desired product (61) by LCMS but the product 
could not be isolated (Entry 1). Use of Parikh–Doering oxidation conditions also resulted 
in product formation, though in low yields (15% from 40, Entry 2). Unfortunately, the 
use of pyridimiun chlorochromate (PCC, Entry 3) and a combination of TPAP 
(Tetrapropylammonium perruthenate) and NMO (N-Methylmorpholine N-oxide, Entry 
6) resulted in no desired product formation.  When PCC was employed in the presence 
of SiO2 as a drying agent; however, the product was formed in 25% yield over two steps 
from 40 (Entry 5). It was also found that the use of DMP (Dess–Martin periodinane) as 
oxidant resulted in approximately 25% yield from 40 (Entry 4). As these results were not 
as high yielding as desired, and any attempts to further functionalize these products 









1 9–BBN (1.5 equiv), THF, H2O2, 23 °C no desired product
2 BH3 • THF (1.5 equiv), NaBO3•4H2O (5 equiv), THF, H2O, 23 °C no desired product
BH3 • THF (15 equiv), NaBO3•4H2O (50 equiv), THF, H2O, 23 °C3 product observed
40 63
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Table A2-2.2.5 Oxidation of the alcohol 
 
 
A2-2.3.  SUBSTITUTED ALLYLIC ALKYLATION SUBSTRATES 
 
 Due to a lack of success in functionalizing indolizidine 40, we instead turned our 
attention to other methods of introducing the challenging tetrasubstituted olefin. In order 
to accomplish this, we proposed introducing susbstituted allylic alkylation precursors. 
One such strategy is described in Scheme A2-2.3.1, using the same key disconnections 
with a 2-allyl substituent in place on compound 68: this would then proceed through the 
same asymmetric allylic alkylation, ring contraction, N–alkylation, and RCM sequence. 


















































Entry Conditions Yield over 2 steps
OHO
1 (COCl)2 (2 equiv), DMSO (3 equiv), Et3N (6 equiv), CH2Cl2, –78 °C→ 23 °C LCMS observed
2
PCC (3 equiv), CH2Cl2, 23 °C no desired product3
SO3 • Py (3 equiv), DIPEA (10 equiv), DMSO, CH2Cl2, 0 °C→ 23 °C
4 DMP (1.5 equiv), CH2Cl2, 23 °C 25% yield
PCC (5 equiv), SiO2, CH2Cl2, 23 °C5 25% yield
6 TPAP (0.1 equiv), NMO (2 equiv), 4Å MS, CH2Cl2, 23 °C no desired product
15% yield
63 61
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In order to test our new retrosynthetic proposal, we first needed to synthesize our 
desired asymmetric allylic alkylation substrate with a 2-allyl substituent (Scheme A2-
2.3.2). Starting with commercially available 5-bromo-2-methoxyphenol 69, TBS 
protection first afforded 70. This was used to form a Grignard reagent, which upon 
addition of CuI and propargyl alcohol afforded homo-allylic alcohol 71 in moderate 
yield. When treated with carbonyl diimidizole (CDI), acylation substrate 72 was formed, 
which was then utilized to acylate O-benzyloxylimide 33 to yield 73. A final alkylation 
with methyl iodide afforded allylic alkylation substrate 68.  
Scheme A2-2.3.2 Synthesis of 2–allyl substituted asymmetric allylic alkylation 
substrate 
 
 With compound 68 in hand, we began to investigate its reactivity of in the 
asymmetric allylic alkylation. We were very pleased to note that using the conditions 
optimized for compound 74, as described in chapter 2.2, proceeded in good yield and 












Mg, 2 h., reflux.;



















24 h, THF, reflux
33, LiHMDS



























Appendix 2-2 – Progress Toward the Total Synthesis of Tylohirsuticine 
	
249	
Table A2-2.3.1 Asymmetric allylic alkylation reaction of 2–allyl substituted 
substrate 
 
 Following our successful synthesis of 74, we proceeded to investigate the 
viability of this substrate in the ring contraction (Scheme A2-2.3.3). Treatment of 
compound 74 with DIBAL-H afforded selective mono-reduction to imide 75, which 
could then undergo reduction in the presence of sodium cyanoborohydride and BF3•Et2O 
to yield 76 in good yield. Unfortunately, all attempts to remove the benzyl protecting 
group on the hydroxamic acid were met with either no reaction or decomposition, and so 
we were never able to investigate further. 
Scheme A2-2.3.3 Selective reduction of imide 
 
 While we were disappointed in these results, we thought a similar strategy might 
still be plausible. To that end, we proposed another retrosynthetic analysis (Scheme A2-
2.3.4). In particular, we were interested in using a different 2-allyl substituted allylic 
alkylation substrate (2-chloroallyl substrate 81) due to previous success with similar 
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though this time there is a different functional handle in place to enable the end-game 
strategy.  
Scheme A2-2.3.4 Alternative retrosynthetic proposal 
 
 We started our investigation again by synthesizing the desired allylic alkylation 
substrate 81 (Scheme A2-2.3.5). Having successfully used this method in the synthesis 
of 68, we treated commercially available 2-chloroallyl alcohol 82 with CDI to afford 
acylating agent 83. This reagent was then utilized in an enolate α–acylation yielding 84 
followed by alkylation to afford allylic alkylation substrate 81 in good yield. 
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 We then proceeded to investigate the reactivity of this substrate toward 
asymmetric allylic alkylation (Table A2-2.3.2). Beginning with our previously optimized 
conditions, we were disappointed to find no reaction was observed under these low 
catalyst loading conditions (Entries 1–2). We proceeded to investigate whether reactivity 
would be observed under standard conditions (Entries 3–4).10 While we were finally able 
to observe some formation of 85, the reaction proceeded slowly and required long 
reaction times and high temperatures. Even after seven days, the reaction had not 
proceeded to full conversion. Additionally, attempts to selectively reduce the resulting 
imide proved unsuccessful, and so we had to again revise our retrosynthetic proposal. 
Table A2-2.3.2 Asymmetric allylic alkylation reaction of 2–chloroallyl substrate 
 
 A2-2.4  FURTHER RETROSYNTHETIC STRATEGIES 
 Having investigated several different strategies, we envisioned combining the 
strengths of our previously outlined retrosynthetic proposals. Due to the reliability of the 
synthesis of pyrrolidine 31a–c, we decided to take advantage of this intermediate by 
forming the tetrasubstituted olefin from an intermediate such as 86a–b through either an 
RCM (X=CH2) or McMurry coupling (X=O) (Scheme A2-2.4.1). Compound 86 could 
arise via a number of different methods dependent on the identity of X, though common 
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Scheme A2-2.4.1 Alternative retrosynthetic proposal 
 
 In the forward sense, we, we demonstrated that compound 31a underwent an 
oxidative cleavage reaction with good yield to afford 90, which could undergo an 
organolithium addition and oxidation sequence to yield 88a (Scheme A2-2.4.2). 
Unfortunately, we were never able to remove the methyl carbamate protecting group 
from 88a.  
Scheme A2-2.4.2 Synthesis of aryl ketone compound 
 
We then proceeded to functionalize 31b–c (Scheme A2-2.4.3) to facilitate 
deprotection. We had previously demonstrated the oxidative cleavage of 31a, and found 
the reaction to proceed smoothly on both the Boc and Cbz protected pyrrolidines as well 
to afford 91a–b. Following the report of Cossy,11 we were able to remove one additional 
methylene under oxidative conditions to yield 92a–b. Unfortunately, we were again 
unable to advance either of these intermediates to the natural product, as the aldehyde 






























88a R=Me,   X=O
88b R=Bn,   X=O
88c R=t-Bu, X=O
89a R=Me,   X=CH2









K2OsO4•2H2O (10 mol %)
NMO (5 equiv); 
NaIO4 (5 equiv)





O 1. 70 (3 equiv), n-BuLi (3 equiv)
 THF, –78 °C, 2 h
~30% yield over 2 steps
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Scheme A2-2.4.3 Synthesis of aldehyde compounds 
 
 In the course of these investigations, it soon became clear that the introduction of 
a carbonyl group into these intermediates led to many challenges due to competitive 
reactivity of the functional group. Therefore, we turned our attention to a method of 
introducing the aryl group at the 2-allyl position, utilizing an oxidative coupling 
introduced by Stahl and coworkers.12 We were pleased to observe reactivity of 31c under 
the reported conditions (Scheme A2-2.4.4), affording desired compound 94 in 30% 
yield. Unfortunately, we were unable to remove the Boc group and attempts to 
investigate this reaction further were thwarted. 
Scheme A2-2.4.4 Synthesis of 2–allyl substituted pyrrolidine compound 
 
A2-2.5   CONCLUSIONS 
 Throughout the course of our investigation into the synthesis of tylohirsuticine 
(39), we were able to demonstrate the synthesis of many interesting new compounds. We 
expanded the scope of our asymmetric allylic alkylation and advanced several of these 
products to synthesize enantioenriched 2,2-disubstituted pyrrolidines, as outlined in 
chapter 2. We were further able to use the olefin functional handle in order to synthesize 
a number of different novel compounds. Although the synthesis of tylohirsuticine (39) 
K2OsO4•2H2O (10 mol %)
NMO (5 equiv); 
NaIO4 (5 equiv)
THF, H2O (1:1), 23 °C,




K2OsO4•2H2O (5 mol %)
NMO (2 equiv)
NMM (1 equiv); 
NaIO4 (4 equiv)
Me2CO, H2O (10:1), 23 °C,






R= Bn 66% yield 
R= t-Bu  86% yield
R= Bn 69% yield 






Fragment 93 (1.5 equiv)
Pd(TFA)2, (5 mol %),
dmphen (10 mol %)
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remains elusive, we hope that the lessons learned throughout our investigations will 
continue to instruct future synthetic efforts towards phenanthroindolizidine alkaloids and 
their analogues. 
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3.1   INTRODUCTION 
Paracyclophanes are a class of molecules that were first described by Cram and 
Steinberg as far back as 1951.1  Cyclophanes (Figure 3.1.1) are macrocyclic molecules 
that contain two aromatic rings within the macrocyclic structure.2  
Figure 3.1.1 Structure of Cyclophanes 
 
                                                
† This research was performed in collaboration with Aaron T. Bosse, Kuangbiao Liao, Wenbin Liu, Zhi 
Ren, John Bacsa, Djamaladdin G. Musaev, and Huw M. L. Davies at Emory University through the Center 
for C-H functionalization. Additionally, parts of this chapter have been published and adapted with 
permission from Liu, W. B.; Ren, Z.; Bosse, A. T.; Liao, K. B.; Goldstein, E. L.; Bacsa, J.; Musaev, D. G.; 
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In 1990, the first naturally occurring cyclophane was isolated from the 
Nostocaceae species Cylindrospermum licheniforme, and so named cylindrocyclophane 
A.3 (Figure 3.1.2) Two years later, cylindrocyclophanes B–F were isolated from the same 
species of algae.4 A further 10 cylindrocyclophanes (A1–A4, C1–C4, F4 and AB4) were 
isolated from a new species of Nostocaceae that was discovered on a parkway in 
Chicago.5 Since the discovery of the cylindrocyclophane class of [7,7]paracyclophanes, a 
number of related classes have been isolated, namely the nostocyclophanes, 6 
ribocyclophanes,7 carbamidocyclophanes,8 and merocyclophanes.9 
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 These [7,7]paracyclophanes have drawn attention recently due to their 
antimicrobial activity. Increasing rates of bacterial resistance have led to a need for new 
types of antimicrobial agents. Some [7,7]paracyclophanes have been demonstrated to 
display MIC values in the range of 0.1-0.2 µM toward drug resistant strains of the gram-
positive bacteria, MRSA,10 along with activity against S. pneumoniae and E. faecalis with 
MIC’s between 0.2-3 µM.11 While these initial results are very promising, limited 
biological evaluations have occurred to date, focusing on isolated natural products and a 
few derivatives. A streamlined synthesis of [7,7]paracyclophanes allowing for access to 
new derivatives would enable more comprehensive biological evaluations and SAR 
(structure activity relationship) studies. 
 Due to the promising biological activity and interesting structural motif, there has 
been previous interest in the synthesis of [7,7]paracyclophanes, though to date only 
cylindrocyclophanes A and F have succumbed to synthesis. The predominant approach 
has been to use a convergent strategy bringing two identical components together, either 
by means of metathesis,12 the Horner-Wadsworth-Emmons reaction,13 or the Ramberg-
Bäcklund reaction14 (Scheme 3.1.1). While these approaches can afford fairly efficient 
syntheses (15-23 steps), the use of dimerization strategies on advanced fragments only 
leads to synthesis of symmetrical [7,7]paracyclophanes and complicates derivatization. 
We decided to utilize a strategy more suited for synthesizing a number of 
[7,7]paracyclophanes (natural and unnatural) from an advanced common intermediate. In 
particular, we believed C-H functionalization would be a useful strategy to afford a 
variety of  [7,7]paracyclophanes in an efficient and divergent manner. 
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Scheme 3.1.1 Previous synthetic strategies toward cylindrocyclophanes 
 
3.2  RETROSYNTHETIC ANALYSIS OF CYLINDROCYCLOPHANE A 
 While we were interested in developing a divergent synthesis for many 
[7,7]paracyclophanes, we decided to first target cylindrocyclophane A, due to the 
previous successful syntheses and its nature as one of the less complex naturally 
occurring [7,7]paracyclophanes. We developed our retrosynthetic strategy (Scheme 3.2.1) 
in a way that could later be adapted to afford some of the more complex 
cylindrocyclophanes and potentially even ribocyclophanes and carbamidocyclophanes. 
We believe that cylindrocyclophane A (95) could arise from reduction and global 
deprotection of 96. Compound 96 could be accessed via a Baeyer-Villiger reaction of 
diester 97, which could itself arise from a double carbonyl addition into Weinreb amide 
98. This compound could be synthesized via Weinreb amide formation and 
tetraacetoxylation15 of 99. Dimerization of compound 100 via C–H insertion would yield 
99. Diazoester 100 would be accessed via diazoester coupling and hydrogenation of 
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into olefin 102.16 This would be one of the most elaborate C–H functionalization based 
strategies reported to date. 
Scheme 3.2.1 Retrosynthetic proposal for cylindrocyclophane A 
 
3.3  SYNTHESIS OF [7,7]PARACYCLOPHANE CORE 
 In order to test the viability of our retrosynthetic proposal, we decided to begin by 
targeting the synthesis of a mostly unfunctionalized [7,7]paracylophane core. In 2016, the 
Davies lab first reported a method for the selective insertion of diazoesters into 
unactivated C-H bonds with catalyst 104 (Scheme 3.3.1A).17 Unfortunately, our original 
efforts into applying those reaction conditions toward the synthesis of 
[7,7]paracyclophanes were unsuccessful due to reactivity at the benzylic position in 
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in mind, we proceeded to develop conditions that would selectively functionalize 
unactivated secondary C-H bonds in the presence of activated benzylic C-H bonds 
(Scheme 3.3.1C).18 Crucial to this selectivity was the development of a new catalyst 105. 
Further details on the development of this reaction can be found in reference 18. 
Scheme 3.3.1 Development of C-H insertion reaction 
 
 We proceeded to explore the utilization of the methodology described above for 
the synthesis of the [7,7]paracyclophane core (Scheme 3.3.2). The synthetic sequence 




















































































11:1 r.r., 16:1 d.r.,
90% ee, 75% yield
1:24 r.r., 28:1 d.r.,
91% ee, 96% yield
+
+
catalyst 104 (1 mol%)
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donor/acceptor carbene transformations. The beginning palladium-catalyzed reaction of 
trifluoroethyl diazoacetate (107) with the aryl iodide 106 generated the aryldiazoacetate 
108 in 87% yield, followed by Rh2(R-2-Cl-5-BrTPCP)4-catalyzed intermolecular C−H 
functionalization of 1-heptyl-4-iodobenzene 106  with 108  to obtain the desired product 
(−)-109  in 83% yield, without any evidence of a structurally isomeric product. 
Furthermore, (−)-109 was formed with good diastereoselectivity (26:1 dr) and 
enantioselectivity (91% ee). A second palladium-catalyzed cross-coupling between (−)-
109 and the same diazoacetate 107 proceeded with an 81% yield to access the 
aryldiazoacetate (−)-110. Finally, a Rh2(R-2-Cl-5-BrTPCP)4-catalyzed intramolecular 
C−H functionalization of 110  formed (−)-111  cleanly with exceptional site selectivity 
and asymmetric induction (>30:1 rr, > 99% ee) and moderate diastereoselectivity (5.6:1 
dr) without enantioenrichment of 109  or 110. Though macrocyclization by means of 
C−H functionalization has been reported for macrolide formation, palladium-catalyzed 
allylic oxidation, sp3 C−H arylation, and via sp2 C−C coupling, the study reported here is 
the first example of an enantioselective macrocyclization by C−H functionalization of 
unactivated sp3 C−H bonds. The initial studies on the macrocyclization sequence utilized 
Rh2(S-2-Cl-5-BrTPCP)4  to obtain the enantiomeric macrocyclic product (+)-111, whose 





Chapter 3 – Synthesis of [7,7]paracyclophanes 
 
263 
Scheme 3.3.2 Synthesis of [7,7]paracyclophane 
 
3.4  CONCLUSIONS 
 We are currently undertaking an investigation into the synthesis of 
[7,7]paracyclophanes due to the antimicrobial activity demonstrated by some members of 
this class of compounds. We have developed a retrosynthetic proposal that we believe 
could lead to the efficient and divergent synthesis of many [7,7]paracyclophanes utilizing 
C-H functionalization. In an effort to prove the feasibility of this strategy, we first 
demonstrated the synthesis of a relatively unfunctionalized [7,7]paracyclophane in an 
efficient and selective manner. Efforts are currently underway to advance this strategy 
toward the synthesis of a naturally occurring [7,7]paracyclophane and eventually 




CH2Cl2, 39 °C, 4Å MS
83% yield, >30:1 r.r.
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3.5  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
3.5.1  MATERIALS AND METHODS 
All solvents were purified and dried by a Glass Contour Solvent System unless otherwise 
stated. The dichloromethane used for the C–H Functionalization was dried and degassed 
at reflux over activated 4 A ̊ molecular sieves for 1 hours under argon, then stored with 
activated 4 molecular sieves under argon atmosphere and was used directly. 1H and 13C 
NMR spectra were recorded at 600 MHz (13C at 150 MHz) on Bruker-600 spectrometer 
or Varian IVONA-600 spectrometer, or 500 MHz (13C at 126 MHz) on Varian INOVA-
500 spectrometer, or 300 MHz (19F at 282 MHz) on Varian Mercury-300. Unless 
otherwise stated, NMR spectra were run in solutions of deuterated chloroform (CDCl3) 
with residual chloroform taken as an internal standard (7.26 ppm for 1H, and 77.16 ppm 
for 13C), and were reported in parts per million (ppm). Abbreviations for signal 
multiplicity are as follow: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
dd = doublet of doublet, etc. Coupling constants (J values) were calculated directly from 
the spectra. IR spectra were collected on a Nicolet iS10 FT-IR spectrometer. Mass 
spectra were taken on a Thermo Finnigan LTQ-FTMS spectrometer with APCI, ESI or 
NSI. Thin layer chromatographic (TLC) analysis was performed with aluminum-sheet 
silica gel plates, visualizing with UV light and/or staining with aqueous KMnO4 stain. 
Melting points (mp) were measured in open capillary tubes with a Mel-Temp 
Electrothermal melting points apparatus and are uncorrected.  Optical rotations were 
measured on Jasco P-2000 polarimeters. Analytical enantioselective chromatographs 
were measured on either Varian Prostar instrument or Agilent- 1100 series instrument, 
and used isopropanol/hexane as gradient. Chiral HPLC conditions were determined by 
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obtaining separation of the racemic products using Rh2(R/S-o-ClTPCP)4 as catalyst for C2 
insertion products.  
The substrates and reagents were purchased from the following suppliers and used 
without further purification (unless otherwise stated): Sigma-Aldrich: 
Triphenylphosphine; Acros Organic: Silver carbonate. Fisher Scientific: Triethylamine. 
Strem: Pd(PPh3)4; Rh2(OAc)4. The following substrates were prepared by procedures 
adapted from literatures: Rh2(S-2-Cl-5-BrTPCP)4.19  
3.5.2  EXPERIMENTAL PROCEDURES 
2,2,2-Trifluoroethyl 2-diazo-2-(4-heptylphenyl)acetate (108)  
 
The procedure is adapted from the literature:20 A 250-ml round-bottom flask with stir bar 
was flame dried under vacuum. Once cool enough all solids were added first: PPh3 (1.65 
mmol, 0.1 equiv.), Pd(PPh3)4 (0.825 mmol, 0.05 equiv.) and Ag2CO3 (8.25 mmol, 0.5 
equiv.). After solids added, the reaction vessel was purged with argon three times. Next 
the liquids were added: toluene (66 ml), Et3N (21.5 mmol, 1.3 equiv.), aryl iodide 106 
(16.5 mmol, 1 equiv.), and finally the 2,2,2-trifluoroethyl 2-diazoacetate 107 (21.5 mmol, 
1.3 equiv.) was added last. The resulted mixture was stirred at room temperature (23 °C) 
for 5 h and then, filtered through a short silica plug (3.5 cm diameter, 5 cm height), 
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purified by column chromatography (5% ether in pentane) to afford 108 as a yellow oil in 
85% yield. Rf = 0.71 (pentane/diethyl ether = 9:1); 1H NMR (600 MHz, CDCl3) δ 7.36 
(d, J = 8.3 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 4.65 (q, J = 8.4 Hz, 2H), 2.60 (t, J = 7.6 Hz, 
2H), 1.63 – 1.57 (m, 2H), 1.36 – 1.22 (m, 8H), 0.87 (t, J = 6.6 Hz 3H); 13C NMR (125 
MHz, CDCl3) δ 163.4, 141.5, 129.1, 124.3, 122.9 (q, J = 277.6 Hz), 121.3, 60.3 (q, J = 
36.9 Hz), 35.4, 31.7, 31.2, 29.1, 29.1, 22.6, 13.9 (The resonance resulting from the diazo 
carbon was not observed); 19F NMR (282 MHz, CDCl3) δ -73.9 (t, J = 8.4 Hz); IR (neat) 
2957, 2927, 2856, 2089, 1715, 1515, 1456, 1410, 1350, 1280, 1242, 1167, 1137, 1074, 
1020, 974, 923, 839, 810, 733, 653; HRMS (+p NSI) calcd for C17H22F3N2O2 (M+H)+ 




The procedure is adjusted from the general procedure for C–H functionalization 
reactions: A 50-ml flame-dried round-bottom flask with condenser was charged with 4 Å 
MS and Rh2(R-2-Cl-5-BrTPCP)4 (0.02 mmol, 1.0 mol%) and then, purged three times 
with argon. 1-n-Heptyl-4-iodobenzene 106 (6.29 mmol, 3.0 equiv.) and distilled CH2Cl2 
(8 ml) were added next, then the mixture was heated to 40 °C and refluxed for at least 15 
min before addition of the diazo compounds. Next, 108 (2.09 mmol, 1.0 equiv.) was 
CF3H2CO2C N2
Rh2(R-2-Cl-5-BrTPCP)4
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purged under argon in a 20-mL scintillation vial, then diluted with distilled CH2Cl2 (8 
ml). Then, under reflux conditions and argon atmosphere, the diazo solution was added to 
the reaction vessel dropwise via syringe pump over 3 h. The reaction mixture was stirred 
at 40 °C for another 30 min, and concentrated under vacuum for crude 1H NMR. The 
crude product was purified by flash column chromatography (3% ether in pentane) to 
afford (-)-109 as an opaque oil in 62% yield. Note: Solvent must be carefully dried 
(distilled over CaH2 and stored on activated 4 Å MS). Rf = 0.71 (pentane/diethyl ether = 
19/1);[α]20D: -18.6°(c = 1.00, CHCl3, 91% ee);  1H NMR (600 MHz, CDCl3) δ 7.56 (d, J 
= 8.2 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.12 (d, J= 8.0 Hz 2H), 6.86 (d, J= 8.1 Hz, 2H), 
4.55 (dq, J = 8.5, 4.1 Hz, 1H), 4.29 (dq, J = 8.5, 4.2 Hz, 1H), 3.32 (d, J = 10.9 Hz, 1H), 
2.57 (t, J= 7.6 Hz, 2H), 2.45 (t, J = 7.7 Hz, 2H), 2.23 – 2.16 (m, 1H), 1.63 – 1.56 (m, 
2H), 1.51 – 1.41 (m 2H), 1.34 – 1.23 (m, 10H), 1.22 – 1.09 (m, 4H), 1.00 (d, J = 6.7 Hz, 
3H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 172.5, 142.3, 137.2, 134.1, 
130.5, 128.6, 128.4, 123.0 (q, J = 277.2 Hz), 90.5, 60.2 (q, J = 36.5 Hz), 57.9, 36.2, 35.6, 
35.3, 33.1, 31.8, 31.3, 31.0, 29.3, 29.2, 29.0, 26.0, 22.7, 17.7, 14.1; 19F NMR (282 MHz, 
CDCl3) δ -73.7 (t, J = 8.5 Hz); IR (neat) 2927, 2855, 1753, 1484, 1464, 1400, 1278, 
1165, 1128, 1061, 1006, 979, 824, 793, 737; HRMS (+p NSI) calcd for C30H41O2IF3 
(M+H)+ 617.2098 found 617.20986; HPLC (R,R-Whelk column, 0 % i-propanol in 
hexane, 1 mL min-1, 1 mg mL-1, 30 min, UV 210 nm) retention times of 14.9 min (major) 
and 17.6 min (minor) 91% ee with Rh2(R-2-Cl-5-BrTPCP)4.  
 
 






The procedure is adapted from literatures: A 50-ml round-bottom flask with stir bar was 
flame dried under vacuum. Once cool enough all solids were added first: PPh3 (0.129 
mmol, 0.1 equiv.), Pd(PPh3)4 (0.065 mmol, 0.05 equiv.) and Ag2CO3 (0.645 mmol, 0.5 
equiv.). After solids added, the reaction vessel was purged with argon three times. Next 
the liquids were added: toluene (5.2 ml), Et3N (1.67 mmol, 1.3 equiv.), aryl iodide 109 
(27, 1.29 mmol, 1 equiv.), and finally the 2,2,2-trifluoroethyl 2- diazoacetate 107 (1.67 
mmol, 1.3 equiv.) was added last. The resulted mixture was stirred at room temperature 
(23 °C) for 5 h and then, filtered through a short silica plug (3.5 cm diameter, 5 cm 
height), eluting with ethyl acetate until elutes clear. The crude product was concentrated 
and purified by column chromatography (2% ether in pentane) to afford product (-)-110 
as a yellow oil in 81% yield. Rf = 0.45 (pentane/diethyl ether = 9/1); 1H NMR (600 MHz, 
CDCl3) δ 7.34 (d, J = 8.3 Hz, 2H), 7.21 (d, J = 8.1 Hz, 2H), 7.16 (d, J = 8.3 Hz, 2H), 7.12 
(d, J = 8.1 Hz, 2H), 4.64 (q, J = 8.4 Hz, 2H), 4.55 (dq, J = 12.7, 8.5 Hz, 1H), 4.29 (dq, J 
= 12.7, 8.5 Hz, 1H), 3.32 (d, J = 10.5 Hz, 1H), 2.57 (t, J= 7.6 Hz, 2H), 2.51 (t, J = 7.7 Hz, 
2H), 2.23 – 2.15 (m, 1H), 1.62 – 1.56 (m, 2H), 1.52 – 1.44 (m, 2H), 1.35 – 1.24 (m, 10H), 
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MHz, CDCl3) δ 172.5, 142.3, 141.3, 134.1, 129.2, 128.6, 128.4, 124.2, 123.0 (q, J= 277.7 
Hz), 122.9 (q, J= 277.7 Hz), 121.3, 60.3 (q, J= 36.9 Hz), 60.2 (q, J= 36.6 Hz), 57.9, 36.2, 
35.6, 35.3, 33.1, 31.8, 31.3, 31.1, 29.3, 29.2, 29.1, 26.0, 22.7, 17.7, 14.1; 19F NMR (282 
MHz, CDCl3) δ -73.7 (t, J = 8.5 Hz), -73.9 (t, J = 8.3 Hz); IR (neat) 2928, 2856, 2090, 
1753, 1717, 1514, 1456, 1409, 1350, 1279, 1242, 1165, 1135, 1074, 976, 923, 839, 733; 




The procedure is adjusted from the general procedure for C–H functionalization 
reactions: A 100-ml flame-dried round-bottom flask with condenser were charged with 4 
Å MS and Rh2(R-2-Cl-5-BrTPCP)4 (0.01 mmol, 1.0 mol%), then purged three times 
under argon. Distilled CH2Cl2 (10.5 ml) was added using oven dried syringes, then the 
mixture was heated to 40 °C and refluxed for at least 15 min before addition of the diazo 
compounds. Next, (-)-110 (1.04 mmol, 1.0 equiv.) was purged under argon in a 20-mL 
scintillation vial, then diluted with distilled CH2Cl2 (10.5 ml). Then, under reflux 
conditions and argon atmosphere, the diazo solution was added to the reaction vessel 
dropwise via syringe pump over 3 h. The reaction mixture was stirred at 40 °C for 
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was purified by flash column chromatography (3% ether in pentane) to afford the product 
(-)-111 as a white solid in 68% yield. Note: Solvent must be carefully dried (distilled over 
CaH2 and stored on activated 4 Å MS). m.p. 141-143 °C Rf = 0.45 (pentane/diethyl ether 
= 9/1); [α]20D: -11.0 °(c = 1.00, CHCl3, 5.6:1 d.r., >99% ee); 1H NMR (600 MHz, CDCl3) 
δ 7.16 (d, J = 8.0 Hz, 4H), 7.01 (d, J = 8.1 Hz, 4H), 4.55 (dq, J = 12.7, 8.5 Hz, 2H), 4.27 
(dq, J = 12.7, 8.4 Hz, 2H), 3.21 (d, J = 11.4 Hz, 2H), 2.58 (dt, J = 13.1, 6.4 Hz, 2H), 2.42 
(dt, J = 13.6, 7.6 Hz, 2H), 2.19 – 2.09 (m, 2H), 1.48 – 1.27 (m, 6H), 1.12 – 0.96 (m, 
10H), 0.96 – 0.85 (m, 4H), 0.80 – 0.68 (m, 2H); 13C NMR (151 MHz, CDCl3) δ 172.7, 
141.8, 134.4, 128.8, 128.2, 122.95 (q, J = 277.3 Hz), 60.21 (q, J = 36.5 Hz), 58.3, 36.4, 
35.5, 32.7, 30.8, 28.3, 26.0, 17.7; 19F NMR (282 MHz, CDCl3) δ -73.7 (t, J = 8.5 Hz); IR 
(neat) 2929, 2856, 1748, 1403, 1385, 1347, 1303, 1275, 1225, 1160, 1123, 1052, 981, 
909, 838, 822, 740, 661; HRMS (+p NSI) calcd for C30H42O2IF3 (M)+ 628.2987 found 
628.29995; HPLC [for better separation, the ester product was reduced to 
((2R,3S,10R,11S)-3,11-dimethyl-1,9(1,4)-dibenzenacyclohexadecaphane-2,10-diyl) 
dimethanol, and the pure major diastereomer of the alcohol derivative was obtained via 
prep HPLC (Ascentis® C18 column, 80% acetonitrile in H2O with 0.1% trifluoroacetic 
acid)] (ADH column, 10 % i-propanol in hexane, 1.0 mL min-1, 1 mg mL-1, 80 min, UV 
210 nm) retention times of 28.69 min (major) and 60.71 min (minor) >99% ee with 
Rh2(R-2-Cl-5-BrTPCP)4.  
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	Figure A3-1.2. 13C NMR (125 MHz, CDCl3) of compound 108. 
	
Figure A3-1.3. 19F NMR (282 MHz, CDCl3) of compound 108.	









































































































































	Figure A3-1.5. 13C NMR (125 MHz, CDCl3) of compound 109. 
	
Figure A3-1.6. 19F NMR (282 MHz, CDCl3) of compound 109.	















































































































































	Figure A3-1.8. 13C NMR (125 MHz, CDCl3) of compound 110. 
	
Figure A3-1.6. 19F NMR (282 MHz, CDCl3) of compound 110.	













































































































































	Figure A3-1.11. 13C NMR (125 MHz, CDCl3) of compound 111. 
	
Figure A3-1.12. 19F NMR (282 MHz, CDCl3) of compound 111.	



























13. X-Ray Crystallographic Data for (+)-29 
 
Crystal Data and Experimental 
 
 
Experimental. Single colorless needle-shaped crystals of 
Aaron-macrocycle were recrystallized from hexane by slow 
evaporation. A suitable crystal 0.57×0.06×0.04 mm3 was 
selected and mounted on a loopon a XtaLAB Synergy, 
Dualflex, HyPix diffractometer. The crystal was kept at a 
steady T = 100(2) K during data collection.The structure was 
solved with the ShelXT (Sheldrick, 2015) structure solution 
program usingthe Intrinsic Phasing solution method and by 
using Olex2 (Dolomanov et al., 2009) as the graphical 
interface. The model was refined with version 2018/3 of 
ShelXL (Sheldrick, 2015)using Least Squares minimisation. 
Crystal Data. C34H42F6O4, Mr = 628.67, monoclinic, P2 (No. 
3), a = 25.1525(4) Å, b = 5.53398(4) Å, c = 27.2474(4) Å, 
 = 117.4652(19)°,  =  = 90°, V = 3365.19(9) Å3, T = 
100(2) K, Z = 4, Z' = 2, (CuK ) = 0.866 mm-1, 42058 
reflections measured, 10947 unique (Rint = 0.0510) which 
were used in all calculations. The final wR2 was 0.0885 (all 
data) and R1 was 0.0363 (I > 2σ(I)). 
Compound  Aaron-macrocycle  
    
Formula  C34H42F6O4  
Dcalc./ g cm-3  1.241  
/mm-1  0.866  
Formula Weight  628.67  
Colour  colourless  
Shape  needle  
Size/mm3  0.57×0.06×0.04  
T/K  100(2)  
Crystal System  monoclinic  
Flack Parameter  -0.02(6)  
Hooft Parameter  -0.00(5)  
Space Group  P2  
a/Å  25.1525(4)  
b/Å  5.53398(4)  
c/Å  27.2474(4)  
/°  90  
/°  117.4652(19)  
/°  90  
V/Å3  3365.19(9)  
Z  4  
Z'  2  
Wavelength/Å  1.54184  
Radiation type  CuK   
min/°  1.980  
max/°  73.814  
Measured Refl.  42058  
Independent Refl.  10947  
Reflections with I > 
2σ(I)  
9975  
Rint  0.0510  
Parameters  797  
Restraints  1  
Largest Peak  0.323  
Deepest Hole  -0.205  
GooF  0.985  
wR2 (all data)  0.0885  
wR2  0.0853  
R1 (all data)  0.0412  
R1  0.0363  

































A colourless needle-shaped crystal with dimensions 0.57×0.06×0.04 mm3 was mounted on a loop. Data were 
collected using an XtaLAB Synergy, Dualflex, HyPix diffractometer equipped with an Oxford Cryosystems low-
temperature device operating at T = 100(2) K. 
Data were measured using  scans with a narrow frame width of 0.5° per frame for 3.5/3.7/10.0 s using CuK  
radiation. The total number of runs and images was based on the strategy calculation from the program CrysAlisPro 
(Rigaku, V1.171.39.43c, 2018). The maximum resolution that was achieved was  = 73.814°. 
The diffraction pattern was indexed using CrysAlisPro (Rigaku, V1.171.39.43c, 2018) and the unit cell was refined 
using CrysAlisPro (Rigaku, V1.171.39.43c, 2018) on 24772 reflections, 59% of the observed reflections. 
Data reduction, scaling and absorption corrections were performed using CrysAlisPro (Rigaku, V1.171.39.43c, 
2018). The final completeness is 98.70 % out to 73.814° in . A numerical absorption correction based on Gaussian 
integration over a multifaceted crystal model was applied using CrysAlisPro 1.171.39.43c (Rigaku Oxford 
Diffraction, 2018). An empirical absorption correction using spherical harmonics as implemented by SCALE3 
ABSPACK algorithm was applied. The absorption coefficient  of this material is 0.866 mm-1 at this wavelength 
(  = 1.54184Å) and the minimum and maximum transmissions are 0.487 and 1.000. 
The structure was solved and the space group P2 (# 3) determined by the ShelXT (Sheldrick, 2015) structure solution 
program using Intrinsic Phasing and refined by Least Squares using version 2018/3 of ShelXL-2014 (Sheldrick, 
2015). All non-hydrogen atoms were refined anisotropically. Hydrogen atom positions were calculated 
geometrically and refined using the riding model.Hydrogen atom positions were calculated geometrically and refined 
using the riding model. 
The value of Z' is 2. This means that there are two independent molecules in the asymmetric unit. 
The Flack parameter was refined to -0.02(6). Determination of absolute structure using Bayesian statistics on Bijvoet 
differences using the Olex2 results in -0.00(5). Note: The Flack parameter is used to determine chirality of the crystal 
studied, the value should be near 0, a value of 1 means that the stereochemistry is wrong and the model should be 






























Figure S13.5: The asymmetric unit contains two molecules of the compound. 
 
 

























The asymmetric unit contains two molecules of the compound. 
Figure A3-2.1.1 X-ray crystal structure of cyclophane 111 






Figure S13.7:  
 
 






























Data Plots: Diffraction Data 
    
    
  
 
Data Plots: Refinement and Data 
    
Reflection Statistics 
 
Total reflections (after filtering)  42062  Unique reflections  10947  
Completeness  0.804  Mean I/   16.19  
hklmax collected  (30, 6, 33)  hklmin collected  (-30, -6, -33)  
hklmax used  (27, 6, 33)  hklmin used  (-30, -6, 0)  
Lim dmax collected  100.0  Lim dmin collected  0.77  
dmax used  22.32  dmin used  0.8  
Friedel pairs  5250  Friedel pairs merged  0  





























Rsigma  0.0423  Intensity transformed  0  
Omitted reflections  0  Omitted by user (OMIT hkl)  4  
Multiplicity  (6310, 4911, 3058, 1507, 1006, 
519, 204, 88, 40, 7, 2)  
Maximum multiplicity  18  








Images of the Crystal on the Diffractometer 
 
Table S13.24: Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters (Å2×103) for 
Aaron-macrocycle_P2. Ueq is defined as 1/3 of the trace of the orthogonalised Uij. 
 
Atom x y z Ueq 
F1 3107.8(7) -1535(3) 3482.8(6) 40.3(4) 
F2 2927.5(7) -699(4) 4163.9(7) 43.1(5) 
F3 3029.6(8) 2168(3) 3682.3(7) 44.3(5) 
F4 6931.1(8) 10422(4) 11116.2(8) 54.0(5) 
F5 6790.1(7) 13309(3) 11567.5(6) 34.1(4) 
F6 7051.5(9) 14083(5) 10937.5(8) 63.2(7) 
O1 4027.6(8) 1790(3) 4704.1(7) 24.9(4) 
O2 4161.9(10) -1186(3) 5309.5(8) 34.6(5) 
O3 6006.0(8) 12270(3) 10110.3(7) 24.8(4) 
O4 5755.0(8) 8401(3) 10163.3(7) 26.6(4) 
C1 3780.7(11) 2906(5) 5830.5(10) 22.6(5) 
C2 4251.8(11) 2953(5) 5616.8(10) 21.2(5) 
C3 4891.6(11) 2815(5) 6079.4(10) 19.9(5) 
C4 5096.8(12) 917(5) 6458.4(10) 23.7(6) 
C5 5675.7(12) 905(5) 6887.6(10) 24.0(6) 
C6 6074.6(11) 2778(5) 6953.4(10) 21.4(5) 
C7 6704.0(11) 2795(5) 7419.2(10) 27.1(6) 
C8 6739.8(12) 2951(5) 7994.2(10) 27.6(6) 
C9 6465.4(12) 5221(5) 8095.4(10) 23.7(6) 
C10 6516.9(12) 5313(5) 8675.3(10) 24.1(5) 
C11 6212.8(12) 7497(5) 8772.7(10) 24.6(6) 
C12 6209.5(11) 7575(5) 9334.4(9) 21.0(5) 
C13 5839.4(11) 9758(5) 9353.0(10) 20.3(5) 
C14 5191.4(11) 9689(5) 8912.1(10) 20.0(5) 
C15 4964.7(12) 11456(5) 8505.7(11) 25.0(6) 
C16 4377.1(12) 11353(5) 8087.6(11) 26.2(6) 
C17 3996.1(11) 9483(5) 8059.1(10) 20.1(5) 
C18 3362.9(11) 9314(5) 7599.5(10) 23.9(6) 
C19 3252.2(12) 7142(5) 7217.6(11) 25.3(6) 
C20 3625.5(12) 7131(5) 6911.5(11) 26.0(6) 























Table A3-2.1.1 Fractional Atomic Coordinates (x104) and Equivalent Isotropic Displacement Parameters 
(Å2x103) for Aaron-macrocycle_P2. Ueq is defined as 1/3 of the trace of the orthogonalised Uij. 





Atom x y z Ueq 
C22 3874.2(12) 5034(5) 6215.9(11) 24.8(6) 
C23 5287.2(11) 4679(5) 6142.9(10) 22.6(5) 
C24 5865.8(12) 4667(5) 6573.4(10) 23.7(5) 
C25 4809.6(11) 7819(5) 8889.4(10) 23.6(5) 
C26 4225.4(11) 7726(5) 8470.6(10) 23.9(5) 
C27 3147.2(12) 2864(6) 5349.5(11) 35.0(7) 
C28 4147.1(11) 936(5) 5211.2(10) 21.4(5) 
C29 3900.7(12) 18(5) 4278.4(10) 26.0(6) 
C30 3240.7(12) -13(6) 3906.9(11) 32.9(7) 
C31 6844.6(11) 7687(6) 9811.7(10) 31.4(6) 
C32 5860.6(11) 9970(5) 9917.2(10) 20.3(5) 
C33 6063.6(11) 12761(5) 10649.8(10) 24.3(5) 
C34 6708.7(12) 12639(5) 11063.1(11) 29.0(6) 
F1B 1848.2(8) 11712(3) 49.8(7) 39.7(4) 
F2B 2053.5(8) 10844(4) 890.5(7) 53.2(6) 
F3B 1882.0(8) 7990(3) 307.4(7) 43.7(4) 
F4B -2001.3(8) -248(4) 4376.9(8) 50.5(5) 
F5B -1810.7(7) -2763(3) 5035.6(6) 32.3(4) 
F6B -1985.5(8) -4054(4) 4231.7(8) 51.2(5) 
O1B 934.2(8) 8649(3) 534.8(7) 23.6(4) 
O2B 917.9(10) 11669(3) 1080.3(8) 33.4(5) 
O3B -990.6(8) -1732(3) 4282.2(7) 22.4(4) 
O4B -804.5(8) 2223(3) 4505.0(7) 26.6(4) 
C1B 1271.4(11) 7679(5) 1922.1(10) 21.6(5) 
C2B 793.8(11) 7555(5) 1304.6(10) 20.6(5) 
C3B 155.1(11) 7692(5) 1223.3(9) 20.3(5) 
C4B -47.0(12) 9629(5) 1421.8(10) 22.4(5) 
C5B -630.8(12) 9684(5) 1349.5(10) 24.4(6) 
C6B -1030.0(11) 7828(5) 1080.7(9) 22.0(5) 
C7B -1664.2(11) 7860(5) 1009.2(10) 26.5(6) 
C8B -1693.1(11) 7697(5) 1557.4(10) 24.2(5) 
C9B -1433.2(11) 5398(5) 1880.1(10) 22.5(5) 
C10B -1508.1(12) 5231(5) 2401.0(10) 22.6(5) 
C11B -1201.5(12) 3046(5) 2755.0(10) 24.1(5) 
C12B -1242.2(11) 2857(5) 3298.8(10) 20.4(5) 
C13B -849.3(11) 741(5) 3648.3(9) 18.1(5) 
C14B -199.2(11) 914(4) 3765.3(9) 17.7(5) 
C15B 47.6(12) -830(5) 3567.6(10) 22.8(5) 
C16B 638.0(12) -664(5) 3658.9(11) 24.7(6) 
C17B 1001.5(11) 1259(4) 3953.6(10) 19.3(5) 
C18B 1643.5(11) 1494(5) 4061.0(10) 23.3(5) 
C19B 1755.6(11) 3697(5) 3779.4(10) 21.7(5) 
C20B 1415.4(12) 3584(5) 3151.1(10) 23.7(5) 
C21B 1548.4(12) 5680(5) 2863.7(10) 23.4(5) 
C22B 1177.7(12) 5569(5) 2236.1(10) 23.1(5) 
C23B -247.0(11) 5842(5) 950.0(10) 22.5(5) 
C24B -828.8(12) 5903(5) 881.9(10) 24.0(6) 
C25B 163.1(11) 2841(5) 4062.7(10) 23.3(5) 
C26B 749.2(11) 3003(5) 4151.5(10) 23.4(5) 
C27B 1901.1(12) 7665(6) 1970.6(11) 33.0(6) 
C28B 890.5(12) 9560(5) 978.9(10) 21.7(5) 
C29B 1057.3(12) 10354(5) 202.4(10) 25.5(6) 
C30B 1713.3(13) 10234(6) 369.5(11) 33.1(7) 
C31B -1887.4(12) 2491(6) 3189.4(11) 31.1(6) 
C32B -879.9(11) 590(4) 4189.4(10) 19.0(5) 
C33B -1060.2(11) -2166(5) 4766.7(10) 21.9(5) 




























Table S13.25: Anisotropic Displacement Parameters (×104) Aaron-macrocycle_P2. The anisotropic displacement 
factor exponent takes the form: -2 2[h2a*2 × U11+ ... +2hka* × b* × U12] 
 
Atom U11 U22 U33 U23 U13 U12 
F1 28.1(9) 59.4(12) 28.7(8) -19.7(8) 9.1(7) 0.2(8) 
F2 27.6(9) 68.3(13) 39.7(10) -10.2(9) 21.0(8) -6.9(9) 
F3 40.1(11) 53.9(12) 37.5(10) 7.1(9) 16.6(8) 20.2(9) 
F4 39.0(11) 61.0(13) 43.9(11) -12.8(10) 3.6(9) 25.4(10) 
F5 36.5(9) 41.8(10) 18.0(7) -5.3(7) 7.4(7) 3.0(8) 
F6 46.0(12) 105.8(19) 36.2(10) -6.7(11) 17.7(10) -38.8(12) 
O1 32.9(11) 22.1(9) 22.0(9) 0.3(7) 14.5(8) 0.7(8) 
O2 54.7(14) 16.9(10) 29.3(10) -1.3(8) 16.8(10) -1.8(9) 
O3 33.2(11) 21.3(9) 19.2(9) -2.1(7) 11.6(8) -1.9(8) 
O4 34.1(11) 25.2(10) 23.5(9) 0.3(8) 15.9(8) -5.2(8) 
C1 21.1(13) 24.2(13) 20.9(12) -2.6(11) 8.2(11) -0.1(11) 
C2 21.6(13) 20.5(12) 20.7(12) 0.1(10) 9.2(11) 0.2(11) 
C3 20.2(13) 22.0(12) 18.5(11) -4.1(10) 9.9(10) 1.0(11) 
C4 24.9(15) 22.7(13) 24.7(13) -3.7(11) 12.3(12) -3.6(11) 
C5 31.0(15) 20.8(13) 21.8(12) 3.5(10) 13.6(12) 5.5(11) 
C6 21.6(13) 24.1(13) 20.5(12) -3.5(11) 11.4(11) 2.4(11) 
C7 22.3(14) 34.1(15) 22.5(13) -4.3(12) 8.3(11) 6.3(12) 
C8 27.9(15) 32.6(15) 18.6(12) 1.8(11) 7.7(11) 8.8(12) 
C9 25.7(14) 25.8(14) 19.4(12) 0.3(11) 10.1(11) 4.1(12) 
C10 24.2(14) 29.1(14) 19.3(12) 1.2(11) 10.3(11) 1.7(11) 
C11 25.9(14) 27.7(14) 19.9(12) 1.0(11) 10.4(11) 3.5(12) 
C12 18.4(12) 27.5(13) 17.2(11) 0.0(10) 8.2(10) 1.2(11) 
C13 20.8(13) 23.6(13) 16.1(12) -0.3(10) 8.3(11) -3.1(11) 
C14 20.1(13) 22.8(13) 17.2(12) -4.3(10) 8.7(11) 0.5(10) 
C15 24.9(15) 21.2(13) 26.5(13) 2.5(11) 9.7(12) 0.3(11) 
C16 27.6(15) 24.3(14) 22.7(13) 4.1(11) 8.1(12) 3.2(12) 
C17 19.4(13) 24.8(13) 16.8(12) -3.9(10) 9.0(11) 4.0(11) 
C18 18.1(13) 28.1(14) 24.0(13) -1.3(11) 8.4(11) 3.3(11) 
C19 21.0(14) 29.5(15) 23.8(13) -2.2(11) 9.2(11) -0.6(11) 
C20 22.9(14) 30.3(15) 25.1(13) -3.4(11) 11.4(12) -0.9(11) 
C21 24.1(14) 27.7(14) 21.8(13) -2.1(11) 9.4(12) 1.0(11) 
C22 22.0(14) 26.5(14) 25.8(13) -3.4(11) 11.0(12) 0.3(11) 
C23 24.9(14) 21.1(12) 22.3(13) 2.5(10) 11.4(12) 2.2(11) 
C24 23.1(14) 22.8(13) 26.5(13) -0.6(11) 12.6(12) -1.8(11) 
C25 25.1(14) 24.7(13) 19.3(12) 5.2(11) 8.9(11) 2.4(11) 
C26 20.0(13) 29.3(14) 22.6(12) -2.0(11) 10.0(11) -5.5(12) 
C27 22.9(14) 52.3(19) 28.1(14) -11.8(14) 10.4(12) -3.4(14) 
C28 18.8(13) 23.8(14) 19.3(12) 2.4(10) 7.0(11) 2.7(10) 
C29 28.5(15) 32.3(15) 20.6(13) -7.7(11) 14.2(12) -1.8(12) 
C30 24.8(15) 49.4(19) 26.5(14) -9.8(13) 13.6(13) -0.6(14) 
C31 21.5(14) 48.2(18) 22.0(13) -2.5(13) 7.7(12) 5.9(13) 
C32 16.9(13) 23.8(13) 18.8(12) -1.7(10) 7.0(11) -0.3(11) 
C33 28.6(14) 25.0(13) 18.5(12) -2.4(11) 10.2(11) 2.8(12) 
C34 29.8(15) 34.0(15) 23.7(13) -3.8(12) 12.7(12) -1.1(13) 
F1B 38.2(10) 52.4(11) 34.2(9) 6.0(8) 21.7(8) -8.8(8) 
F2B 37.3(11) 92.0(16) 23.4(8) -7.7(10) 8.3(8) -25.9(11) 
F3B 38.2(10) 50.4(11) 49.1(10) 11.1(9) 25.6(9) 12.8(9) 
F4B 39.5(11) 60.0(12) 61.5(12) 34.4(10) 31.4(10) 23.2(9) 
F5B 33.3(9) 40.6(10) 31.5(8) 7.2(7) 22.1(7) 1.0(7) 
F6B 40.4(11) 73.9(14) 41.0(10) -22.3(10) 20.3(9) -26.3(10) 
O1B 30.8(10) 23.9(9) 19.2(8) -2.0(7) 14.1(8) -1.5(8) 
O2B 60.9(14) 17.3(9) 35.3(11) -0.6(8) 33.5(11) -0.6(9) 
O3B 32.1(10) 18.1(9) 21.2(9) 1.5(7) 15.9(8) -1.6(8) 
O4B 35.2(11) 24.0(10) 24.3(9) -5.2(8) 16.8(9) -3.6(8) 























Table A3-2.1.2 Fractional Atomic Coordinates (x104) Aaron-macrocycle_P2. The anisotropic displacement 
factor exponent takes the form: -2 2[h2a*2 x U11+…2hka* x b* x U12] 





Atom U11 U22 U33 U23 U13 U12 
C2B 23.0(13) 18.3(12) 20.8(12) 0.7(10) 10.3(11) 0.1(11) 
C3B 24.2(13) 19.8(12) 15.0(11) 5.0(10) 7.4(10) 3.0(11) 
C4B 27.5(15) 18.8(13) 20.4(12) -1.6(10) 10.5(12) -2.2(11) 
C5B 30.8(15) 22.1(13) 23.1(13) 3.8(11) 14.6(12) 5.9(11) 
C6B 22.8(13) 25.5(13) 15.1(11) 8.0(10) 6.7(10) 4.3(11) 
C7B 22.2(13) 34.2(15) 21.2(12) 9.7(12) 8.4(11) 4.6(12) 
C8B 21.1(13) 27.8(14) 22.9(12) 4.8(11) 9.5(11) 4.1(11) 
C9B 22.6(14) 25.2(13) 19.1(12) 2.6(11) 9.0(11) 4.1(11) 
C10B 24.5(14) 22.3(13) 19.8(12) -0.9(10) 9.3(11) 1.4(11) 
C11B 26.1(14) 26.8(14) 20.6(12) 1.0(11) 11.7(11) 4.4(11) 
C12B 20.5(13) 21.6(12) 19.6(12) 2.4(10) 9.7(10) 3.7(11) 
C13B 19.2(13) 18.2(12) 16.9(11) -1.8(10) 8.5(10) -1.4(10) 
C14B 17.3(13) 19.8(12) 15.4(11) 4.7(10) 7.1(10) 1.9(10) 
C15B 23.7(14) 18.3(13) 25.2(13) -1.8(10) 10.2(12) -0.7(10) 
C16B 23.2(14) 22.7(13) 30.8(14) 1.0(11) 14.8(12) 5.8(11) 
C17B 16.8(13) 23.6(13) 16.6(11) 7.1(10) 7.0(11) 3.6(10) 
C18B 18.4(14) 28.9(14) 20.9(12) 4.7(11) 7.6(11) 3.6(11) 
C19B 18.4(13) 24.7(13) 20.9(12) 0.6(10) 8.2(11) 0.8(11) 
C20B 25.2(14) 24.0(13) 20.4(12) 1.3(11) 9.0(11) -2.7(11) 
C21B 23.8(14) 24.0(13) 22.9(13) 1.3(11) 11.3(11) -0.4(11) 
C22B 25.2(14) 21.7(13) 21.0(12) 1.2(11) 9.6(12) -2.2(11) 
C23B 26.9(15) 19.1(12) 19.3(12) -0.2(10) 8.8(11) 2.3(11) 
C24B 24.3(15) 22.2(13) 21.4(13) 0.1(11) 7.1(12) -2.4(11) 
C25B 26.9(14) 24.9(13) 22.3(12) -3.2(11) 15.0(11) 0.0(12) 
C26B 22.4(13) 26.8(13) 21.3(12) -5.6(11) 10.4(11) -5.9(11) 
C27B 23.8(15) 45.9(18) 27.8(14) 6.3(14) 10.4(12) -4.1(14) 
C28B 24.0(14) 20.3(13) 21.7(13) -0.2(10) 11.3(11) 3.1(11) 
C29B 31.3(16) 28.1(14) 19.4(12) 1.3(11) 13.8(12) -1.2(12) 
C30B 31.0(16) 45.9(18) 22.1(14) 1.6(13) 11.9(13) -6.7(14) 
C31B 23.8(14) 42.4(17) 28.2(14) 9.0(13) 12.9(12) 6.4(13) 
C32B 16.8(13) 20.0(12) 19.6(12) 2.1(10) 7.9(10) 1.2(10) 
C33B 26.8(14) 23.0(13) 17.8(12) 3.4(10) 11.7(11) -0.3(11) 
C34B 27.1(14) 34.8(15) 23.0(13) 3.9(12) 12.7(12) -1.9(13) 
Table S13.26: Bond Lengths in Å for Aaron-macrocycle_P2. 
 
Atom Atom Length/Å 
F1 C30 1.342(3) 
F2 C30 1.328(3) 
F3 C30 1.347(4) 
F4 C34 1.328(3) 
F5 C34 1.345(3) 
F6 C34 1.331(3) 
O1 C28 1.356(3) 
O1 C29 1.438(3) 
O2 C28 1.201(3) 
O3 C32 1.361(3) 
O3 C33 1.435(3) 
O4 C32 1.199(3) 
C1 C2 1.543(3) 
C1 C22 1.522(4) 
C1 C27 1.527(4) 
C2 C3 1.521(3) 
C2 C28 1.506(3) 
C3 C4 1.394(4) 
C3 C23 1.388(4) 
C4 C5 1.385(4) 
Atom Atom Length/Å 
C5 C6 1.395(4) 
C6 C7 1.505(4) 
C6 C24 1.393(4) 
C7 C8 1.530(3) 
C8 C9 1.518(4) 
C9 C10 1.525(3) 
C10 C11 1.517(4) 
C11 C12 1.535(3) 
C12 C13 1.540(3) 
C12 C31 1.527(3) 
C13 C14 1.515(3) 
C13 C32 1.518(3) 
C14 C15 1.388(4) 
C14 C25 1.393(4) 
C15 C16 1.390(4) 
C16 C17 1.388(4) 
C17 C18 1.508(4) 
C17 C26 1.392(4) 
C18 C19 1.529(4) 
C19 C20 1.516(3) 






















Table A - .1.3 Bond Lengths in Å for Aaron-macro ycle_P2 





Atom Atom Length/Å 
C21 C22 1.520(3) 
C23 C24 1.385(4) 
C25 C26 1.385(4) 
C29 C30 1.494(4) 
C33 C34 1.490(4) 
F1B C30B 1.347(3) 
F2B C30B 1.319(3) 
F3B C30B 1.348(4) 
F4B C34B 1.326(3) 
F5B C34B 1.341(3) 
F6B C34B 1.342(3) 
O1B C28B 1.361(3) 
O1B C29B 1.437(3) 
O2B C28B 1.194(3) 
O3B C32B 1.363(3) 
O3B C33B 1.430(3) 
O4B C32B 1.201(3) 
C1B C2B 1.554(3) 
C1B C22B 1.528(3) 
C1B C27B 1.527(3) 
C2B C3B 1.519(3) 
C2B C28B 1.509(3) 
C3B C4B 1.398(3) 
C3B C23B 1.390(4) 
C4B C5B 1.389(3) 
C5B C6B 1.386(4) 
Atom Atom Length/Å 
C6B C7B 1.515(3) 
C6B C24B 1.392(4) 
C7B C8B 1.531(3) 
C8B C9B 1.513(4) 
C9B C10B 1.518(3) 
C10B C11B 1.517(4) 
C11B C12B 1.535(3) 
C12B C13B 1.545(3) 
C12B C31B 1.522(3) 
C13B C14B 1.518(3) 
C13B C32B 1.514(3) 
C14B C15B 1.384(3) 
C14B C25B 1.394(4) 
C15B C16B 1.391(3) 
C16B C17B 1.391(4) 
C17B C18B 1.508(3) 
C17B C26B 1.393(3) 
C18B C19B 1.534(3) 
C19B C20B 1.522(3) 
C20B C21B 1.520(3) 
C21B C22B 1.525(3) 
C23B C24B 1.388(4) 
C25B C26B 1.382(3) 
C29B C30B 1.497(4) 
C33B C34B 1.493(3) 
 
Table S13.27: Bond Angles in ° for Aaron-macrocycle_P2. 
 
Atom Atom Atom Angle/° 
C28 O1 C29 116.5(2) 
C32 O3 C33 117.09(19) 
C22 C1 C2 110.3(2) 
C22 C1 C27 111.9(2) 
C27 C1 C2 110.8(2) 
C3 C2 C1 112.92(19) 
C28 C2 C1 111.1(2) 
C28 C2 C3 109.3(2) 
C4 C3 C2 122.7(2) 
C23 C3 C2 119.3(2) 
C23 C3 C4 117.9(2) 
C5 C4 C3 121.0(2) 
C4 C5 C6 121.2(2) 
C5 C6 C7 121.8(2) 
C24 C6 C5 117.4(2) 
C24 C6 C7 120.8(2) 
C6 C7 C8 114.0(2) 
C9 C8 C7 114.6(2) 
C8 C9 C10 112.8(2) 
C11 C10 C9 113.5(2) 
C10 C11 C12 115.6(2) 
C11 C12 C13 109.6(2) 
C31 C12 C11 111.5(2) 
C31 C12 C13 110.5(2) 
C14 C13 C12 113.5(2) 
C14 C13 C32 109.11(19) 
Atom Atom Atom Angle/° 
C32 C13 C12 110.7(2) 
C15 C14 C13 120.7(2) 
C15 C14 C25 117.8(2) 
C25 C14 C13 121.4(2) 
C16 C15 C14 121.0(2) 
C15 C16 C17 121.5(2) 
C16 C17 C18 122.0(2) 
C26 C17 C16 117.2(2) 
C26 C17 C18 120.8(2) 
C17 C18 C19 113.9(2) 
C20 C19 C18 114.4(2) 
C21 C20 C19 114.0(2) 
C20 C21 C22 113.4(2) 
C21 C22 C1 115.8(2) 
C24 C23 C3 121.0(2) 
C23 C24 C6 121.5(2) 
C26 C25 C14 120.8(2) 
C25 C26 C17 121.7(2) 
O1 C28 C2 111.8(2) 
O2 C28 O1 122.5(2) 
O2 C28 C2 125.7(2) 
O1 C29 C30 108.6(2) 
F1 C30 F3 106.4(2) 
F1 C30 C29 110.4(2) 
F2 C30 F1 107.6(2) 
F2 C30 F3 106.9(2) 
























Table A3-2.1.4 Bond Angles in ° for Aaron-macrocycle_P2 




























Atom Atom Atom Angle/° 
F3 C30 C29 112.3(3) 
O3 C32 C13 110.0(2) 
O4 C32 O3 123.4(2) 
O4 C32 C13 126.7(2) 
O3 C33 C34 109.0(2) 
F4 C34 F5 106.6(2) 
F4 C34 F6 107.0(2) 
F4 C34 C33 112.4(2) 
F5 C34 C33 111.1(2) 
F6 C34 F5 106.6(2) 
F6 C34 C33 112.8(2) 
C28B O1B C29B 116.5(2) 
C32B O3B C33B 116.90(19) 
C22B C1B C2B 109.3(2) 
C27B C1B C2B 110.27(19) 
C27B C1B C22B 111.7(2) 
C3B C2B C1B 113.15(18) 
C28B C2B C1B 110.5(2) 
C28B C2B C3B 108.9(2) 
C4B C3B C2B 122.1(2) 
C23B C3B C2B 120.1(2) 
C23B C3B C4B 117.9(2) 
C5B C4B C3B 120.8(2) 
C6B C5B C4B 121.3(2) 
C5B C6B C7B 121.5(2) 
C5B C6B C24B 117.9(2) 
C24B C6B C7B 120.6(2) 
C6B C7B C8B 113.2(2) 
C9B C8B C7B 114.5(2) 
C8B C9B C10B 112.8(2) 
C11B C10B C9B 113.4(2) 
C10B C11B C12B 115.3(2) 
C11B C12B C13B 109.76(19) 
C31B C12B C11B 111.1(2) 
C31B C12B C13B 109.9(2) 
C14B C13B C12B 113.73(19) 
C32B C13B C12B 109.69(19) 
C32B C13B C14B 109.43(19) 
Atom Atom Atom Angle/° 
C15B C14B C13B 120.5(2) 
C15B C14B C25B 118.0(2) 
C25B C14B C13B 121.5(2) 
C14B C15B C16B 121.2(2) 
C15B C16B C17B 121.1(2) 
C16B C17B C18B 122.5(2) 
C16B C17B C26B 117.2(2) 
C26B C17B C18B 120.2(2) 
C17B C18B C19B 113.5(2) 
C20B C19B C18B 113.1(2) 
C21B C20B C19B 113.9(2) 
C20B C21B C22B 112.4(2) 
C21B C22B C1B 115.1(2) 
C3B C23B C24B 121.0(2) 
C23B C24B C6B 121.1(2) 
C26B C25B C14B 120.7(2) 
C25B C26B C17B 121.8(2) 
O1B C28B C2B 110.6(2) 
O2B C28B O1B 123.2(2) 
O2B C28B C2B 126.2(2) 
O1B C29B C30B 107.9(2) 
F1B C30B C29B 110.3(2) 
F2B C30B F1B 108.0(2) 
F2B C30B F3B 106.6(3) 
F2B C30B C29B 113.1(2) 
F3B C30B F1B 106.9(2) 
F3B C30B C29B 111.6(2) 
O3B C32B C13B 109.8(2) 
O4B C32B O3B 123.7(2) 
O4B C32B C13B 126.4(2) 
O3B C33B C34B 108.36(19) 
F4B C34B F5B 107.0(2) 
F4B C34B F6B 107.1(2) 
F4B C34B C33B 113.1(2) 
F5B C34B F6B 106.4(2) 
F5B C34B C33B 111.4(2) 
F6B C34B C33B 111.6(2) 
 
Table S13.28: Torsion Angles in ° for Aaron-macrocycle_P2. 
 
Atom Atom Atom Atom Angle/° 
O1 C29 C30 F1 176.0(2) 
O1 C29 C30 F2 -63.5(3) 
O1 C29 C30 F3 57.5(3) 
O3 C33 C34 F4 -66.4(3) 
O3 C33 C34 F5 174.3(2) 
O3 C33 C34 F6 54.6(3) 
C1 C2 C3 C4 57.5(3) 
C1 C2 C3 C23 -120.4(2) 
C1 C2 C28 O1 118.2(2) 
C1 C2 C28 O2 -61.6(3) 
C2 C1 C22 C21 -169.3(2) 
C2 C3 C4 C5 -177.3(2) 
C2 C3 C23 C24 177.3(2) 
C3 C2 C28 O1 -116.5(2) 
Table A3-2.1.5 Torsion Angles in ° for Aaron-macrocycle_P2 





Atom Atom Atom Atom Angle/° 
C3 C2 C28 O2 63.7(3) 
C3 C4 C5 C6 -0.5(4) 
C3 C23 C24 C6 0.8(4) 
C4 C3 C23 C24 -0.7(3) 
C4 C5 C6 C7 179.7(2) 
C4 C5 C6 C24 0.5(3) 
C5 C6 C7 C8 -63.9(3) 
C5 C6 C24 C23 -0.7(3) 
C6 C7 C8 C9 -61.2(3) 
C7 C6 C24 C23 -179.9(2) 
C7 C8 C9 C10 -179.4(2) 
C8 C9 C10 C11 -176.6(2) 
C9 C10 C11 C12 175.5(2) 
C10 C11 C12 C13 -175.0(2) 
C10 C11 C12 C31 62.3(3) 
C11 C12 C13 C14 60.4(3) 
C11 C12 C13 C32 -176.5(2) 
C12 C13 C14 C15 -116.8(3) 
C12 C13 C14 C25 61.1(3) 
C12 C13 C32 O3 130.1(2) 
C12 C13 C32 O4 -51.4(3) 
C13 C14 C15 C16 177.5(2) 
C13 C14 C25 C26 -177.3(2) 
C14 C13 C32 O3 -104.2(2) 
C14 C13 C32 O4 74.3(3) 
C14 C15 C16 C17 -0.2(4) 
C14 C25 C26 C17 -0.2(4) 
C15 C14 C25 C26 0.6(4) 
C15 C16 C17 C18 -178.4(2) 
C15 C16 C17 C26 0.7(4) 
C16 C17 C18 C19 113.9(3) 
C16 C17 C26 C25 -0.5(3) 
C17 C18 C19 C20 -61.7(3) 
C18 C17 C26 C25 178.6(2) 
C18 C19 C20 C21 179.5(2) 
C19 C20 C21 C22 177.5(2) 
C20 C21 C22 C1 -179.7(2) 
C22 C1 C2 C3 59.7(3) 
C22 C1 C2 C28 -177.0(2) 
C23 C3 C4 C5 0.6(3) 
C24 C6 C7 C8 115.2(3) 
C25 C14 C15 C16 -0.4(4) 
C26 C17 C18 C19 -65.1(3) 
C27 C1 C2 C3 -175.9(2) 
C27 C1 C2 C28 -52.6(3) 
C27 C1 C22 C21 66.9(3) 
C28 O1 C29 C30 103.6(3) 
C28 C2 C3 C4 -66.7(3) 
C28 C2 C3 C23 115.4(2) 
C29 O1 C28 O2 1.7(4) 
C29 O1 C28 C2 -178.0(2) 
C31 C12 C13 C14 -176.4(2) 
C31 C12 C13 C32 -53.2(3) 
C32 O3 C33 C34 97.2(3) 
C32 C13 C14 C15 119.2(2) 
C32 C13 C14 C25 -62.9(3) 
C33 O3 C32 O4 3.4(4) 





























Atom Atom Atom Atom Angle/° 
O1B C29B C30B F1B 176.8(2) 
O1B C29B C30B F2B -62.1(3) 
O1B C29B C30B F3B 58.1(3) 
O3B C33B C34B F4B -61.4(3) 
O3B C33B C34B F5B 178.1(2) 
O3B C33B C34B F6B 59.4(3) 
C1B C2B C3B C4B 57.0(3) 
C1B C2B C3B C23B -122.2(2) 
C1B C2B C28B O1B 126.1(2) 
C1B C2B C28B O2B -55.0(4) 
C2B C1B C22B C21B -170.6(2) 
C2B C3B C4B C5B -178.9(2) 
C2B C3B C23B C24B 178.6(2) 
C3B C2B C28B O1B -109.0(2) 
C3B C2B C28B O2B 69.9(3) 
C3B C4B C5B C6B 0.1(4) 
C3B C23B C24B C6B 0.5(4) 
C4B C3B C23B C24B -0.7(4) 
C4B C5B C6B C7B 179.0(2) 
C4B C5B C6B C24B -0.3(3) 
C5B C6B C7B C8B -65.2(3) 
C5B C6B C24B C23B 0.0(3) 
C6B C7B C8B C9B -61.8(3) 
C7B C6B C24B C23B -179.3(2) 
C7B C8B C9B C10B -176.1(2) 
C8B C9B C10B C11B -174.9(2) 
C9B C10B C11B C12B 177.5(2) 
C10B C11B C12B C13B -173.2(2) 
C10B C11B C12B C31B 65.1(3) 
C11B C12B C13B C14B 55.9(3) 
C11B C12B C13B C32B 178.8(2) 
C12B C13B C14B C15B -117.0(2) 
C12B C13B C14B C25B 61.6(3) 
C12B C13B C32B O3B 131.5(2) 
C12B C13B C32B O4B -50.3(3) 
C13B C14B C15B C16B 178.3(2) 
C13B C14B C25B C26B -178.1(2) 
C14B C13B C32B O3B -103.0(2) 
C14B C13B C32B O4B 75.1(3) 
C14B C15B C16B C17B 0.2(4) 
C14B C25B C26B C17B -0.5(4) 
C15B C14B C25B C26B 0.6(4) 
C15B C16B C17B C18B 179.9(2) 
C15B C16B C17B C26B -0.1(4) 
C16B C17B C18B C19B 115.1(3) 
C16B C17B C26B C25B 0.2(4) 
C17B C18B C19B C20B -63.6(3) 
C18B C17B C26B C25B -179.7(2) 
C18B C19B C20B C21B -176.7(2) 
C19B C20B C21B C22B -177.3(2) 
C20B C21B C22B C1B 177.7(2) 
C22B C1B C2B C3B 59.8(3) 
C22B C1B C2B C28B -177.7(2) 
C23B C3B C4B C5B 0.4(3) 
C24B C6B C7B C8B 114.1(3) 
C25B C14B C15B C16B -0.4(4) 
C26B C17B C18B C19B -64.9(3) 





























Atom Atom Atom Atom Angle/° 
C27B C1B C2B C28B -54.6(3) 
C27B C1B C22B C21B 67.1(3) 
C28B O1B C29B C30B 99.4(3) 
C28B C2B C3B C4B -66.3(3) 
C28B C2B C3B C23B 114.5(2) 
C29B O1B C28B O2B 4.0(4) 
C29B O1B C28B C2B -177.0(2) 
C31B C12B C13B C14B 178.4(2) 
C31B C12B C13B C32B -58.7(3) 
C32B O3B C33B C34B 99.1(2) 
C32B C13B C14B C15B 119.9(2) 
C32B C13B C14B C25B -61.4(3) 
C33B O3B C32B O4B 4.5(3) 






























Table S13.29: Hydrogen Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103) for Aaron-macrocycle_P2. Ueq is defined as 1/3 of the trace of the orthogonalised Uij. 
 
Atom x y z Ueq 
H1 3838.87 1417.26 6044.01 27 
H2 4207.62 4485.31 5421.4 25 
H4 4840.99 -360.14 6422.28 28 
H5 5801.05 -375.76 7136.72 29 
H7A 6916.88 4159.71 7370.2 33 
H7B 6906.2 1334.9 7398.66 33 
H8A 6538.59 1555.85 8047.23 33 
H8B 7157.54 2870.15 8269.03 33 
H9A 6045.69 5298.2 7825.73 28 
H9B 6663.7 6623.82 8041.48 28 
H10A 6340.63 3858.89 8736.64 29 
H10B 6937.65 5329.69 8943.77 29 
H11A 5801.39 7546.94 8483.22 30 
H11B 6410.9 8941.41 8737.19 30 
H12 6017.59 6097.78 9373.73 25 
H13 6022.18 11219.04 9293.16 24 
H15 5209.75 12729.35 8513.21 30 
H16 4236.17 12564.47 7821 31 
H18A 3269.88 10780.41 7380.3 29 
H18B 3091.16 9221.46 7761.05 29 
H19A 3335.86 5676.06 7435.97 30 
H19B 2831.8 7113.21 6948.5 30 
H20A 3539.25 8588.14 6690.01 31 
H20B 4046.03 7171.75 7180.08 31 
H21A 3093.65 4881.95 6279.45 30 
H21B 3620.75 3509.13 6761.73 30 
H22A 4296.5 5121.09 6477.84 30 
H22B 3772.08 6505.72 5998.13 30 
H23 5162.07 5955.91 5892.69 27 
H24 6120.38 5949.12 6609.47 28 
H25 4948.78 6619.38 9158.69 28 
H26 3979.76 6457.4 8463.97 29 
H27A 3082.42 4291.05 5128.85 52 
H27B 2861.64 2813.75 5491.26 52 
H27C 3099.11 1459.46 5125.95 52 
H29A 4033.67 -1564.23 4443.05 31 
H29B 4111.57 420.45 4067.88 31 
H31A 7042.46 9106.84 9774.92 47 
H31B 7063.15 6277.03 9804.09 47 
H31C 6827.48 7745.84 10156.27 47 
H33A 5836.99 11583.49 10740.57 29 
H33B 5905.86 14354.71 10655.57 29 
H1B 1216.17 9191.66 2079.88 26 
H2B 842 6011.03 1153.47 25 
H4B 212.4 10895.87 1604.28 27 
H5B -756.36 10992.28 1484.09 29 
H7BA -1884.57 6514.62 775.82 32 
H7BB -1859.37 9339.1 821.4 32 






















Table A3-2.1.6 Hydrogen Fractional Atomic Coordinates (x104) and Equivalent Isotropic 
Displacement Parameters (Å2x103) for Aaron-macrocycle_P2. Ueq is defined as 1/3 of the trace 
of the orthogonalised Uij. 





Atom x y z Ueq 
H8BB -2108.59 7825.21 1481.74 29 
H9BA -1009.95 5319.97 1980.83 27 
H9BB -1627.82 4021.27 1645.32 27 
H10C -1346.11 6682.04 2619.1 27 
H10D -1932.21 5164.79 2297.27 27 
H11C -781.77 3079.64 2841.42 29 
H11D -1376.03 1600.41 2538.96 29 
H12B -1091.09 4361.57 3506.93 24 
H13B -1015.29 -759.67 3443.49 22 
H15B -185.46 -2136.09 3370.18 27 
H16B 792.41 -1858.43 3520.68 30 
H18C 1755.56 43.85 3930.99 28 
H18D 1899.36 1608.16 4456.72 28 
H19C 1637.8 5146.66 3904.52 26 
H19D 2181.16 3813.56 3892.11 26 
H20C 1515.18 2084.57 3028.49 28 
H20D 989.07 3560.12 3038.74 28 
H21C 1970.68 5661.14 2959.15 28 
H21D 1465.5 7188.06 2996.65 28 
H22C 757.11 5506.24 2145.69 28 
H22D 1272.99 4079.35 2106.12 28 
H23B -124.41 4542.27 810.61 27 
H24B -1088.59 4636.94 700.23 29 
H25B 8.95 4029.39 4202.81 28 
H26B 981.32 4312.22 4348.7 28 
H27D 1963.79 6182.78 1821.78 50 
H27E 2191.46 7799.8 2352.75 50 
H27F 1943.79 9005.6 1767.83 50 
H29C 949.16 11971.7 260.87 31 
H29D 825.95 9956.17 -186.45 31 
H31D -2039.34 1012.82 2988.64 47 
H31E -2127.92 3820.41 2975.5 47 
H31F -1901.78 2409.07 3534.97 47 
H33C -874.84 -872.72 5031.91 26 
H33D -868.03 -3675.15 4937.83 26 
 
Citations 
CrysAlisPro Software System, Rigaku Oxford Diffraction, (2018). 
O.V. Dolomanov and L.J. Bourhis and R.J. Gildea and J.A.K. Howard and H. Puschmann, Olex2: A complete 
structure solution, refinement and analysis program, J. Appl. Cryst., (2009), 42, 339-341. 
Sheldrick, G.M., Crystal structure refinement with ShelXL, Acta Cryst., (2015), C27, 3-8. 






























# PLATON/CHECK-( 70414) versus check.def version of 310314   for Entry: aaron-ma 
# Data: Aaron-macrocycle_P2.cif - Type: CIF      Bond Precision   C-C = 0.0040 A 
# Refl: Aaron-macrocycle_P2.fcf - Type: LIST4                       Temp = 100 K 
#                                                X-Ray         Nref/Npar =   9.2 
# Cell  25.1525(4)  5.53398(4)  27.2474(4)           90 117.4652(19)          90 
# Wavelength 1.54184    Volume Reported    3365.19(9)   Calculated   3365.19(10) 
# SpaceGroup from Symmetry P 2        Hall: P 2y                 monoclinic 
#                 Reported P 1 2 1          P 2y                 monoclinic 
# MoietyFormula C34 H42 F6 O4 
#      Reported C34 H42 F6 O4 
#    SumFormula C34 H42 F6 O4 
#      Reported C34 H42 F6 O4 
# Mr        =    628.68[Calc],    628.67[Rep] 
# Dx,gcm-3  =     1.241[Calc],     1.241[Rep] 
# Z         =         4[Calc],         4[Rep] 
# Mu (mm-1) =     0.866[Calc],     0.866[Rep] 
# F000      =    1328.0[Calc],    1328.0[Rep]  or F000' =   1332.85[Calc] 
# Reported   T Limits: Tmin=0.487              Tmax=1.000  AbsCorr=GAUSSIAN 
# Calculated T Limits: Tmin=0.940 Tmin'=0.611  Tmax=0.968 
# Reported   Hmax= 30, Kmax=  6, Lmax= 33, Nref=  10947        , Th(max)= 73.814 
# Obs in FCF Hmax= 30, Kmax=  6, Lmax= 33, Nref=  10947[  7307], Th(max)= 73.814 
# Calculated Hmax= 31, Kmax=  6, Lmax= 33, Nref=  13617[  7546], Ratio=1.45/0.80 
# Reported   Rho(min) = -0.20, Rho(max) =  0.32 e/Ang**3 (From CIF) 
# Calculated Rho(min) = -0.19, Rho(max) =  0.31 e/Ang**3 (From CIF+FCF data) 
# w=1/[sigma**2(Fo**2)+(0.0388P)**2+  1.0793P], P=(Fo**2+2*Fc**2)/3 
# R= 0.0363(  9975), wR2= 0.0885( 10947), S = 0.985      (From CIF+FCF data) 
# R= 0.0363(  9975), wR2= 0.0885( 10947), S = 0.985      (From FCF data only) 
# R= 0.0363(  9975), wR2= 0.0885( 10947), S = 0.985, Npar=  797, Flack  -0.02(6) 
#=============================================================================== 




>>> The Following Improvement and Query ALERTS were generated - (Acta-Mode) <<< 
#=============================================================================== 
Format: alert-number_ALERT_alert-type_alert-level text 
 
230_ALERT_2_C Hirshfeld Test Diff for    F3     --  C30     ..        6.0 su 
761_ALERT_1_C CIF Contains no X-H Bonds ......................     Please Check 
762_ALERT_1_C CIF Contains no X-Y-H or H-Y-H Angles ..........     Please Check 
911_ALERT_3_C Missing # FCF Refl Between THmin &amp; STh/L=  0.600         84 Why ? 
915_ALERT_3_C Low Friedel Pair Coverage ......................         60 % 
#=============================================================================== 
008_ALERT_5_G No _iucr_refine_reflections_details   in the CIF     Please Do ! 
142_ALERT_4_G su on b - Axis Small or Missing ................    0.00004 Ang. 
242_ALERT_2_G Low       Ueq as Compared to Neighbors for .....        C30 Check 
242_ALERT_2_G Low       Ueq as Compared to Neighbors for .....        C34 Check 
242_ALERT_2_G Low       Ueq as Compared to Neighbors for .....       C30B Check 
242_ALERT_2_G Low       Ueq as Compared to Neighbors for .....       C34B Check 
720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          6 Note 
791_ALERT_4_G The Model has Chirality at C1      .............          R Verify 
791_ALERT_4_G The Model has Chirality at C1B     .............          R Verify 
791_ALERT_4_G The Model has Chirality at C2      .............          S Verify 
791_ALERT_4_G The Model has Chirality at C2B     .............          S Verify 
791_ALERT_4_G The Model has Chirality at C12     .............          R Verify 
791_ALERT_4_G The Model has Chirality at C12B    .............          R Verify 
791_ALERT_4_G The Model has Chirality at C13     .............          S Verify 





























802_ALERT_4_G CIF Input Record(s) with more than 80 Characters          ! Info 
910_ALERT_3_G Missing # of FCF Reflections Below Th(Min) .....          1 Why ? 
912_ALERT_4_G Missing # of FCF Reflections Above STh/L=  0.600        147 Note 
#=============================================================================== 
 
ALERT_Level and ALERT_Type Summary 
================================== 
5 ALERT_Level_C = Check. Ensure it is Not caused by an Omission or Oversight 
18 ALERT_Level_G = General Info/Check that it is not Something Unexpected 
 
2 ALERT_Type_1 CIF Construction/Syntax Error, Inconsistent or Missing Data. 
5 ALERT_Type_2 Indicator that the Structure Model may be Wrong or Deficient. 
3 ALERT_Type_3 Indicator that the Structure Quality may be Low. 
12 ALERT_Type_4 Improvement, Methodology, Query or Suggestion. 
1 ALERT_Type_5 Informative Message, Check. 
#=============================================================================== 
 
2 Missing  Experimental  Info Issue(s) (Out of  54 Tests) -   96 % Satisfied 
0 Experimental  Data  Related Issue(s) (Out of  28 Tests) -  100 % Satisfied 
5 Structural  Model   Related Issue(s) (Out of 117 Tests) -   96 % Satisfied 























A3-3.1   MODEL STUDIES TOWARD CYLINDROCYCLOPHANE A 
 Due to our ambitious retrosynthetic proposal outlined in Chapter 3.2, we believed 
that it was important to probe the viability of our end-game proposal. We began by 
investigating the C–H acetoxylation reaction (Scheme A3-3.1.1A). We were pleased to 
find that under the standard conditions reported by Yu and coworkers,1 112 afforded a 
69% yield of diacetoxylated product 113 and an additional 25% of the monoacetoxylated 
product. With these results in mind, we decided to investigate further and probe the 
viability of a tetraacetoxylation reaction. We decided to investigate using previously 
                                                
* This research was performed in collaboration with Aaron T. Bosse and Huw M. L. Davies at Emory 
University and Hojoon Park and Jin-Quan Yu at The Scripps Research Institute through the Center for C-H 
functionalization.  
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synthesized [7,7]paracyclophane 111 as a precursor to Weinreb amide 114 in order to 
quickly access a tetraacetoxylation substrate. We were pleased to discover that Weinreb 
amide 114 could readily be synthesized from cyclophane 111 in good yield (Scheme A3-
3.1.1B). This diamide 114 could then be subjected to the diacetoxylation reaction with 
twice the amount of reagents to afford a moderate yield of the tetracetoxylated 
[7,7]paracyclophane 115 (Scheme A3-3.1.1C), along with significant amounts of the 
triacetoxylated, diacetoxylated and monoacetoxylated products. We believed that further 
investigation of the acetoxylation in collaboration with the Yu lab at The Scripps 
Research Institute could lead to even more promising results.   






































HFIP, 80 °C, 48 h





HFIP, 80 ºC, 48 h
69 % yield
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  Next, we turned our investigation to the carboxy-inversion reaction (Scheme A3-
3.1.2). First, we saponified ester 111 to form 116 in good yield, which unfortunately 
resulted in some epimerization of the benzylic stereocenters. Nevertheless, we proceeded 
to investigate the oxidative decarboxylation of 116,2 which proceeded to form 117 in 
good yield; however epimerization was again observed. Further studies in this area are 
ongoing. 
Scheme A3-3.1.2 Oxidative Decarboxylation Reaction 
 
A3-3.2   PROGRESS TOWARD CYLINDROCYCLOPHANE A  
 Following our successful synthesis of a [7,7]paracyclophane through successive 
C-H functionalization and promising results for our end-game strategy on model 
compounds, we proceeded to target the total synthesis of our first naturally occurring 
[7,7]paracyclophane, cylindrocyclophane A. Our retrosynthetic proposal for this 
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Scheme A3-3.2.1 Retrosynthetic proposal for cylindrocyclophane A 
 
 We began our investigation with the primary C-H insertion of iodo diazoester 103 
into olefin 102 (Scheme A3-3.2.2).3 We were pleased to observe very good reactivity and 
selectivity to afford olefin 101, which could undergo subsequent hydrogenation in the 
presence of Crabtree’s catalyst to afford aryl iodide 118. This aryl iodide could then be 
subjected to palladium catalyzed cross-coupling with diazoester 107 to yield diazoester 
100 in good yield.4 This diazoester 100 can then selectively insert into the unactivated C-
H bond of another molecule of 118 to afford aryl iodide 119, again in good yield and 
selectivity.5 Another palladium catalyzed diazoester coupling with diazoester 107 yields 
diazoester 120, which can then undergo intramolecular C-H insertion to afford 
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on [7,7]paracylophane 99 allows for the possibility of differentiating between them 
toward the synthesis of cylindrocyclophane A.  
Scheme A3-3.2.2 Synthesis of a [7,7]paracyclophane enroute toward 
cylindrocyclophane A  
 
 With [7,7]paracyclophane 99 in hand, we proceeded to investigate our end-game 
strategy toward the synthesis of cylindrocyclophane A (Scheme A3-3.2.3). We were 
pleased to observe selective deprotection of the trichloroethyl ester to afford diacid 121 in 
good yield.6 The carboxylic acid functionality in 121 can then be selectively transformed 














































OCH2CCl3 90% yield, >30:1 rr, 
>20:1 dr, 97% ee
H
Rh2(R-p-phTPCP)4
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investigate the reactivity of this compound toward acetoxylation. We were pleased to 
observe a good yield of tetraacetoxylated compound 98 under similar conditions to those 
developed for synthesis of 115, though we believed the yield could be optimized further. 
Scheme A3-3.2.3 Investigation of acetoxylation toward cylindrocyclophane A 
 
 While we had observed good yields of tetracetoxylated compound 98 from 122 
under the conditions originally disclosed by Yu and coworkers, we believed that further 
optimization would be useful. In collaboration with the Yu group, we investigated the 
same reaction conditions for the synthesis of 98, but with the addition of ligand 123 
(Scheme A3-3.2.4). We were extremely pleased to observe improved reactivity for the 
formation of tetracetoxylated compound 98, affording the desired compound in up to 
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Scheme A3-3.2.4 Optimization of tetraacetoxylation reaction 
 
A3-3.3   CONCLUSIONS  
 Following our initial investigations toward the synthesis of [7,7]paracyclophanes 
described in Chapter 3, we have expanded our studies to target intermediates we consider 
capable of advancing to cylindrocyclophane A. Throughout these studies, we have 
investigated the viability of our end-game strategy involving tetraacetoxylation and 
carboxy-inversion, as well as the synthesis of a more functionalized [7,7]paracyclophane. 
In addition, we have optimized the previously disclosed acetoxylation to favor 
tetraacetoxylation of a bis-Weinreb amide. With this advanced intermediate in hand, we 
hope to complete the synthesis of our first naturally occurring [7,7]paracylophane, 
cylindrocyclophane A, in the near future. 
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Pd(OAc)2 (20 mol %)
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for New Compounds 
 
A4.1  CONTENTS 
The following notebook cross-reference provides the file name for all original 
spectroscopic data obtained for new compounds presented within this thesis. The 
information is organized by chapter and sequentially by compound number. All 1H NMR, 
13C NMR, as well as 19F NMR and any two-dimensional NMR data for Chapters 1 and 2, 
if applicable, are electronically stored on the Caltech NMR laboratory server 
(mangia.caltech.edu, most typically under the usernames ‘ylu3’, ‘htakada’, ‘egoldstei’ or 
‘egoldste’) and on the Stoltz group server. Electronic copies of all IR spectra can also be 
found on the Stoltz group server. All laboratory notebooks are stored in the Stoltz group 
archive. Researchers at Emory University obtained the data in Chapter 3. 
A4.2  NOTEBOOK CROSS-REFERENCE TABLES 


































9 YL-1-129-1H (Indy) 
YL-1-129-13C 
(Florence) - YL-1-129 
10 YL-1-131-1H (Indy) 
YL-1-131-13C 
(Florence) - YL-1-131 
































































































































































28c elg-ix-091-char (Indy) 
elg-ix-091-char 
(Indy) - elg-ix-091 
29c elg-ix-163-char (Indy) 
elg-ix-163-char 
(Indy) - elg-ix-163 
34a HT-143-forData (Indy) 
HT-143-13C 
(Indy) - ht-143 
34b elg-ix-197-char (Indy) 
elg-ix-197-char 
(Indy) - elg-ix-197 
34c elg-ix-223-char (Indy) 
elg-ix-223-char 
(Indy) - elg-ix-179 





35a HT-150-forData (Indy) 
HT-150-13C 
(Indy) - HT-150 
35b elg-ix-181-char (Indy) 
elg-ix-181-char 
(Indy) - elg-ix-181 











35c elg-ix-181-char-2 (Indy) 
elg-ix-181-char-2 
(Indy) - elg-ix-181 





30a HT-152-forData (Indy) 
HT-152-13C 
(Indy) - HT-152 
30b elg-ix-205-char (Indy) 
elg-ix-205-char-2 
(Indy) - elg-ix-205 
30c elg-ix-207-char (Indy) 
elg-ix-207-char-2 
(Indy) - elg-ix-207 













31b elg-ix-061-char (Indy) 
elg-ix-061-char 














31e elg-ix-215-char (Indy) 
elg-ix-215-char 










41 HT-161-forData (Indy) 
HT-161-13C 
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